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The mammary gland is an extremely interesting and unique tissue to study 
as it undergoes the vast majority of its development in the adult. It undergoes 
successive cycles of proliferation, differentiation and apoptosis with each pregnancy 
and thus is an ideal tissue in which to study questions relating to each of these 
processes. The aim of the work described in this thesis has focussed on isolating 
genes that control these processes. The technique of differential display RT-PCR 
was used to screen mRNA populations for significant changes in gene expression 
throughout pregnancy in the murine mammary gland. 
As a result of this analysis, eight potential 3' cDNA fragments were 
identified that showed a range of expression profiles. Database searches revealed 
the majority of these clones to represent as yet unknown cDNAs. One clone, which 
was identified as the murine homologue of TBP1 was chosen for further analysis. 
TBPI is a member of a family of Mg 2 dependent ATPases, and functions as a 
component of a larger multi-protein complex, the 26S proteasome. This complex 
acts to degrade short-lived intracellular proteins in a ubiquitin dependent manner. 
TBPI expression increased around thy 10 gestation in the mammary gland. 
Analysis of protein levels confirmed that the increase in TBP1 expression observed 
was due to an overall increase in the 26S proteasome. The increase in TBP1 
expression observed by differential display was at the stage when the mammary 
gland begins to respond to lactogenic hormones by differentiating and expressing 
the milk protein f3-casein. Studies in mammary epithelial cells (MEC) revealed the 
increase in the proteasome level was not lactogenic hormone dependent as the 
expression profile from the display results may have implied. 
We further cloned murine homologues of two other ATPases, TBP7 and 
Sug2 and performed a yeast two hybrid assay to determine if these ATPases 
interacted with one another. In order to address the role of TBPI and the 26S 
proteasonie in the mammary gland, a series of studies using a peptide inhibitor of 
the proteasome were performed on MECs. These results suggested that proteasome 
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function was essential for MECs, and inhibition of the proteasome leads to the 
induction of apoptosis. This study showed that death was occurring from a specific 
stage in the cell cycle and that this was a p53 dependent response. To address the 
question of TBPI function more specifically, a dominant negative TBP1 construct 
was generated. Constitutive expression studies suggested that TBP1 function was 
indeed essential for cell survival. The results presented demonstrate that 
proteasome function is an essential component of a cell's regulatory function, and 
that if this function is disrupted then the cell will undergo apoptosis. A greater 
understanding of the function of the 26S proteasome in the processes of 
proliferation, differentiation and apoptosis should lead to an enhanced perception of 
the role proteolysis plays in normal mammary gland development. 
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Scientific interest in the mammary gland can be dated back at least a few 
centuries. The first detailed anatomical descriptions of the breast and its blood 
supply were described in the 19th century. This settled the details of the gross 
anatomical structure of the gland but the later introduction of the light microscope 
produced a number of misconceptions about gland secretion. Examination of 
sections of lactating mammary gland led early histologists to suggest that secreted 
milk consists of the tips of the mammary cells themselves, which broke off into the 
lumen of the gland. This misconception was later dispelled and a firm 
understanding of gland development and milk secretion was established at the start 
of this century. Recent advances such as the introduction of the electron 
microscope, and the pioneering animal studies by endocrinologists in the first half 
of this century have enhanced our knowledge of this structure. This early work 
provided the basis for the description of the biochemical pathways involved in 
gland development and has led the way to a new generation of studies on mammary 
gland development and function. This work is now based on genetic manipulation 
of these pathways to elucidate definitive roles for the genes known to be involved in 
mammary development. 
The mammary gland holds great interest to biologists as it is in the unique 
position of being a structure that develops almost exclusively in the adult. The 
gland is a feature unique to mammals and its prime purpose is to synthesise and 
secrete milk for the nourishment of mammalian young. Scientific interest in the 
mammary gland arises from two fronts. The mammary epithelial tree is a site of 
neoplastic transformation and therefore is of great interest to cancer biologists. 
Normal development of the gland is of interest to developmental biologists as the 
mammary gland is a tissue that has the ability to undergo successive rounds of 
proliferation, differentiation, and apoptosis. It is therefore one of the few tissues in 
which questions relating to all three of these processes can be addressed. 
Determination of the cellular pathways through which this process of organ growth 
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and differentiation occurs may lead to a better understanding of why the mammary 
gland has such a high neoplastic transformation potential. 
1.2 Mammary Gland Morpholoay 
1.2.1 Embryonic Development 
The functional and structural development of the mammary gland can be 
divided into distinct stages. These include fetal growth, growth of the gland at 
puberty, development of the gland during pregnancy and lactation, and involution 
of the gland following weaning (Figure 1.1). Although the major part of gland 
development occurs during pregnancy the organ is already formed in the embryo. 
Embryonic development of the gland is influenced by steroid hormones and signals 
from the surrounding mesenchyme. In mouse embryos the anlage of the mammary 
gland is visible at around day 11.5. This develops into a small epithelial bud on day 
12.5 which increases in size slowly until it reaches the resting period (day 15.5). At 
day 16 a primary sprout begins to grow into the mammary fat pad precursor tissue. 
Mammary rudiments form in both sexes, but by day 14 in male embryos the 
mammary mesenchyme condenses around the epithelium and causes detachment of 
the gland from the epidermis. This process is associated with massive necrosis in 
the epithelium and this destruction is driven by androgens (Kratochwil, 1977). 
Ceriani (1970) demonstrated that embryonic rat mammary glands (day 16) had the 
potential to respond to lactogenic hormones in culture. These glands were seen to 
express a casein-like material e.g. a phosphoprotein which comigrated with casein. 
Two tissue compartments are involved in mammary development: the parenchyma 
which is the epithelial component, and the stroma composed of connective tissue 
elements. These two compartments are separated by a basement membrane that 
consists of extracellular matrix materials (Imagawa et al., 1990). Morphogenesis of 




Figure 1.1 Whole Mount Sections of Murine Mammary Gland. Whole 
mammary gland from virgin, pregnant. lactating, or involuting mice were fixed and 
stained to show the developing mammary glands in these mice. This figure was 
obtained from the Biology of the Mammary Gland Web Page 
(http:\\.mammaiy.nih.gov). 
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and epithelial-mesenchymal interactions have been observed during embryonic 
development. The gland interacts with two different types of mesenchyme: a 
mammary mesenchyme surrounding the epidermal bud which contains steroid 
receptors, and the future fat pad which consists of preadipocytes. At birth in the 
mouse the mammary free consists of up to 20 branches. 
1.2.2 Postnatal Development 
In postnatal life the mammary parenchyma consists of lumina surrounded by 
single or multiple layers of epithelial cells with a basal layer of myoepithelial cells. 
The luminal epithelium is specialised for the synthesis and secretion of milk 
proteins and is organised into structures called ducts, terminal end buds (TEB), 
alveoli and lobules. Major ducts serve as channels and reservoirs for the milk 
during lactation. Terminal end buds are specialised groups of cells at the ends of 
ducts that function as the sites of cell proliferation in the growing gland (Figure 
1.2). Alveolar cells, present in resting adult glands and during pregnancy, are the 
prime components of milk synthesis during lactation. The clusters of alveoli 
developing during the later stages of pregnancy are called lobules. Myoepithelial 
cells form an almost continuous sheath around the major ducts and contract in 
response to oxytocin during lactation. This results in the alveoli releasing milk into 
the mammary ducts (Pitelka, 1978). 
The extent of mammary gland growth between birth and puberty is limited 
to a low level of ductal elongation and branching. The growth rate of the mammary 
gland at this stage is comparable to the overall growth of the animal. Accelerated 
ductal growth commences with the start of puberty and it is at this stage that 
terminal end buds are first observed. The terminal end buds are specialised 
structures at the end of the growing ducts. They consist of two distinct cell types, 
the body cells that give rise to mammary epithelial cells, and the cap cells which are 
the precursor of myoepithelial cells. This pattern of growth continues until the 
constraints of the fat pad are met, and at this stage the proliferative rate is 
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Figure 1.2 Mammary Gland Terminal End Bud. This is represented by a section 
through the terminal end bud of the gland. The relative positions of the cap and body 
cells are shown. The cap cells differentiate to give rise to the myoepithelial cells. 
The terminal end bud is surrounded by a basal lamina composed of fibroblasts and an 
outer layer of adipocytes. This figure was taken from the Biology of the Mammary 
Gland Web page (http:\\mammary.nih.gov). 
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significantly reduced (Williams and Daniel, 1983). In mice mammary gland growth 
plateaus at around 5 to 6 months of age. At this stage DNA synthesis is observed 
only within the alveolar cells suggesting that this is the renewing cell population in 
the adult. Following puberty mammary gland growth results in a highly branched 
ductal system. Variations in mammary epithelial cell proliferation have been 
observed during the oestrous cycle. In general the most rapid DNA synthesis 
occurs during diestrous when the glands are the least developed (Bresciani, 1971). 
1.2.3 Development During Pregnancy 
The most dramatic changes observed in the mammary gland occur following 
the onset of pregnancy. Profound cell proliferation occurs where the interductal 
spaces seen in the virgin are gradually filled due to increased branching and 
lobuloalveolar development. Cell division during pregnancy occurs within both the 
alveolar and ductal cell populations. Maximal rates of division are observed early 
in pregnancy, around day 5 of gestation, the stage of implantation of the embryo 
(Bresciani, 1971). Proliferation within these cellular compartments continues 
throughout pregnancy and also during early lactation. Terminal differentiation of 
alveolar epithelial cells is completed at the end of gestation and this process results 
in the onset of milk secretion at parturition. Distinct steps of cellular differentiation 
take place during pregnancy and lactation and are defined by the sequential 
activation of milk protein genes. Low levels of milk proteins can be detected in 
virgin mice during oestrous and their activation increases dramatically during 
pregnancy. WDNM1 mRNA increases in early pregnancy (day 5), which is 
following by an increase in 13-casein mRNA around mid pregnancy (day 10). WAP 
mRNA is known to be expressed in the later stages of pregnancy (day 15) and a-
lactalbumin mRNA is expressed just prior to parturition (Robinson et aL, 1995). 
The activation of these milk protein genes can be used as markers of the early 
proliferation of the gland (WDNIM1), the commencement of differentiation ((3-
casein), terminal differentation (WAP), and the attainment of a secretory ability (a- 
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lactalbumin). 
The ability to produce milk is the primary characteristic which divides 
mammals from any other class of species and allows birth to occur at a relatively 
early stage of development. At parturition a series of changes occurs which 
transform the alveoli into a fully secretory state. The majority of the studies in 
lactogenesis have been performed on ruminants and these have divided this process 
into two stages. The initial stage occurs during pregnancy when the gland is 
sufficiently differentiated to secrete small quantities of milk components, such as 
casein and lactose. This early secretion product is called colostrum. The second 
stage of lactogenesis is defined by the onset of copious milk secretion at parturition. 
It is triggered by a decrease in circulating levels of progesterone and a maintainance 
of prolactin concentrations (Linzell and Peaker, 1971). Removal of the milk from 
the alveoli is achieved by contraction of the myoepithelial cells surrounding the 
alveoli and ducts. The composition of milk varies dependent on the species 
examined. In rodents the major milk proteins are the caseins and whey proteins. a-
and f3-casein are involved in micelle formation which act to transport minerals 
within milk. The whey proteins are ct-lactalbumin and whey acidic protein (WAP). 
The exact function of WAP is unclear at present but the correct temporal expression 
is a prerequisite for differentiation of the mammary gland (Burdon et al., 199:1). a-
lactalbumin is a calcium metalloprotein which is involved in lactose synthesis. 
1.2.4 Gland Remodelin 
Following lactation the mammary gland undergoes a remodeling stage 
called involution which results in a restructured gland. Involution is characterised 
by a co-ordinated process of alveolar programmed cell death (apoptosis) and 
lobular-alveolar remodelling. This is an extremely rapid process and in rodents the 
mammary gland can be restructured completely within a few days following the 
initiation of apoptosis. The triggers for involution have not yet been identified but 
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potential candidates are the removal of lactogenic hormones induced in response to 
suckling, and an accumulation of apoptosis-inducing factors in the unsuckled milk 
such as TGFI3 related molecules (Streuli et al., 1997). Involution of the mammary 
gland occurs in two distinct phases. The initial phase involves the apoptosis of 
alveolar cells. This apoptotic process start at around day I after weaning, peaking 
on day 3 and is followed by a subsequent decrease in the rate of apoptosis. The 
apoptotic process is characterised by a number of morphological changes. These 
commence with a loss of cell junctions and other specialised plasma membrane 
structures such as microvilli. At the same time the nuclear chromatin condenses 
and divides into one or several large masses at the nuclear periphery. The nucleolus 
disaggregates and the nuclear membrane adopts internal folds. The nucleus may 
subsequently split into several fragments. Membrane blebbing then follows and the 
cell ulimately breaks down into apoptotic bodies which are phagocytosed by 
neighbouring cells (Wyllie et al., 1980). The apoptotic process is a relatively short 
reaction, which in vitro was shown to occur in approximately one hour. Apoptosis 
is not restricted to the involution period of gland development. Humphreys and co-
workers (1996) have observed a significant rate of apoptosis in the body cells of the 
terminal end bud. A spacial restriction of apoptosis was shown to occur suggesting 
that apoptosis may fbnction to maintain the structure of the terminal end bud and 
also play a role in the formation of the duct in the developing mammary gland. 
During the second stage of involution the lobular-alveolar structure of the gland is 
destroyed as matrix degrading metalloproteinases degrade both the basement 
membrane and stromal ECMs. Both of these stages of involution are characterised 
by changes in gene expression or activity. The net result of this process is a 
replacement of most of the epithelial cells by adipose tissue and a gland which is 
morphologically very similar to that observed in the virgin animal. 
An essential feature of the mammary gland is its ability to regenrate a 
functional epithelium following cycles of lactation and involution. This would 
suggest that progenitor or stem cells exist within the gland. It is well documented 
that any part of the mouse mammary epithelial tree upon implantation into a cleared 
fat pad can reproduce a function mammary gland with the correct structures present. 
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Williams and Daniels (1983) demonstrated a population of undifferentiated cells 
present in the outer layers of the developing TEB. These cells, the cap cells are 
thought to be one type of stem cell present in the mammary gland. Recently 
Kordon and Smith (1998) have demonstrated that an entire functional mammary 
gland can be produced from a single cell. The experimental model involved 
infecting mammary epithelial cells with mouse mammary tumour virus and 
performing serial transplantation of clonally derived outgrowths. Second 
generation glands were observed to contain the same viral insertion sites providing 
evidence for self-renewal of the original stem cell. This study estimated that a 
single mammary epithelial stem cell may have the capacity to produce 
approximately 1012_1013  multipotent, proliferation-competent offspring before 
reaching proliferative senescence. These observations suggest that mutations in this 
stem cell population may be responsible for early manifestations of malignancy and 
for this reason are of great interest to the study of mammary gland development. 
1.3 Experimental Manipulation of the Mammary Gland 
The following sections describe in detail some of the effects specific genes 
have on mammary gland development. The mammary gland undergoes the vast 
majority of its growth postpubertally and this enables experiments on development 
to be performed on juvenile or adult glands. The following is a brief description of 
the three major technologies using to study mammary gland development. Defined 
amounts of growth factors have been mixed with ethylene/vinyl acetate copolymer 
to produce a hard pellet, which can then be surgically implanted in small pieces 
(<1mg) directly in front of the growing ductal tree (Daniels et aL, 1972). This 
method when combined with morphometric analysis can be used to determine the 
response of specific cell or tissue types to the administered factors. Recent 
advances by Edwards and colleagues (1996) have utilised transplantation 
methodologies to determine the effects of overexpressing a particular gene of 
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interest on gland morphogenesis and proliferation. Using this method the gene of 
interest is introduced into primary cultures of mammary epithelial cells using a 
retroviral vector. These cells are then transplanted into a cleared mammary fat pad 
where they reform the epithelium. Some of these cells will subsequently express 
the introduced gene. Insights into development can be examined by inappropriate 
expression of genes using this method. It is also particularly useful in examining 
the neoplastic changes caused by the introduction of a single oncogene. Tissue 
specific transgenic or knockout mice have been generated using the promoters of 
milk protein genes. In particualr the WAP promoter and the promoter of the ovine 
milk protein gene, j3-lactoglobulin (BLO) have been used extensively. This 
approach directs overexpression of the gene of interest specifically to the mammary 
epithelium where the effects of a particular gene can be examined. This is 
particularly useful when the gene of interest may cause embryonic defects when 
deleted or overexpressed in the whole animal. In some cases when a transgenic 
animal is produced, if the animal is compromised due to this gene disruption then 
very little mammary tissue exists. This is mainly due to loss of fat from the gland 
and complicates examination of any mammary gland phenotype. Directing 
expressing to the mammary gland itself overcomes some of these problems. More 
recently a number of systems have been described which allow inducible expression 
or deletion of a gene. These include the tetracycline system (Gossen a al., 1995) or 
the Cre-Lox system (Lakso et al., 1992, Pichel a al., 1993). The major advantage 
of these systems is that they allow the effects of disruption or deletion of a specific 
gene to be examined at a particular stage of development. They are particularly 
useful when the gene to be examined is known to be essential for embryonic 
development. Expression of the mutated gene later in development allows the 
effects of the gene to be examined in the developed animal. These technologies 
have been developed in part due to the uniqueness of the gland and have provided a 
basis for specialised approaches to study developmental, neoplastic and functional 
studies in the mammary gland. 
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1.3.1 Hormonal Regulation of Mammary Gland Development 
1.3.1.1 Oestrogen 
The role that systemic hormones play on mammary gland development has 
been recognised for some time. More recently the availability of transgenic mice 
has identified the precise roles that these hormones play in vivo in mammary gland 
development. Oestrogen has been described as playing a major role in ductal 
elongation in the gland. The observation that ductal outgrowth was greatly 
accelerated during pregnancy led to this suggestion but more conclusive proof was 
obtained when mice deficient in the oestrogen receptor (ER) a gene were produced 
(Korach et at, 1996). Analysis of the mammary glands of females with this 
deletion at 4 months of age revealed the presence of a primitive ductal rudiment 
devoid of TEBs, whereas a fully developed ductal free was observed in wild-type 
siblings. Mammary transplantation experiments revealed that ductal outgrowth was 
dependent on the presence of ER in the stroma but not in the epithelium. The data 
from these mice suggested that although ER are detected in both the epithelial and 
stromal compartments of the mammary gland, epithelial morphogenesis induced by 
oestrogen is a stromal mediated event and that the epithlial ER is not necessary for 
oestrogen induced mammary epithelial proliferation (Cunha et at, 1997). 
1.3.1.2 Progesterone 
Progesterone functions in preventing lactogenesis by maintaining high 
circulating levels until just prior to parturition. Females lacking progesterone 
receptors (PR) show more severe reproductive defects than the ER deficient mice. 
Due to this the effects of progesterone on mammary development was studied on 
ovariectomised PR deficient animals by giving exogenous oestrogen and 
progesterone. The addition of both of these hormones to control animals resulted in 
extensive arborization of the ductal free and some alveolar development, whereas 
this was virtually absent in the PR deficient mice (Lydon et at, 1995). The function 
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of the PR is mainly linked to the epithelium in contrast to the ER, which exerts its 
effects through the stroma. 
1.3.1.3 Growth Hormone 
Slow release implants of growth hormone (OH) have also been shown to 
regulate TEB and ductal growth (Dembinski and Shin, 1987). Indeed the 
stimulation of mammary development at puberty is a OH dependent event. This 
OH effect is thought to be mediated through insulin-like growth factor-i (IGF-1), 
produced in the stromal compartment (Kleinberg, 1997). A synergistic action 
between IGF-i and oestrogen results in TEB development. Growth hormone 
receptors are members of a large haematopoietin receptor superfamily. These 
receptors, which include the prolactin receptor, signal through a series of tyrosine 
kinases to stimulate transcription of target genes. This signalling pathway will be 
described in detail for the prolactin receptor. 
1.3.1.4 Prolactin 
Prolactin was first purified in 1933 and has been shown to regulate gonadal 
and behavioural functions, and it also exerts multiple effects on the immune system 
(Henninghausen et al, 1997). The best characterised role that prolactin plays is in 
the proliferation and functional differentiation of lobulo-alveolar structures in the 
mammary gland during pregnancy and to stimulate lactogenesis. These properties 
are mediated through the activation of genes involved in growth control and 
differentiation. In additional to the role prolactin plays in the differentiation of the 
mammary gland, a mitogenic role has been described. Prolactin is synthesised in 
the lactotrophic cells of the anterior pituitary. Its signalling pathway is described in 
section 1.4.1. The establishment of the prolactin pathway has come from details 
elucidated from mice deficient in some of these components. Deletion of the 
prolactin gene results in ductal arborization in adult virgins suggesting a role in 
ductal morphogenesis during puberty (Horseman et aL, 1997). As prolactin 
deficient mice do not ovulate the effect observed may be indirect. Females with 
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only one intact prolactin receptor allele fail to lactate after their first pregnancy 
(Ormandy et aL, 1997). This suggested that epithelial proliferation and 
differentiation during pregnancy requires a threshold level of prolactin receptor 
which cannot be obtained with just one functional allele. Mammary gland 
development in these mice was normal in any subsequent pregnancies suggesting 
that continued hormonal stimuli leads to a functional gland. It is currently unknown 
whether other growth pathways can compensate for a decreased prolactin receptor 
population. 
1.3.1.5 Oxytocin 
Oxytocin is a hormone that acts to regulate parturition and lactation. It 
induces the contraction of myoepithelial cells surrounding the alveoli and thus 
induces milk ejection. Oxytocin knock-out mice were shown to be fertile and able 
to deliver pups, but the pups died within 24 hours due to lack of milk. This could 
be reversed with an exogenous injection of oxytocin which restored milk ejection in 
response to suckling. These mice show a partial involution during lactation despite 
suckling and the presence of lactogenic hormones (Wagner et al., 1997). These 
studies suggested a role for oxytocin in post-partum milk ejection and also alveolar 
cell proliferation. 
1.3.2 Growth Factor Regulation of Gland Development 
1.3.2.1 Transforming Growth Factor Beta 
The transforming growth factor 13 (TGF13) family play a role in mammary 
development. TGF13 is a secreted growth and differentiation factor that exists in 
three different isoforms. It exerts a range of biological functions that are dependent 
on the target cell. Interaction of TGF(3 with its cell surface receptors results in 
29 
either a stimulation or inhibition of cell proliferation. Its antiproliferative effects 
are best documented on epithelial cells, whereas the stimulatory activity affects 
mainly cells of a mesenchymal origin such as fibroblasts. TGFP has also been 
observed to effect cell differentiation, which is thought to be related to its ability to 
modulate cell interaction with the extracellular matrix. TGFI3 is widely expressed 
during development and its biological activity has been implicated in epithelial-
mesencymal interactions e.g. in branching morphogenesis of the lung, kidney and 
mammary gland (Silberstein and Daniel, 1987; Robinson et al., 1991 and Rogers et 
aL, 1993). All three TGFI3 isoforms are expressed in the mammary gland although 
their expression patterns overlap in both the epithelial and mesenchymal 
compartments. Exogenous TGFf3 was observed to inhibit both the formation and 
growth of ductal buds and to stimulate production of extracellular matrix. 
Overexpression of active TGFI3I in the mammary glands of transgenic mice 
resulted in the formation of a hypoplastic ductal tree (Pierce et at., 1993). This was 
further evidence in support of a role for TGFJ3 in regulation of the ductal tree. In 
vitro studies on mammary epithelial cells treated with exogenous TGFJ3 resulted in 
the induction of an epithelial to fibroblastic transdifferentiation (Miettinen et at, 
1994). The effect observed was reversible and the change in cell morphology 
correlated to a loss of epithelial markers and an increase in expression of 
mesenchymal markers. Silberstein and colleagues (1992) observed that the 
periductal ECM acts as a TGFJ3 1 reservoir. Their studies revealed that TGF1 was 
acquired, maintained, and lost from this compartment during ductal growth and 
morphogenesis. 
1.3.2.2 Inhibins and Activins 
The inhibins and activins are also members of the TGFP superfamily. To 
date three types of activins, activin A (J3A(3A), activin B (13BJ3B),  and activin AB 
(13A13B) and two types of inhibins, Ilk (inhibin A) or f3B (inhibin B) have been 
described. Activins and inhibins were first identified as gonadal factors which 
influence the production of follicle stimulating hormone in the pituitary. 
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Subsequently they have been shown to play roles in neuroendocrine regulation and 
also modulate luteotrophic hormone, growth hormone and adrenocorticotrophic 
hormone production. Mice deficient in the inhibin 13B gene have no activin B or 
AB activity as well as a loss of inhibin B activity. These mice show retardation of 
ductal elongation and alveolar morphogenesis during puberty and pregnancy 
respectively (Robinson and Henninghausen, 1997). Mammary transplantation 
experiments have revealed this defect in development to be linked to the stroma. 
An abnormal morphology of TEBs was observed in the J3B mice which implied the 
defect was due to a disruption in the balance between cell proliferation and cell 
death in the TEB. Although the j3B deficient mice contain less mammary tissue 
than their wild type siblings, the alveolar epithelial cells displayed a differentiated 
phenotype compatible with milk protein gene transcription. The expression of 
WAP and f3-casein during late pregnancy and lactation was similar in the IIB 
deficient mice to that seen in the wild type littermates (Robinson and 
Henninghausen, 1997). It was proposed that these proteins have a paracrine mode 
of action on the mammary gland and this was further supported by observations in 
mice carrying a PA mutation. These mice have malformations in the secondary 
palates and an absence of teeth and whiskers, all of which depend on epithelial-
mesenchymal interactions (Matzuk et aL, 1995). The exact mechanism through 
which inhibins and activins exert their effect on the mammary gland is not yet clear 
but there is some suggestion that they may be local mediators of hormonal signals. 
1.3.2.3 Transforming Growth Factor Alpha and Epidermal Growth Factor 
Transforming growth factor a (TGFa) has also been implicated in the 
growth of the mammary gland. TGFa is a secreted growth factor that binds to the 
same receptor as epidermal growth factor (EGF), and it acts as a potent mitogen for 
several cell types. TGFa promotes the proliferation and formation of 
lobuloalveolar structures in the mammary gland. Dickson and colleagues (1986) 
suggested that TGFct may be involved in local control of the growth and 
development of the mammary gland by acting as an intermediate in the action of 
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steroid hormones. The EGF-like growth factors and receptors are predominantly 
associated with breast cancer e.g. elevated levels of TGFct is seen in 70% of all 
breast cancers. Transgenic mice expressing mutant TCIFa were observed to be 
fertile but did not lactate sufficiently to support a lifter. Adult virgin mice displayed 
alveolar gland hyperplasia. Pregnant transgenics showed a marked proliferation of 
stromal cells and an increase in alveolar secretion when compared to wild type 
littermates. These mutant mice subsequently developed adenocarcinomas following 
multiple pregnancies (Matsui et at, 1990). Mating of the TFGct and TGFI3 
transgenic mice revealed that these growth factors oppose the action of each other 
during mammary gland development. The effects that EGF exerts on mammary 
gland development have been studied using EGF containing pellets. Implantation 
into the mammary gland of ovariectomised mice revealed that EGF binding was 
restricted to the cap cells of the end buds, the ductal myoepithelium and the stroma 
surrounding the ducts and end buds (Coleman et at, 1988). This resulted in end 
bud stimulation and the growth effects of EUF were observed to be synergistic 
when combined with TGFct (Vonderhaar et at, 1987). 
1.3.2.4 Colony Stimulating Factor-1 
Colony stimulating factor 1 (CSF1) is a homodimeric growth factor 
originally identified in the regulation of proliferation, survival and differentiation of 
mononuclear phagocytes. It also plays an additional role in maternal-fetal 
interactions during pregnancy. A natural mutant, op (osteopetrosis) exists in the 
gene encoding CSF1. The major phenotype of these mice is the absence of 
functional osteoclasts and a failure in tooth eruption, but lactation is also severely 
compromised. Reduced ductal growth during pregnancy was observed together 
with the precocious development of lobules. An absence of milk secretion was also 
observed in the op mice (Pollard and Henninghausen, 1994). These mice revealed a 
previously unsuspected role for CSF1 in mammary development. CSF1 was 
observed to play a role in the regulation of branching morphogenesis during mid 
pregnancy and also be involved in the switch to lactation. The precise mechansim 
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by which CSF1 regulates these functions is presently unknown. It is unclear 
whether CSF 1 exerts its effects within the mammary gland by directly affecting 
alveolar epithelial cell growth, or whether CSF1 affects gland development through 
the macrophages resident in the mammary gland. A third possibility exists that 
CSF1 affects another tissue, which produces a hormone or growth factor that acts to 
regulate mammary gland development e.g. the placental trophoblasts. This latter 
explanation fits best with the observation that exogenous administration of CSF 1 to 
op/op mice cannot restore the lactation defect. The very high concentrations of 
CSF1 found in the utero-placental unit during pregnancy cannot be mimicked by 
systemic administration. 
1.3.2.5 Insulin-like Growth Factor 
Insulin-like growth factors (IGF) have been observed to play a role in gland 
development. Overexpression of IGF1 and the IGF binding protein 3 (IGFBP3) 
during late pregnancy and lactation was observed to have no effect on gland 
development and lactation. In contrast to this there was a delayed involution in 
these animals. Extensive lobulo-alveolar units remained in these mice and 
apoptotic cells were rare within these structures (Neushwander et aL, 1996). These 
results demonstrated a role for IGF 1 and IGFBP3 in the involution process in the 
mammary gland. Overexpression studies with IGF2 were observed to generate 
mammary adenocarcinomas (Bates et aL, 1995). 
1.3.3 Cell Cycle Regulation of Mammary Gland Development 
A number of proteins involved in the control of the cell cycle have been 
demonstrated to be elevated in a high proportion of human malagnancies. This has 




Transgenic mice overexpressing a non-degradable form of cyclin A during 
pregnancy and lactation have been produced. Cyclin A is a protein that functions 
during S phase of the cell cycle. These mice appeared to lactate normally and have 
no obvious defect in lobuloalveolar or ductal development, but they displayed an 
increased rate of apoptosis and nuclear abnormalities including karyomegaly and 
multinucleation. In contrast to this mice overexpressing the cyclin dependent 
kinase 2 (cdk2), which functions with cyclin A during S phase, were observed to 
have normal mammary glands. When these mice were mated and double transgenic 
animals produced, a more pronounced phenotype was observed than with either 
alone. The female mice displayed nuclear abnormalities, similar to the cyclin A 
transgenics but they showed an increased apoptosis. The apoptosis rate observed 
was four fold higher than that observed when mice overexpress cyclin A alone. 
These double transgenics had an impaired lobuloalveolar development and 
occasionally displayed lactational problems suggesting that cyclin A and cdk2 act in 
synergy to regulate mammary gland development during pregnancy (Bortner and 
Rosenberg, 1995). 
1.3.3.2 Cyclin E 
The 1) and E type cyclins are involved in regulating the progression of the 
cii phase of the cell cycle. Alteration of cyclin E expression has been associated 
with breast cancers. Overexpression of cyclin E in the developing secretory 
epithelium of the gland results in a hypeqilastic lactating gland (Bortner and 
Rosenberg, 1997). Ten percent of these transgenic mice further developed 
mammary adenocarcinomas suggesting deregulation of this protein can indeed 
induce neoplastic transformation of the mammary gland. 
1.3.3.3 CyclinD 
Aberrant expression of cyclin Dl, like cyclin E, has been associated with 
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breast cancer as well as a variety of other human malignancies. Cyclin Dl 
knockout mice develop to term but have reduced body size and a reduced viability. 
They also display neurological impairment and a retinal defect. Of the few 
homozygous mice that survive to adulthood, these develop mammary tissue that has 
the capacity to fully differentiate but these females are unable to nurse their pups 
due to a defect in pregnancy associated mammary proliferation. The phenotype 
displayed is a dramatic impairment of the expansion of the mammary epithelium, in 
particular the development of alveolar lobules in virtually absent in these mutant 
mice (Sicinski et at, 1995). It is well documented that the proliferation observed in 
early pregnancy is a steroid driven event and the results obtained from the cyclin Dl 
knockout mice have suggested that this event may be driven by cyclin Dl. 
1.3.3.4 Tumour Suppressor Protein 1)53 
The tumour suppressor protein p53 is implicated as a mediator of apoptosis 
in a wide range of tissues. It is involved in the cellular response to DNA damage. 
p53 functions to initiate a cell cycle arrest during which the cell can repair the 
damaged DNA and re-enter the cycle (Lane, 1992), or if the damage is excessive 
p53 can mediate an apoptotic response. Although this pathway is functional in the 
mammary gland the apoptotic response observed during involution was shown to be 
p53 independent (Li et at, 1996). Knockout mice for p53 displayed no difference 
in involution when compared to control mice. These results suggested that 
apoptosis of the mammary alveolar cells and the collapse of lobulo-alveolar 
structures progressed independently of p53 function. 
1.3.3.5 Temperature Sensitive Simian Virus 40 Antigen 
Transgenic mice expressing the temperature sensitive simian virus (SV40) 
Tag in the mammary gland have been produced. Tag binds to p53 and the 
retinoblastoma protein (pRb) thereby inactivating them. As both of these proteins 
have a critical function in regulating the cell cycle their effect on mammary 
development was analysed using the 5V40 Tag mouse. These mice were unable to 
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nurse their young at the first pregnancy due to an impairment in alveolar 
development. As a result the fat pad of these mice was not completely filled during 
pregnancy. An increase in apoptosis (5% compared to 0.2% in wild-type mice) was 
observed during late pregnancy in these transgenics and the mice did not develop 
mammary tumours until they had progressed through 3 to 5 pregnancies (Li et at, 
1996). These studies demonstrated that p53-independent apoptotic pathways exist 
within the mammary gland and that activity of the pRb protein is a pre-requisite for 
a functional mammary gland. 
1.3.4 Fatty Acid Regulation of Gland Development 
1.3.4.1 Adipocytes 
The importance of epithelial-mesenchymal interactions in the mammary 
gland have been displayed in mice carrying a deletion in either the TGFI3 or inhibin 
gene. Adipose tissue has also been demonstrated to be of prime importance in the 
regulation of epithelial cell growth. In vitro coculture systems have shown that 
extraparenchymal adipose tissue produced both substrate and soluble factors which 
had the capability to stimulate epithelial cell growth. When mammary epithelial 
cells were cultured with adipocytes a duct-like morphogenesis occurred along with 
the formation of a basement membrane (Wiens et aL, 1987). These cells were able 
to functionally differentiate when grown in the absence of collagen gels. The role 
of lipid stores in fat cells was examined further and revealed that unsaturated fatty 
acids, linoleic acid in particular, could stimulate the proliferation of mammary cells. 
Saturated fatty acids in contrast were inhibitory to growth (Wichs et at, 1979). 
Linoleic acid was further reported to stimulate growth only in synergism with 
another growth promoting factor, such as EGF. Kidwell and colleagues (1982) 
proposed that a hormonal mechanism was driving this fat cell stimulation. It was 
hypothesised that prolactin could cause fatty acid release from the fat cells 
promoting fatty acid uptake by the epithelium, which itself may promote mammary 
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epithelial tree growth. What is clear from these studies is that fat cells have the 
capability of exerting a regulatory influence on the growth potential of the epithelial 
component of the mammary gland. 
1.3.5 Extracellular Matrix Regulation of Mammary Gland Development 
The ECM is an important component of the cellular environment. It is 
composed of glycoproteins, proteoglycans and glycosaminoglycans that are 
secreted and assembled locally. These organise into a network to which cells 
adhere. The mammary gland epithelial and mesenchymal components are separated 
by a basement membrane (BM). The BM is the major structure of the ECM with 
which the mammary epithelial cells have direct physical contact. It consists of four 
ubiquitous components: laminin, entactin, type IV collagen and perlecan, a heparin 
sulfate proteoglycan. The other ECM components of the mammary gland are 
located predominantly in the stroma and include type I and III collagens, and ECM 
glycoproteins such as fibronectin (Lochter and Bissell, 1995). The BM functions in 
controlling normal development by positively regulating genes necessary for 
morphogenesis and differentiation and negatively regulating expression of genes 
which would compromise tissue specific function. Both laminin, required for milk 
protein production (Streuli et c-iL, 1991), and collagen, essential for epithelial 
morphogenesis (Lee et all, 1985) have positive effects on mammary gland 
development. ECM binding by growth factors e.g. TGF[3, can function as a local 
store of growth factor that can persist after the growth factor production has ceased. 
Some ECM proteins contain intrinsic growth factor activity. This is achieved by 
repeated EGF-like sequences. These include the ECM protein laminin, the activity 
of which is localised to the EGF-like domain. Presently it is unclear whether 
laminin acts through the EUF receptor as well as integrin receptors. The effects that 
ECM proteins have on epithelial cells are mediated by specific receptors. The 
integrins are the best characterised of the ECM receptors and are heterodimeric 
proteins that are classified into subgroups according to their P subunit. The ligand 
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specificity of these receptors has been observed to be cell type specific e.g. the 
a1j31 integrin acts as a collagen receptor in platelets, but is both a collagen and 
laminin receptor in endothelial cells (Hynes, 1992). Most integrins are expressed 
by a variety of cell types, although some such as the (32 group have a more limited 
tissue distribution. Targeted disruption of integrin genes are generally lethal 
demonstrating that one integrin carries out an essential function than no other 
integrin provides. 
1.3.5.1 Matrix Metalloproteinases 
The matrix metalloproteinases (M?vIPs) and their inhibitors, the tissue 
inhibitors of metalloproteinases (TIMPs), are major regulators of ECM catabolism 
in mammalian cells. MMPs are generally secreted as inactive multidomain 
proenzymes, which are cleaved by a mechanism as yet unknown to form an active 
enzyme. The MtvlPs function predominantly during involution when major 
remodeling is required. Expression of MMPs remains low at day 3 after weaning, 
whereas TIMP1 was upregulated at this time shifting the proteolytic balance in 
favour of inhibition. At day 4 involution an upregulation of mRNA and protein 
levels of the protelytic enzymes gelatinase A, stromelysini and the serine proteinase 
urokinase-type plasminogen activator (uPA) has been observed. This correlated to 
a downregulation of the inhibitor TIMPI which results in an active tissue 
remodeling and destruction of the basement membrane (Lund et aL, 1996). The 
expression of these ECM regulating proteins correlates with the two stages of 
involution observed within the mammary gland. The mammary gland also displays 
a significant amout of proteinase activity during virgin gland development and 
pregnancy, stages where ECM remodeling is required. Mice overexpressing 
stomelysini (SLI) show profound changes in mammary gland function. In virgin 
mice this results in a premature branching morphogenesis, differentiation and 
hyperproliferation. These mice are predisposed to forming mammary gland 
tumours. During pregnancy the epithelial cells undergo an unscheduled apoptosis. 
This is thought to be a consequence of SLI initiating degradation of the basement 
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membrane. This degradation induces apoptosis by inducing expression of the 
caspase interleukin- 1 f3 converting enzyme (ICE), a protease involved in the 
terminal events during apoptosis. When SL1 is overexpressed during lactation the 
mammary glands contain smaller collapsed alveoli and resemble an early involution 
phenotype (Sympson et at, 1994). These results suggested a role for SL-1 in 
regulating stromal-epithelial interactions in the gland. Transgenic mice 
overexpressing TIMP-1 showed a delay in alveolar development early in 
pregnancy. By late pregnancy no discernible difference was observed between 
TIMP-1 overexpressing and wild-type mice. Lactational development was similar 
to control glands but fatty infiltration was accelerated during involution (Alexander 
et at, 1996). The involution process was itself slightly delayed in these mice. 
Crossing TIMP-1 transgenic mice with SL-1 transgenic mice was observed to block 
the premature involution observed during pregnancy with ectopic SL-1 expression. 
1.3.5.2 Glucocorticoid Effects on Mammary Gland Development 
Glucocorticoids are thought to act as survival factors in mammary epithelial 
cells. Hydrocortisone pellets implanted in the mammary gland have little effect on 
the first stage of involution but completely inhibit the second remodelling stage, 
despite being added 3 days following weaning. (Lund et at, 1996). 
Dexamethasone, as well as progesterone, have been shown to inhibit involution in 
the mammary gland. The function of the transcription factor AP-1 was observed to 
be impaired when mammary glands were exposed to dexamethasone (Feng et at, 
1995). Many of the genes which are upregulated during involution e.g. SL-1, uPA, 
c-jun and sulphated glycoprotein-2 (SGP-2) have been shown to contain AP-1 
response elements within their promoter regions suggesting that dexamethasone 
exerts its inhibitory effects on involution by preventing the expression of the 
necessary MIMPs. These results suggest that in vivo gene expression of MMPs is 
under hormonal control. Manipulation of this class of proteins in vivo has 
demonstrated the requirement for a critical balance between the ECM-degrading 
proteinases and their inhibitors. This has revealed the role the ECM plays in the 
regulation of epithelial cell function and morphology during mammary gland 
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development and involution 
1.4 Signalling Pathways in the Mammary Gland 
1.4.1 Prolactin Signalling 
The signalling pathway of prolactin was made accessible by the cloning of 
the prolactin receptor in 1988 (Boutin et at, 1988). It is a transmembrane receptor 
which belongs to the cytokine receptor superfamily. Alternative spliced products 
exist resulting in receptors which have either long or short cytoplasmic tails. Both 
forms of this receptor can bind prolactin and dimerise activating the Janus Kinase2 
(Jak2), Fyn, and mitogen activated protein (MAP) kinase. In vitro work has shown 
that only the long form of the prolactin receptor can activate the transcription of the 
milk protein gene, 0-casein. (Das and Vonderhaar, 1995). Activation of Jak2, 
situated on the box region near the membrane of the prolactin receptor results in 
phosphorylation of two Stat proteins, Stat5a and Stat5b in the case of prolactin. 
Tyrosine phosphorylation of the Stat proteins results in dimerisation and 
translocation to the nucleus where they induce transcription of genes containing y-
interferon activation sites (GAS) [Figure 1.3]. 
Stat5a and Stat5b have a 96% similarity and display an identical pattern of 
expression during pregnancy and lactation. It was thus expected that Stat5a and 
Stat5b deficient mice would display similar phenotypes. Stat5a deficient mice were 
unable to lactate due to the failure of the gland to develop fully and to undergo 
functional differentiation during pregnancy (Lui et at, 1997). Statsb levels and 
phosphorylation in these mice were greatly reduced suggesting that Stat5b requires 
the presence of Stat5a for efficient phosphorylation. The mechanism underlying 
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Figure 1.3 Prolactin Signalling Pathway. Prolactin binding to its receptor results 
in phosphorylation of Jak2, which in turn phosphorylates Stat5. This results in Stat5 
dimerising and translocating to the nucleus where it binds y-interferon sites (GAS) 
and activates transcription of its target genes e.g. milk protein genes. At present it is 
assumed that integrin signalling also interacts with this pathway but the exact 
signalling components are unknown. 
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necessary to achieve and maintain a state of cell differentiation, which itself may be 
a pre-requisite for fill Stat5b activation. In contrast to this Stat5b deficient mice 
displayed a different phenotype where liver gene expression and growth rates were 
affected. The fertility in these mice was severely compromised (Udy et at, 1997) 
but the mice which were able to mate maintained their pregnancies, delivered 
normal litters and could lactate. Both promoters of the milk protein genes of WAP 
and j3-casein contain GAS sites, but only WAP gene expression was reduced in 
Stat5a deficient mice suggesting that the regulation of 13-casein gene expression is 
controlled by other transcription factors. Although work from in vitro studies on 
the signalling pathways of Stat5a and Stat5b described them to be indistinguishable, 
in vivo these proteins may have distinct functions or conversely the relative amount 
of each protein may be the determining factor. 
1.4.2 LAR Signalling 
An additional signalling pathway that has been disrupted and shown to 
display a mammary phenotype is the LAR pathway. LAR is a protein tyrosine 
phosphatase (PTPase) which signals via the LAR receptor to function in regulating 
tyrosine phosphorylation through either cell-cell or cell-matrix interactions. LAR 
has a broad tissue distribution and its expression is regulated during pregnancy. 
Expression is maximal on day 16 gestation in wild type mice. LAR knockout .mice 
have been observed to display no obvious phenotypes with the exception of a 
mammary gland abnormality. These mice are unable to produce milk due to an 
impaired terminal differentiation at late pregnancy. This failure to terminally 
differentiate results in a inability to switch to the lactation state and the mammary 
glands of these mice display a rapid involution postpartum (Schaapveld et at, 
1997). These observations would suggest that LAR mediated signalling plays an 
important role in mammary gland development and function. 
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1.5 Mammary Gland Overview 
The development of the mammary gland requires the sequential activiation 
of a variety of hormones, growth factors, transcription factors, and ECM 
components at specific stages in gland development. This complement of factors, 
when activated correctly results in a functional gland expressing milk proteins in the 
lactation period following pregnancy. Most of the work that has lead to the 
assignment of gene function in gland development has arisen from transgenic or 
knockout mice. Although these mice were useful in detailing an absolute 
requirement for a gene product, they gave no information pertaining to the time 
window in which the particular gene was required. The introduction of new 
technologies allowing time specific, tissue specific gene deletion or inactivation 
systems e.g. Cre-mediated gene deletion systems (Wagner et al., 1997, Lakso et al., 
1992, Pichel et al., 1993) and tetracycline mediated gene expression systems 
((Jossen ci al., 1995) should provide new opportunities to examine specific 
windows of gene expression. The information available on mammary gland 
development to date may yet be revealed to be an oversimplified view of this 
developmental process and new technologies may further enhance our 
understanding of this unique organ. 
The aim of this study was to use the technique of differential display in an 
attempt to identify genes that showed altered patterns of expression during 
pregnancy in the murine mammary gland. We chose to examine gene expression 
during pregnancy with particular relevance to specific stages of development e.g. 
day 5 gestation marks the peak of proliferation in the gland, day 10 gestation marks 
the onset of differentiation, and day 15 gestation marks terminal differentiation. As 
part of this work I identified a gene which functions as part of a protein degradation 
pathway. The following sections describe this pathway of protein degradation in 
detail. The revelance of proteolysis to mammary gland development will be 
discussed later. 
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1.6 Proteolytic Pathways Within the Cell 
In the late 1930s Schoenheimer, using isotope tracer techniques, was the 
first to show that proteins within an animal are in a dynamic state, being 
continuously synthesised and degraded. The early progress in proteolysis research 
was hampered by technical hurdles but work in the last 20 years has demonstrated 
that the system responsible for the majority of intracellular degradation is the 
ubiquitin-proteasome system. The development of a cell-free lysate from rabbit 
reticulocytes in the 1970s allowed the biochemical dissection of this pathway to 
begin (reviewed in Hershko and Ciechanover, 1992). This initial work identified 
that ubiquitin conjugation of the substrate was an essential feature of degradation. 
At the same time the study of proteasomes was initiated but the connection with 
ubiquitin dependent proteolysis was not realised until 1987 when a protease capable 
of degrading ubiquitinated protein conjugates was purified (Hough et aL, 1987). 
Within mammalian cells two distinct proteolytic pathways can be identified. 
Proteins which enter the cell from the extracellular environment e.g. receptor 
mediated endocytosed proteins, are degraded by lysosymes. Lysosomal 
degradation of intracellular proteins occurs only under conditions of stress. 
Although lysosomes are important degradative organelles most of their proteolysis 
is relatively non-specific. The vast majority of intracellular degradation that occurs 
is mediated by the ubiquitin-proteasome pathway. This complex is involved in the 
selective turnover of proteins under basal metabolic conditions. Other proteolytic 
enzymes exist within cells e.g. the ICE-like proteases, which are crucial for 
apoptosis, and the calpains. Although systems other than the proteasome exist 
evidence suggests that these secondary systems are limited in either their range of 
substrates or under the conditions in which they are functional. 
Cells are often required to switch from one cellular state to another in 
response to environmental signals or as part of regulated developmental pathways. 
Switches of this manner require rapid dismantlement of existing regulatory 
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networks, which are often dependent on protein degradation. Selective proteolysis 
offers two main advantages over other possible control mechanisms. It is a fast 
process which enables a cell to rapidly reduce the level of a defmed protein and it is 
also an irreversible process, ensuring complete loss of protein function with no 
chance of inappropriate reactivation. These features help explain why selective 
protein degradation plays a prime regulatory role in systems which rely on timing 
controls. The specificity of protein degradation must be extremely high as 
degradation of proteins at inappropriate times would have serious consequences to 
the cell. 
1.6.1 The ubiguitin-proteasome pathway 
Conjugation to ubiquitin is an essential step in the degradation of many 
short-lived eukaryotic proteins. The pathway for proteasome mediated degradation 
is shown in figure 1.4. Initially ubiquitin must be activated prior to addition to the 
substrate. Adenylation of ubiquitin is mediated through a ubiquitin activating 
enzyme, El. This reaction generates a ubiquitin-El thiolester which is 
subsequently passed onto an ubiquitin-conjugating enzyme, E2. E2 enzymes 
function either alone or in conjunction with an ubiquitin-protein ligase, E3 to 
catalyse substrate ubiquitination. The ubiquitinated substrate is then subject to 
further rounds of ubiquitination, ubiquitin removal by deubiquitinating enzymes or 
degradation by a multicatalytic protease, the 26S proteasome. The proteasome 
functions to degrade ubiquitinated proteins to short peptides, most of which are 
rapidly hydrolysed to amino acids by cytosolic endopeptidases. A portion of the 
peptides generated by the proteasome are presented to the immune system on the 
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Figure 1.4 Ubiquitin-Proteasome Degradation Pathway. Native proteins are 
ubiquitinated by a three enzyme cascade (El-E3), which results in ubiquitin linkage 
to a lysine residue on the protein. Further ubiquitin molecules are linked to the first 
one, forming a chain of ubiquitin on the protein. These chains are recognised by the 
26S proteasorne, where the ubiquitin bonds are cleaved by an isopeptidase and the 
substrate is unfolded by an ATPase, all located in the 19S cap or regulatory complex. 
The degraded peptides generated by this complex are either degraded into their 
constituent amino acids or are presented as antigenic peptides on MHC class I 
molecules. 
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1.6.2 Protein Ubiguitination 
The prime step which determines whether a particular protein will be 
degraded by the proteasome is its modification by ubiquitin. This reaction is 
catalysed by a series of enzymes. Although a wealth of information has been made 
available recently on this proteolytic system, the precise mechanism by which 
ubiquitin transfer is achieved remains poorly understood. The ubiquitin-proteasome 
system is a highly conserved pathway that is very similar in species as distant as 
yeast and mammals. For these reasons I shall describe the system utilised by the 
yeast Saccharyomyccs cerevisiae as the genome of this organism is now filly 
sequenced. 
1.6.2.1 Ubiguitin Activating Enzyme (El) 
The initial stage in targeting a specific protein for degradation is the 
activation of ubiquitin. Ubiquitin is a 76 amino acid protein which is highly 
conserved and present in all eukaryotes. It has been shown to be essential for cell 
viability (Finley ci aL, 1994). Activation of ubiquitin involves the formation of an 
El-ubiquitin thiolester. El has been purified from a variety of sources and was 
demonstrated to exist as a homodimer of 210kDa. Two further El enzymes have 
been cloned in yeast, wheat and humans (Table 1.1). These genes have been shown 
to highly conserved in evolution e.g. the human and yeast proteins are 53% 
identical (Hershko and Ciechanover, 1992). El proteins contain two short stretches 
of amino acids which resemble a nuclear localisation signal, in addition to regions 
which are characteristic of nucleotide binding proteins. Conditionally lethal alleles 
of El-encoding genes have been isolated in mammalian cell lines, and a gene 
encoding yeast El, UBA 1 was found to be essential for growth (Ciechanover, 
1994), whereas another, UBA2 is required for viability (Dohmen ci aL, 1995). The 
hypothesis held with regard to the three distinct El enzymes suggests that each of 
these enzymes may prefer a specific set of E2 enzymes or that they may reside in a 
particular cellular compartment thus the requirement for more than one enzyme 
exists. 
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Protein Size (kDa) Function 
Ubal 114 Essential for viability. Forms thiolester 
with ubiguitin 
Uba2 71 Essential for viability. 	Predominantly 
nuclear in expression 
Uba3 33 Function unknown. 
Table 1.1 S. cerevisiae El enzymes. 
1.6.2.2 Ubiguitin Conjugating Enzyme (E2) 
Ubiquitin is transferred from the El enzyme to an E2 enzyme by the process 
of transthiolation. These proteins subsequently mediate the transfer of ubiquitin to 
the substrate protein with or without the involvement of an ubiquitin-protein ligase 
(E3). Examination of rabbit reticulocyte lysates revealed the presence of multiple 
E2 isoforms and genetic analysis has confirmed that these proteins are encoded by a 
family of related genes. In yeast 13 E2 related enzymes have been identified and 
these are listed in Table 1.2. Structurally these proteins all contain a core of 
approximately 150 amino acids which display 35% sequence homology. The active 
site cysteine residue that is required for the formation of the thiol ester with 
ubiquitin is found in this domain. Some of the E2 enzymes that have been 
identified are small 14-18kDa proteins that consist almost exclusively of this 
conserved domain. Other enzymes have C-terminal extensions which are either 
neutral e.g. Ubcl, or highly acidic e.g. Ubc4, Ubc5 and Ubc7. Mutational analysis 
of E2 enzymes have shown a range of phenotypes exist (Table 1.2) suggesting that 
these enzymes have different functions or that they display distinct substrate 
specificities. Multiple E2 enzymes have been shown to be required for the 
degradation of one substrate. The best example of this is the yeast MATct2 
transcriptional repressor. Four E2 enzymes are involved in the degradation of this 
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protein. Ubc6 and Ubc7 have been shown to complex and function in one pathway 
for a2 degradation (Chen et aL, 1993). Mutants lacking either one of these 
enzymes display distinct phenotypes suggesting that these proteins can act 
independently in the degradation of other substrates. Analysis of in vitro protein 
ubiquitination has suggested that there may be some redundancy within this group 
of enzymes. Any one of three different E2 enzymes can ubiquitinate the tumour 
suppressor protein p53 in vitro. During mitosis cyclins are also ubiquitinated by a 
number of E2 enzymes, the only difference between these proteins being that some 
enzymes produce fewer ubiquitin-conjugated molecules than others. Whether this 
overlay in function occurs in vivo is yet to be elucidated. 
1.6.2.3 Ubiciuitin-Protein Liase (E3 
The component of the ubiquitin conjugation system that is most directly 
involved in substrate recognition is E3. Two species of E3, E3a and E313 were 
initially isolated from reticulocyte extracts. E3cz is the most thoroughly studied of 
these enzymes and it was first described as an enzyme necessary, in addition to El 
and E2 for the ligation of ubiquitin to specific proteins (Hershko et aL, 1983). E3 
enzymes promote the addition of multiple ubiqutins to the substrate protein and are 
also involved in the formation of polyubiquitin chains. Purification of the enzyme 
revealed that E3a existed as a homodimer which contained sites which recognised 
N-terminal residues of the substrate (the N-end rule, which will be discussed in 
section 1.6.3.1). The enzyme has two distinct sites, one which recognises basic 
residues whilst the other recognises hydrophobic N-terminal residues (Reiss et aL, 
1988). The signals responsible for the binding of acidic amino termini to E3cz 
remain unclear as yet. This class of enzymes also contains a site which binds E2 
enzymes in addition to ubiquitin. It is hypothesised that the ubiqutin site might be 
required for the addition of multiple ubiquitin chains to the 
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Protein Size (kDa) Function 
Ubcl 24 Essential in the absence of Ubc4 and UbcS. 
Endocytosis of membrane proteins 
Ubc2IRad6 20 DNA Repair, induced mutagenesis, and N-
end rule pathway 
Ubc3/Cdc34 34 Essential 	for viability, 	01/S 	phase 	cell 
cycle progression 
Ubc4 16 92% identical to JibeS. Functional overlap 
with UbcS 
UbeS 16 Degradation of abnormal protein, MATa2 
and ubiquitin-fusion proteins 
Ubc6/Doa2 28 Degradation of MATa2. 	Localised to 
endoplasmic reticulum/nuclear envelope. 
Ubc7 18 Functional overlap with Ubc6. 
Ubc8 25 No phenotype found in null mutant. 
Ubc9 18 Essential for viability 
02/Mitosis cell cycle degradation 
Ubc 1 0/Pas2 21 Peroxisome biogenesis 
Ubcll 17 Function unknown 
Ubc 12 21 Function unknown 
Ubcl3 18 Function unknown 
Table 1.2 S. cerevisiae E2 Enzymes. The human homologues of these enzymes 
are named Ubch. 
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substrate. The yeast homolgues of these proteins are listed in Table 1.3. Although 
the properties of E3 (x described above have been attributed to this class of enzyme, 
distinct groups of E3 ligases exist. Studies on p53 degradation by the human 
papilloma virus protein E6 have revealed a new E3 protein, E6 associated protein 
(E6-AP). E6-AP, together with E6 binds p53 and stimulates its degradation. The 
E6-AP/E6 complex has not been shown to bind any E2 enzymes. Despite this E6-
AP can transfer ubiquitin from E2 to the substrate protein suggesting that it must at 
least transiently interact with E2 enzymes (ScheiTher et aL, 1995). The C-terminal 
350 residues of E6-AP show sequence similarity to a number of proteins in a range 
of organisms and has been named the HECT domain (homologous to E6-AP 
carboxyl-terminus). The HECT domain contains an absolute conserved cysteine 
residue essential for ubiquitin thoiolester formation and substrate ubiquitination. 
Five different HECT domain proteins have been identified in yeast, some of which 
are essential for viability. Ubr2 has been identified in sequence as similar to Ubri 
(22% identical) although to date no data has been published on Ubr2. The 
cyclosome/anaphase promoting complex (APC) has properties that suggest it may 
function as an E3. APC is composed of three subunits, none of which have 
homology to any known E3s, and is involved in catalysing the degradation of cyclin 
B in control of cell cycle progression. Although to date there is no clear mechanism 
defining the function of an E3 enzyme it seems highly probable that a number of 
additional E3-like factors will be identified in the near future. 
The successive action of the El to E3 enzymes results in the formation of 
isopeptide bonds between the c-amino groups of lysine residues in the substrate and 
the carboxyl-terminal glycine residues of ubiquitin. Branched polyubiquitin chains 
are formed by the sequential addition of monomers of ubiquitin to lysine 48 of the 
substrate bound ubiquitin (reviewed in Ciechanover, 1994). 
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Ubri -Related 
Ubrl/Ptrl 	 1 225 	 Degradation of N-end rule substrates 
Ubr2 	 217 	Not determined 
Hect-Domain Proteins 
Rsp5/Npil 	 92 	 Essential for viability. Forms a 
thiolester with ubiquitin 
lJfd4 	 168 	Degradation of ubiquitin fusion 
proteins 
Tomi 	 374 	 Essential for viability. Irigger Of 
Mitosis 
Hct4 	 103 	 Not determined 
168 	 1 Not determined 
Table 1.3 S. cerevisiae E3-like Proteins. Potential E3-like proteins that are less 
well characterised are not listed. Additional E3-like proteins exist in humans e.g. 
E6-AP, and APC. 
1.6.2.4 Deubiguitinating Enzymes 
The vast majority of the research on the ubiquitin conjugation system has 
focused on the enzymes which attach ubiquitin to proteins but more recently the 
regulatory events that control protein deubiquitination has become of prime 
importance. M essential step in the function of this system is the recycling of free 
ubiquitin. Ubiquitin is cleaved from substrates by a group of enzymes known as 
deubiquitinating enzymes, ubiquitin carboxyl-terminal hydrolases, or ubiquitin 
isopeptidases. In vitro studies have revealed that these enzymes can be classified 
into two major groups; small proteins which cleave ubiquitin from peptides and a 
group of larger proteins which can generally cleave ubiquitin from a range of 
protein substrates. The majority of work has focused on the later class of protein, 
which are also known as ubiquitin specific proteases (11bps). The Ubp family of 
enzymes is large, with 16 enzymes identified in S. cerevisiae (Table 1.4). The 
family is extremely divergent but all members of the family contain a short 
n 
consensus sequence. This sequence is composed of cysteine (Cys) and histidine 
(His) boxes which are thought to form the active site of the enzyme. The high 
number of deubiquitinating enzymes identified has suggested that these enzymes 
can differentially control protein turnover rates. The possibility also exists that 
Ubps can display a degree of substrate specificity and that they may be expressed in 
different cellular compartments. Yeast mutants in a range of 15bps have been 
observed to display very little phenotypic aberrations suggesting that a degree of 
redundancy exists in this class of enzymes. Evidence in support of a substrate 
specific modulation of degradation was gained from studies of a Ubp in Drosophila, 
the fatfacets (fáj) gene. Huang and colleagues (1995) have shown the fafgene was 
required for normal eye development, and that embryos from homozygous mutant 
mothers died at an early stage in development. Mutations in the conserved Cys and 
His boxes in Faf show identical effects as those flies containing null mutations. 
These studies have suggested that it is the deubiquitinating activity of Faf that is 
critical to its biological function. Huang has shown that Faf functions to reverse the 
ubiquitination of specific proteins thus preventing their degradation by the 
proteasome. Mutations in components of the 20S proteasome were observed to 
reverse the defect seen infafflies. The murine homologue of this gene (Fam forfat 
facets in mouse) has been demonstrated to be widely expressed during 
postimplantation development. This suggested that Fain was not associated with a 
single developmental event (Wood et aL, 1997). 
It is hypothesised that Ubps function to alter the balance between the rates 
of ubiquitination and deubiquitination and thus act as negative regulators of the 
ubiquitin system. 15bps can function in several ways to enhance protein 
ubiquitination or degradation. These enzymes are required to generate ubiquitin 
monomers. Ubiquitin is synthesised as a precursor protein which requires the 
action of 15bps to remove C-terminal amino acids. Activated ubiquitin can itself 
form adducts with intracellular nucleophiles e.g. amines or glutathione. This 
process could consume the pool of free ubiquitin very rapidly if they were not 
immediately broken down. Long ubiquitin chains are assembled on intracellular 
proteins and in some situations this can result in the inappropriate tagging of a 
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protein. Ubps in this system can function to prevent the inappropriate degradation 
of proteins resulting in a highly selective degradation system. Proteasomes and E3 
enzymes can bind ubiquitin chains and these need to be quickly disassembled to 
prevent inhibition of proteasomes. A variety of evidence now exists for a number 
of different types of deubiquitinating enzymes. An editing ubiquitin isopeptidase 
has been described within the 19S cap complex of the proteasome. The enzyme is 
though to function in two manners: to shorten polyubiquitin chains to facilitate 
translocation of the substrate towards the proteolytically active sites of the 
proteasome, and to deubiquitinate the substrate which may be essential for the 
complete degradation of the substrate (Lam et al., 1997). This editing Ubp may 
also function to release partially degraded proteins from the complex e.g. for the 
proteolytically processed NFiB precursor p105. Mammalian isopeptidase T (isoT), 
which is the functional homologue of yeast Ubpi4, exclusively acts on unanchored 
ubiquitin chains. Yeast mutants lacking Ubp14 have defects in ubiquitin mediated 
degradation of a number of substrates and show an accumulation of unanchored 
ubiquitin oligomers (Hadari et aL, 1992). The phenotype displayed by the yeast 
Ubp14 mutant could be reversed by expression of human isoT. The observation 
that ubiquitinated species accumulated in yeast cells carrying certain Ubp mutants 
e.g Ubp14 and Ubp4 was of surprise initially. It was expected that these mutations 
would show no alteration in degradation due to the high number of Ubp enzymes. 
These results suggested that the Ubp enzymes may exert a very high substrate 
specificity or as an alternative theory that these ubiquitinated species accumulate in 
cellular compartments where they are inaccessible to the majority of Ubps. Work in 
mammalian systems have described a regulatory function for Ubps. The human tre-
2 oncogene (yeast homologue Ubp4) is an inactive form of a deubiquiting enzyme 
that is tumorigenic. The deregulation of growth observed in tre-2 mutant cells may 
be attributed to a failure to degrade short-lived peptides which are essential for cell 
proliferation (Papa and Hochstrasser, 1993). DUB-i is a murine Ubp which is an 
erythroid cell specific, immediate early gene induced by interleukin 3 (IL-3). 
Mutants in DUB-i show a GI cell cycle arrest suggesting a growth regulatory role 
for this Ubp (Zhu et al., 1996). A vast number of deubiquitinating enzymes have 
been described recently and our current knowledge of these enzymes and their 
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Protein Size (kfla) Function 
Ubp 1 93 Cleaves ubiquitin protein fusions. 	No phenotype 
reported for mutant 
Ubp2 145 Cleaves ubiquitin protein fusions. 	No phenotype 
reported for mutant 
Ubp3 102 Cleaves ubiquitin protein fusions. 	No phenotype 
reported for mutant 
Ubp4/Doa4 105 Degradation 	of 	ubiquitin 	system 	substrates. 
Maintenance of ubiquitin pools. 	Mutant has slight 
growth defect. 
UbpS 92 Cleaves ubiquitin protein fusions. 	No phenotype 
reported for mutant 
Ubp6 57 Not determined 
Ubp7 123 Cleaves ubiguitin protein fusions. Mutant is viable 
Ubp8 54 Mutant has a slight growth defect 
TJbp9 86 Cleaves ubiguitin protein fusions. Mutant is viable 
Ubpl OIStr4 90 Mutant has a defect in chromatin-mediated gene 
silencing 
Ubpll 83 Not determined 
Ubpl2 143 Not determined 
JJbpl3 84 Not determined 
Ubpl4 91 Degradation of MATt2 and other proteins. 	Cleaves 
ubiquitin oligomers with free C-terminus in vivo and in 
vitro 
Ubpl 5 143 Mutant has slight growth defect 
Ubpl6 57 Not determined 
Yuhl 26 Cleaves ubiquitin from small adducts. No phenotype 
reported for mutant 
Table 1.4 S. cerevisiae Deubiquitinating Enzymes. 
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catalytic complex. This can be joined on either end by a 195 regulatory complex or 
an 11 S-activator complex. This results in two different types of proteasome present 
within the cell, a 20S-19S complex (also called the 26S proteasome) and an 20S-
ii. S complex. The following sections describe the structure and function of each of 
the three possible components of an active proteasome. 
1.6.4.1 The 205 Proteasome 
The 20S core proteasoine contains all of the catalytic activity of the 26S 
proteasome. It was originally identified by electron microscopy as a ring-like 
structure which was interpreted as a side-on view of a cylindrical particle (150A in 
height and I bA in diameter) composed of four stacked rings, with each ring being 
composed of 7 subunits. These particles were shown to be 700kDa protein 
complexes composed of 14 subunits with sizes ranging from 19 to 36kDa. The vast 
majority of the early research on proteasome structure was obtained from studies 
using the archeon Therinoplasma acidophilum. The T. acidoph i/urn proteasome has 
been observed to be structurally highly similar to proteasomes from higher species. 
This proteasome is composed of 4 stacked rings that are derived from two related 
subunit types, a and P. The a subunits form the outer two heptameric rings and the 
0 subunits the inner rings giving a 007070 structure. In yeast there are 14 genes 
which encode subunits of the 20S proteasome and these can be grouped into seven 
a-type and seven 13-type subunits (Tablel.5 and Table 1.6). All of these subunits 
are closely related in sequence to the a or 13 subunits in Thermoplasma. Sequence 
similarity also exists between the a and 0 subunits suggesting that all proteasome 
subunits were derived from a single ancestral gene early in evolution which has 
been confirmed by phylogenetic analysis (Hughes, 1997). 
Of the seven a-type subunits identified all but one are required for viability 
in yeast. These subunits are characterised by three conserved a-boxes, which are 
located within the N-terminal two-thirds of the proteins. A highly variable C-
terminus is the region that confers specificity to the seven different a subunits. 
Several of these subunits contain sequences which resemble tyrosine kinase or 
cAMP/cGMP dependent kinase phosphorylation sites. Four of the mammalian (X-
type subunits have been observed to contain nuclear localisation signals (NLS), and 
work performed on a Drosophila a subunit has confirmed that these NLS are 
functional (Knuehl et at, 1996). The mode of nuclear localisation is unclear at 
present but it has been hypothesised that regulation of the phosphorylation state of 
the a subunits may allow the NTIS to become accessible when the proteasome is 
required to function in a nuclear capacity. Mason and co-workers (1996) have 
identified two phosphorylated a subunits in rat proteasome adding support to this 
hypothesis. It was shown that the elimination of a NTIS in one of the a subunits 
could not be compensated for by the activity of another subunit. Although the NLS 
is functional it was not seen to be able to promote complete nuclear translocation 
suggesting that the subunits are subject to an additional control mechanism to 
determine cellular location. Two subunits (Pre 6 and Pre 10) have been observed to 
contain KEKE motifs suggesting that these proteins function in interacting with 
other proteins. As these two a subunits are neighbours it has been suggested that 
they may form the point of association with the regulatory complex (Kopp et at, 
1997). 
The 3-type subunits differ from the a-type subunits as they are less 
conserved between each other. They also lack the conserved N-terminal a-box 
domain found in the a subunits. In mammals three additional non-essential 13 
subunits can be found. LMP2, LMP7, and MECL1 can replace constitutive 
components of the proteasome (X, Y, and Z subunits) when stimulated by the 
cytokine interferon-y (IFN-y). Mice carrying deletions of the LMP2 or LMP7 genes 
show a mild phenotype with altered cleavage properties of the 20S proteasome and 
an impairment in MJ{C Class I antigen presentation (Stohwasser et at, 1996). Five 
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Protein Size (kDa) Function 
Sell 28 Unknown 
Doa5IPup2 29 Required 	for 	sporulation, 
degradation of ubiquitinated 
proteins 
PreS 26 Unknown 
Pre6 28 Unknown 
Pre8 27 Point mutation can be suppressed 
overexpression 
Pre9 29 Only 	non-essential 	20S 
proteasome subunit 
PrelO 32 Unknown 
Table 1.5 8. cerevisiae 20S Proteasome a subunits. 
of the seven f3-type subunits were found to be synthesised as proproteins, from 
which the propeptides were cleaved as the proteasome matured. The role that these 
prosequences play seems to differ between archaebacteria and eukaryotes as the 
prosequences are not required in archaebacteria for proteasome assembly. In yeast 
the Doa3 13 subunit propeptide was seen to be required for Doa3 incorporation into 
the proteasome (Chen and Hochstrasser, 1996). The propeptide has been suggested 
to have a chaperone-like function. This sequence was observed not to be required 
for proteasome assembly but was an absolute requirement for maturation of specific 
subsets of active sites. The 20S proteasome is a threonine protease and its active 
sites lie within the central core of the 20S complex. Processing of the f3 subunits 
generates the N-terminal active sites which can cleave peptides following 
hydrophobic residues (chymotrypsin-like activity), basic residues (tryspin-like 
activity), and acidic residues (peptidylgiutamyl peptide hydrolysing [PGPHII 
M. 
activity). Three of the 0 subunits contain active site threonines in comparison to a 
single active site in T. acidophilum. Genetic studies in yeast have suggested that 
co-operation is required between the 0 subunits to generate the active sites. These 
have shown that mutations are required in two subunits for loss of one particular 
cleavage activity (Kopp etal., 1997). For example in yeast Prel and Pre2 are both 
required for chymotyrpsin-like activity, Pupi and Pup3 for trypsin-like activity 
(Arendt and Hochstrasser, 1997), and Pre3 and Pre4 for PGPH activity. Each of the 
active 0 subunits contains a hydrophobic pocket that is thought to be the substrate 
binding pocket as it binds peptide aldehyde inhibitors of the proteasome. 
Prel 	 23 	 Degradation of ubiquitinated proteins. 
Required for cleavage after hydrophobic 
residues 
Pre2fDoa3/Prg 1 	23* 	 Functional overlap with Pre 1. Has an N- I I 	active threonine site 
Pre3 	 21* 	 Essential for viability and degradation of 
ubiquitinated proteins. Predicted to have 
an N-terminal active threonine residue. 
Pre4 	 126** 	 I Functional overlay with Pre3 
Pre7 	 1 25** 	 I Unknown 
Pupl 	 254* 	 Predicted to have an N-terminal active 
threonine residue. 
23 
Table 1.6 S. cerevisiae 20S Proteasome 13 subunits. Additional three subunits 
(LMP2, LMP7, and MECL1) present in human proteasome are not listed. * 
represents the size of the processed 13  subunit, and ** represents the size of protein 
after predicted processing. 
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The 20S proteasome is assembled as immature precursor complexes of 13S 
or 16S. The a subunits and unprocessed f3 subunits are present in the 13S 
complexes and these can be processed to directly generate the 20S complex. The 
16S complex represents the predominant proteasome precursor population and is 
again composed of a subunits with unprocessed 3 subunits. A chaperone protein, 
hsc73 has been found associated with the 16S complex and is thought to function in 
keeping the complex in a functional conformation (Scbmidtke et at, 1997). There 
is some evidence to suggest that the a subunits form the framework for the correct 
assembly of the 0 subunits. The a subunits may also affect the proteolytic activities 
of the complex. A yeast mutant of the a subunit PrelO has been observed to have 
an effect on cleavage ability (Emori et at, 1991). The generation of a precursor 
complex is thought to prevent the formation of proteolytically active sites until the 
central hydrophobic chamber has been sealed from the rest of the cell. 
The resolution of S. cerevisiae 20S proteasome crystal structure at 2.4A has 
revealed the structure of this complex. In T. acidoplilum two sites of entry into the 
central proteolytic channel can be found. These are approximately 13A in diameter 
and thought to be of a diameter that an unfolded protein could pass through. In 
contrast to this the proteolytic chamber of the yeast 20S proteasome has been 
observed to be inaccessible. Groll and colleagues (1997) observed that the N-
termini of 5 a subunits project into this opening filling it completely in several 
layers. No access is available to the interior of this complex without subunit 
rearrangement. There are smaller side windows present at the interface between the 
a and 13 subunits which may be permeable to unfolded polypeptide chains. These 
openings are approximately 1 OA in size and are surrounded by charged residue side 
chains. This observation has revealed a distinct structural difference between the T. 
acidophilum proteasome and the eukaryotic proteasome and has led to an alteration 
in the assumed method of peptide entry into the chamber. The studies were 
performed on purified 20S proteasomes and the effects that the regulatory or 
activatory complexes exert can only be guessed. It seems reasonable to assume that 
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as these complexes promote acceleration in peptide degradation and antigen 
processing that they may function to open up the entry pore of the proteasome in 
viva 
1.6.4.2 The 19S Cap or Regulatory Complex 
In vivo the 20S proteasome has been observed to function in completely 
breaking down proteins in an ATP-independent manner if the protein is first 
denatured. This complex is unable to degrade stably folded proteins and requires 
the addition of an ATP-dependent regulatory complex (RC) to attain this function. 
Given this observation it seems logical to assume that the function of the RC is to 
act in unfolding proteins. The RC is positioned in trans on either end of the 20S 
proteasome and generates the 26S proteasome. It is also a multiprotein complex 
which is composed of at least 15 subunits (Table 1.7). Functionally this complex 
has been compared to the E. coil proteases, CIpAP and CIpXP. CIpA and ClpX are 
ATP-dependent activators of the CIpP protease. These proteins form a complex 
that displays some similarity to the 26S proteasome e.g. a central catalytic protease 
CIpP surrounded on either end by an ATP-dependent activator CIpA or ClpX. In 
the absence of ClpP, C1pA and ClpX function as chaperones to disassemble 
multisubunit proteins. These chaperones are thought to act in such a way as to alter 
protein activity, or if coupled to a protease, destroy the protein (reviewed in 
Gottesman, 1989). 
Six of the components of this complex are members of a family of related 
ATPases and this accounts for the ATPase activity observed with the RC. These 
proteins are members of the AAA family (ATPases Associated with a variety of 
cellular Activities) which are characterised by a highly conserved module of 230 
amino acids present in one or two copies in each protein. The proteins within this 
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family show extensive sequence conservation despite the fact that they display a 
very diverse range of cellular functions. These range from cell cycle expression, 
gene expression in yeast and the human immunodeficiency virus (HIV), vesicle 
mediated transport, peroxisome assembly, and 26S proteasome function 
(Confalonieri and Duguet, 1995). The six proteasomal AlPases all contain a single 
conserved domain or ATPase module. Structurally this functional domain is highly 
conserved e.g. approximately 65% identical between these proteins. Two potential 
nucleotide binding sites are found within this region. The order of nucleotide 
preference of the proteasome is ATP>CTP>UTP>GTP (Hoffman and Rechsteiner, 
1996b). It has been established that all four nucleotides can support conjugate 
degradation although only ATP and CTP can promote assembly of the complex. 
The C-terminal region of the ATPases are also highly conserved in contrast to the 
N-terminal which is more divergent in sequence. This region of the protein is 
thought to confer the substrate specificity on the protein (Dubiel et at, 1992). The 
ATPases within the proteasome are thought to function in unfolding the substrate in 
readiness for journey through the catalytic core of the complex. They also provide 
the energy to drive the degradation process although this function could be achieved 
by a single ATPase. At present it is unclear why so many ATPases are associated 
with the proteasome. They may function in providing alternative binding sites for 
particular substrates or they may have functions additional to protein denaturation 
which have yet to be discovered. It is assumed that a single 26S proteasome 
complex contains equal amounts of each ATPase, but work from Manduca sexta 
has described an upregulation of a particular subset of ATPases during programmed 
cell death (Dawson et at, 1994). These workers suggested that multiple 
populations of 26S proteasomes exist within the cell each containing different 
ATPase subunits. To date there is little evidence to support this hypothesis and the 
major assumption from biochemical purification studies is that each RC contains all 
six ATFases. 
Protein Size (kDa) Function 
Sugl/Cim3 45 ATPase subunit. 	Required for 021M cell 
cycle progression and for the degradation of 
ubiguitinated proteins. 
MSS1/Cim5 52 ATPase subunit. 	Required for G2/M cell 
cycle progression. 
Sug2/Crl 13 49 ATPase subunit. May play a transcriptional 
role 
TBP1/Ytal 48 ATPase subunit. May play a transcriptional 
role 
TBP7/Yta2 48 ATPase subunit. May play a transcriptional 
role with TBP1. 
S4IYta5 49 ATPase subunit. Required for 02/M cell 
cycle progression and for the degradation of 
ubiguitinated proteins. 
Nini 32 Essential for viability and degradation of 
ubiquitinated proteins. Important for nuclear 
integrity. 
Sen3 104 Essential for viability and degradation of 
ubiguitinated proteins. 
Nasl/llrd2 109 Low level of similarity to Sen3. 
Suni 30 Ubiquitin 	chain 	binding 	(S5a) 	subunit. 
Deletion mutant is viable. 
Sun2 60 Essential for viability 
Nas2 25 Non-essential subunit. 
Nas3 38 Similar to mouse Mov-34 gene product. 
Table 1.7 S. cerevisiae Regulatory Complex subunits. At least one component of 
the mammalian 26S proteasome (S5b) is not encoded in the yeast genome. 
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Of the non-ATPase subunits identified S5a ( or SUN-i in yeast) is the best 
studied. This protein has been identified as the component of the complex that 
binds multiubiquitinated proteins. S5a binds only to multiubiquitinated chains and 
not to free ubiquitin. A highly conserved element within this subunit is thought to 
represent the sequence that binds ubiquitin chains (Ferrell ci at, 1996). Little 
information on the function of the remaining non-ATPase subunits of the RC is 
available. Si or SEN3 in yeast, has been identified as a gene which encodes a 
factor affecting the tRNA splicing endonuclease system (Dubiel ci at, 1995). This 
would suggest that the 26S proteasome may function in some manner in RNA 
metabolism. Nm-I in yeast has been identified as S14 and is shown to be essential 
for cell viability (Kominami ci at, 1995). Mutation of Nm-i results in an 
accumulation of ubiquitinated proteins and cells arrested at GuS and G2I1\4 
transition stages. This work suggested that Nm-i interacted with the cdk CDC28 in 
S. cerevisiae. The precise function of the remaining proteins of this complex are 
unknown at present but it seems highly probable that they serve to recognise 
substrates within this complex. 
1.6.4.3 The 115 Activator Complex 
Not all 20S proteasomes are assembled into a 265 proteasome complex, 
some assemble with an 11 S activator complex, or PA2 8. Evidence suggests that 
both of these proteasome complexes coexist within cells. Each of these complexes 
serves specific ftinctions: the 265 complexes perform the housekeeping functions 
e.g. ubiquitin dependent protein degradation. The 205 or 20S-1 15 proteasomal 
complexes have been shown to cleave low molecular mass peptidic substrates such 
as degradation intermediates. The 20S and 20S-11S complexes have been shown to 
be inefficient in degrading whole proteins and also ubiquitinated proteins 
(Rechsteiner ci at, 1993). The 115 activator is an 1 8OkDa complex which is 
mainly composed of two homologous subunits, a and ft More recently a third 11 S 
subunits has been identified. A third protein, y or Ki antigen, has been identified as 
homologous to the a and 13  subunits. All three of these proteins show a high degree 
of sequence similarity apart from a highly variable internal segment of 17-34 amino 
acids which may function to confer subunit specific properties (Aim et at, 1995). 
The a and f3 subunits preferentially form a hexameric complex with alternating 
subunits. Purified a subunits can form heptamers in solution which have 
biochemical properties similar to the aI0 complex but it is unclear whether this 
occurs in vivo. The y subunit also generates a hexameric ring structure which can 
associate with the 205 proteasome in vitro. At present it is unclear why two types 
of i IS complexes are present in cells and what the functions of these individual 
complexes are. 
To date the cL'13 complex is the most widely understood of the 115 activator 
complexes. Song and co-workers (1997) have demonstrated that one particular 
residue on the a subunit is required for binding to and activation of the proteasome. 
Mutations in the carboxyl-terminal tyrosine residue abolished any activity the a 
subunit displayed previously, a subunit binding to the proteasome and activation of 
this complex have been shown to be separate events. Analysis of a number of 
mutant a proteins have identified a loop and a neighbouring proline residue on one 
face of the a subunit to be critical for proteasome activation (Zhang a at, 1998). 
In humans the proteasome a subunit C2 contains an epitope which binds to the 11 S 
activator complex. Blocking antibodies have been observed to only partially block 
115 activation therefore it seems likely that additional sites are important for 
activator binding and activity (Kania a at, 1.996). 13 subunits alone have been 
observed to display no stimulatory effect on proteasome activity but this complex 
did function in reducing the concentration of a subunit required for activation. 
These studies suggested that a functional interaction existed between these two 1 I 
subunits. }CEKE motifs were identified in the a sequence suggesting a role in 
interaction with other proteins. Deletion of this motif does not affect subunit 
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binding to the 205 proteasome suggesting that the KEKE motifs within the 11 S 
activator a subunits do not directly interact with the KEKE motifs observed in some 
205 proteasome a-type subunits. It has been hypothesised that these sequence 
motifs may play a role in the association between a and 0 subunits (Song et al., 
1997). 0 subunits alone have been observed to display no stimulatory effect on 
proteasome activity but this complex could function in reducing the concentration 
of a subunit required for activation. The mechanism by which the 0 subunits 
influence a subunit function is unclear, but may be related to protein interactions. 
The crystal structure of the CLJ(3 uS activator has been examined and this revealed 
that this complex, much like the 19S RC, may function to cause conformational 
changes in the 205 proteasome. These changes may facilitate the opening of a 
channel in the proteasome a subunits through which substrates can pass (Knowlton 
et at, 1997). 
The y subunit was originally identified as the nuclear protein Ki antigen. 
Sequence analysis shows this subunit to contain a nuclear localisation signal but 
studies in HeLa cells have shown that like the a and 13  subunits its expression is not 
restricted to one cellular compartment (Tanahashi a at, 1997). The exact cellular 
function of lIS complexes composed of y subunits is presently unknown. The 
expression of a and (3 subunits is upregulated by IFN-y. This contrasts to the y 
protein which is downreguated by IFN-y signalling. These initial results suggested 
that the uS activator may serve an immunological function. Further evidence for 
this comes from studies where the ci protein was overexpressed. An enhanced 
presentation of antigenic peptides on MHC class I was observed (Groettrup et at, 
1996). The uS activator complex has been shown to stimulate proteasome 
peptidase activity but not its ability to stimulate breakdown of full-size proteins. 
This data has been assumed to suggest that antigen processing by the proteasome 
may occur in successive steps conducted by various proteasomal complexes (Yang 
et at, 1995). For example the 26S proteasomal complexes may degrade the 
ubiquitinated substrate into degradation intermediates which the 20S-11S 
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proteasome complex further processes into peptides of 8-10 amino acid residues 
suitable for assembly on MHC Class I proteins. The size of peptide generated by 
the proteasome is thought to represent the distance between two active sites within 
the catalytic core of the proteasome. This two step pathway hypothesis matches the 
observation that only a small number of peptides presented on MHC Class I are 
degraded by the 26S proteasome. This pathway may be responsible for the 
generation of peptides from ubiquitinated antigens. The precise genetic dissection 
of these immuno-proteasome pathways will give more insight into the exact 
mechansim by which these two complexes interact to generate an immune response 
to intracellular antigens. 
1.6.5 Proteasome Localisation 
The subcellular localisation of the proteasome has been examined in a wide 
range of tissues and a pivotal theme has emerged. In zygotes and early embryos the 
proteasome is found to be largely cytoplasmic in expression although it becomes 
increasingly nuclear as development progresses. The nuclear or cytoplasmic 
distribution of the complex has been observed to vary dependent on the specific 
tissue examined but a common thought appears to be a more concentrated nuclear 
expression in dividing or cancerous cells. In non-dividing cells e.g. Drosophila 
salivary glands the proteasome has failed to be detected in the nucleus (Hoffman 
and Rechsteiner, 1996). These generalisations hold true for the majority of model 
systems studied. Other components of the ubiquitin mediated degradation system 
have been found localised in the nucleus. The ubiquitin activating enzyme, El is 
largely nuclear in expression suggesting that a large proportion of intracellular 
degradation occurs with the nuclear compartment. In addition to this the role that 
the proteasome plays in the degradation of transcription factors leads to the 
hypothesis that a particular protein may be stable in the cytoplasm but could be 
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Table 1.8 Levels of the 20S proteasome in Tissues or Cell Types. For 
lymphocytes it was assumed that 1mg protein = 10 7 Cells, and for all other cell types 
it was assumed that 1mg protein = 2 A 106  cells. (Adapted from Hoffman and 
Rechsteiner, 1996). 
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rapidly degraded after entry into the nucleus. If such a compartment specific 
degradation mechanism exists it provides a highly effective control mechanism for 
protein stability. 
The expression levels of the 26S proteasome are highly varied between 
tissues. In rat thymus and testes it accounts for 2% of total protein whereas in 
human lymphocytes it represents as little as 0.01% of proteins (Kumatori el al., 
1990). Table 1.8 summarises the expression levels of the proteasome in a range of 
tissues. The 26S proteasome has been observed to be a relatively stable enzyme. 
Hendil (1988) demonstrated that 26S proteasomes in HeLa cells had a half-life of 
approximately 5 days. This constrasts to rat liver where a half-life of 12-15 days 
was observed (Tanaka and Ichihara, 1989). Expression studies have shown that the 
proteasome accumulates in cells undergoing developmental processes. These 
studies have revealed the proteasome to be a highly expressed, highly stable 
degradation complex. 
1.7 Natural Substrates of the Ubiguitin-Proteasome De2radation 
Pathway 
1.7.1 The transcription factor NFicB 
The NFicBIReI family of transcription factors, in response to a wide range of 
extracellular signals regulate expression of immunoglobulin genes and also 
participate in T cell activation, HIV infection, and differentiation. NFKB is a 
heterodimeric transcription factor usually composed of p50 and p65 subunits. In its 
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inactive form it is sequestered in the cytoplasm and following activation the 
complex translocates to the nucleus to stimulate gene transcription. NFicB is 
rendered inactive in two manners. First the p50 subunit exists as an inactive p105 
precursor protein. This preprotein is proteolytically processed by the proteasome 
e.g. the C-terminal prodomain is cleaved. The exact manner in which the 
proteasome achieves proteolytic processing as opposed to complete degradation is 
unclear. It has been suggested that the undegraded portion of p105 may fail to enter 
the proteasome due to a bound ubiquitin group that fails to be cleaved or because 
this domain of p105 is inherently resistant to unfolding by the ATPases in the 19S 
regulatory complex. The second mechanism by which NFicB is rendered inactive is 
by its tethering in the cytoplasm by an inhibitor protein, IicBct. IicBa in response to 
signalling events can be phosphorylated on two specific serine residues (Ser 32 and 
36). This phosphorylation stimulates the ubiquitination of nearby lysine residues 
and subsequent degradation of the inhibitor. Mutation of either of these serine 
residues prevents ubiquitination of this protein (Chen et aL, 1995). A protein kinase 
with specificity towards the N-terminal serine residues has been identified (Chen a 
aL, 1996). Phosphorylation of JicBct has been observed to be dependent on 
ubiquitination of.tjiis kinase suggesting that ubiquitination is not only required for 
protein degradation but also for phosphorylation. The N-termini of p105 and IicBct 
have been shown to be related in sequence and function by masking the nuclear 
localisation signal on the p65 subunit of NFicB. In modifying this transcription 
factor the 265 proteasome has been shown to function in both complete degradation 
and limited proteolysis. 
1.7.2 Cyclin Degradation 
Progression of the cell cycle is entirely dependent on the sequential 
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activation and inactivation of cyclin dependent kinases (cdks). There are two main 
classes of cyclins: the mitotic and GI cyclins. Cyclin B is synthesised during 
interphase and then rapidly degraded at the end of metaphase. Degradation of this 
protein allows the cells to exit mitosis and divide. Analysis of cyclin B revealed 8 
amino acid residues called the destruction box, which are essential for degradation. 
Mutation of one residue in the destruction box e.g. Arginine to Cysteine results in 
stabilisation of cyclin B (Glotzer a' at, 1991). The destruction box does not serve 
as the ubiquitination site of this protein but it may be involved in directing 
recognition by an E3 enzyme. Cyclin B is associated with cdc2 to form the 
complete M-phase promoting factor (MPF). A complex of cdc 16, cdc23 and cdc27 
(called the anaphase-promoting complex), that has been shown to function as an E3 
enzyme, interacts with IJbc4 to mediate degradation of the B-type cyclins. 
1.7.3 The Tumour Suppressor Protein p53 
It has been known for several years that p53 associates with E6 proteins 
from two strains of human papilloma virus (HPV). The interaction between these 
two proteins has been observed to result in the ubiquitination and degradation of 
p53. The p53-E6 complex recruits an additional protein named E6-AP, which acts 
as an E3 protein ligase, which directly ubiquitinates p53 and the protein is 
subsequently degraded (Scheffner et al., 1990). The targeting of p53 for this 
pathway is thought to occur by an N-terminal PEST sequence in addition to protein 
phosphorylation. This mechanism explains the low levels of p53 protein found in 
HPV-transformed cervical carcinoma cell lines and contributes to the 
tumourogenicity of these oncoproteins. p53 is extremely unstable in vivo in a range 
of cell lines which are not infected with HPV suggesting that a normal counterpart 
of E6 exists. Recently the oncoprotein mdm2 has been identified as binding and 
catalysing the degradation of p53 in vivo (Kubbutat etal., 1997) 
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1.7.4 MUC Class I Antigen Presentation 
WC Class I molecules carry peptide fragments derived from endogenously 
expressed proteins from the endoplasmic reticulum to the surface of cells for 
display to cytotoxic T lymphocytes. Before peptide presentation can occur the 
cytoplasmic antigens must be cleaved into peptide fragments and transported into 
the lumen of the endoplasmic reticulum. The system which catalyses this process is 
the ubiquitin-proteasome pathway. Treatment of cells with IFN-y results in an 
increase in expression of three components of the 20S proteasome (LTvIP2, LMP7, 
and MECL-l) and also a stimulation of I 15 activator complexes. This alteration in 
proteasome structure results in an enhanced generation of peptides terminating with 
basic or hydrophobic residues (reviewed in Weissman, 1997). These are the types 
of peptides preferentially loaded onto MHC Class I molecules. Prior to the 
discovery of 115 activator complexes it was assumed that the 265 proteasome 
catalysed the degradation of peptides for this pathway. It is becoming clear that the 
generation of antigenic peptides by the proteasome is not as simple as assumed. 
The current hypothesis sugested that only some antigens are fully processed by the 
26S proleasome whereas in other situations degradation intermediates are 
generated. These intermediate degradation products may then be processed to 8-10 
amino acid peptides by the 20S-1IS proteasome complexes. Mutants in 
components of the 115 activator complex are required to detail the precise role this 
complex plays in antigen presentation. 
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1.8 Protein Degradation by Ubiguitin-Proteasome-like Pathways 
1.8.1 Ubiciuitin Dependent Endocytosis of Cell Surface Proteins 
As a general rule cell surface proteins are rapidly endocytosed and if not 
recycled to the plasma membrane, are directed to the lysosome where they are 
degraded by vacuolar proteases (Robinson et aL, 1996). This pathway is utilised by 
the yeast ct-factor pheromone receptor, Ste2. Internalised Ste2 was seen to follow 
an endocytic pathway to the vacuole. Yeast mutants which are defective in receptor 
endocytosis led to the identification of ubiquitinated forms of Ste2 (Hicke and 
Riezman, 1996). In support of this, internalisation of ligand bound receptors is 
inhibited in yeast cells deficient in specific E2 enzymes. Phosphorylation of Ste2 
on specific serine residues occurs prior to ubiquitination. A similar pathway has 
been described for the Ste6 protein suggesting that ubiquitin may be used as a signal 
for endocytosis and vacuolar targeting. The exact mechanism by which this is 
achieved is unclear as is the reason why ubiquitinated Ste2 is not targeted to the 26S 
proteasome. These questions clearly need to be addressed to determine the 
importance that ubiquitin plays in protein degradation. 
1.8.2 Proteasome Dependent Degradation of Endoplasmic Reticulum 
Associated Proteins 
Secretion of proteins is mediated by their uptake into the endoplasmic 
reticulum (ER). Proteins entering the ER enter in an unfolded state and are 
subsequently folded and secreted. Inefficiently folded proteins were previously 
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thought to be eliminated directly in the ER but little was known about the 
proteolytic system that regulated this process. Recent studies have described a role 
for the 26S proteasome in the degradation of these ER associated proteins. The first 
indication of this role of the proteasome came from the study of the cystic fibrosis 
transmembrane conductance regulator (CFTR). CFTR is an intergral membrane 
protein which functions by mediating chloride transport across the apical plasma 
membrane of epithelial cells. Addition of a specific proteasome inhibitor was seen 
to stimulate production of ubiquitinated CFTR derivatives (Ward et aL, 1995). 
MHC Class 1, which is a membrane protein, associates with f32 microglobulin and 
antigenic peptide in the ER and then transits through the secretory pathway to the 
plasma membrane for presentation of antigen to cytotoxic T cells. Wiertz and 
coworkers (1996) demonstrated that a gene product of the human cytomegalovirus 
(CMV) US1 1 could target MHC Class Ito the cytosol where it was degraded by the 
proteasome. Again the mechanism by which these two pathways come together is 
unknown. It is possible that the CFTR is targeted to the proteasome degradation 
pathway by virtue of its large cytoplasmic domain. The sequence of events thought 
to occur when these two pathways overlap are glycosylation of the protein in the ER 
followed by retrograde transport out of the ER, possibly in association with a 
chaperone protein. The protein is then tagged by ubiquitin and degraded as normal 
by the proteasome. 
1.8.3 Ubiguitin-Free Proteolysis by the 26S Proteasome 
As a general rule all proteins degraded by the 26S proteasome were thought 
to require ubiquitination prior to their binding to the regulatory complex. Studies of 
the metabolic enzyme ornithine decarboxylase (ODC) have disputed this claim. 
ODC is involved in polyamine synthesis and is degraded in an ATP-dependent 
manner by the proteasome. The prime difference between this protein and others 
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which are degraded by the proteasome is that it is not ubiquitinated prior to 
breakdown. In constrast ODC targeting to the proteasome is dependent on its 
association with another protein, antizyme. This interaction results in the 
destruction of ODC, while sparing antizyme. How this degradation is catalysed 
without the presence of ubiquitin is unknown but it clearly suggests that this 
degradation pathway contains many more control mechansims than have been 
identified at present. 
1.8.4 Ubiguitin-Like Modifying Proteins 
A number of ubiquitin related proteins have been discovered in yeast as well 
as other organisms in recent years. Although the sequence of these ubiquitin-like 
proteins has highly diverged from ubiquitin they were named as such due to their 
ability to be posttranslationally conjugated to other proteins. The best defined role 
for ubiquitin lies in facilitating degradation of proteins by the 26S proteasome but it 
has also been shown to be crucial in altering protein function in mechansims 
distinct from the proteasome. For example histone FJ2A when ubiquitinated is a 
relatively stable protein. Ubiquitin tagging is also found to be essential for receptor 
internalisation and transport to the lysosome (described in section 1.8.1) as well as 
for activating a protein kinase which phosphorylates IicBct in vitro (described in 
section 1.7.1). 
The best studies of the ubiquitin-like (UbI) proteins is the mammalian 
ubiquitin cross-reactive protein (UCRP). UCRP exists as a preprotein containing 
two domains which are related to ubiquitin. Ligation of UCRP to its substrate, 
which has yet to be identified, results in localisation to intermediate filaments. The 
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ability of this protein to form thiolester bonds is extremely inefficient suggesting 
that a specific UCRP activating enzyme may exist (Narasimhan et aL, 1996). 
The other major Uhl studied to date is SUMO-1 (small ubiquitin-related 
modifier). SUMO-1 (SMT3 in S. cerevisiae) is a 101 residue protein which is 18% 
identical to ubiquitin. Sequence comparisons of EST (expressed sequence tag) 
databases have suggested that there are at least two addition variants of SUMO-1, 
named SUMO-2 and SUMO-3. Like UCRP, SUMO-1 is ligated to other proteins 
and some of these substrates have been identified. It associates with the PML 
proto-oncogene, the human DNA repair proteins Rad5 1 and Rad52, and the cell 
death domain of Fas (reviewed in Saitoh et aL, 1997a). SUMO-1 was also 
discovered as a modifier of the GTPase-activating protein of Ran, RanGAP1 and 
the function of SUMO-1 has been analysed in more detail within this pathway. Ran 
is a small GTPase required for nuclear transport. To facilitate an enhanced rate of 
GTP hydrolysis an activating protein, RanGAP-1 is required. Two forms of 
RanGAP-1 are found in vertebrates: an unmodified 70kDa form and a 90kDa form 
conjugated to SUMO-1. Conjugation of SUMO-1 to RanGAP-1 is required to 
target RanGAP-1 to its binding protein, RanBP-2. This modification of these 
proteins is essential for import of the complex through nuclear pore complexes 
(Mahajan et aL, 1997). The precise mechanism by which SUMO-1 modifies 
RanGAP- 1 to allow targeting to the nuclear pore is unknown. Two hybrid analysis 
has revealed that SUMO-1 associates with the death domains of Fas/APO-1 and 
tumour necrosis factor (TNF) receptors, all of which are involved in signalling 
apoptosis. Mutations inactivating the death domains of these proteins prevent an 
interaction with SUMO-1 and inhibit apoptosis (Okura et al., 1996). 
In a manner similar to ubiquitin SUMO-1 also requires processing to cleave 
four amino acids from its C-terminus prior to substrate conjugation. The enzymes 
which are involved in SUMO-1 conjugation to substrate are not fully characterised. 
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The strongest candidate for an E2 which acts on SUMO-1 is the lJbc9 enzyme. In 
Xenopus IJbc9 forms a complex with SUMO-1, RanGAP-1 and RanBP-2 (Saitoh et 
aL, 1997b). Desterro and colleagues (1997) have shown that human Ubc9 could 
form a thioester with SUMO-1 but not with ubiquitin suggesting that Ubc9 is a 
SUMO-1 conjugating enzyme rather than a ubiquitin conjugating enzyme. These 
observations would suggest that Uhl proteins may be conjugated to substrate by 
different enzymes which function in a similar pathway to ubiquitination. The 
common theme between ubiquitin and ubiquitin-like proteins is that they both 
function by modifying a protein. This modification targets the substrate to a 
specific structure or site within the cell. Many fundamental questions pertaining to 
the function of this system remain unanswered, and these should be addresed when 
more substrates of Uhl conjugation are discovered. 
1.9 Proteolysis Overview 
Protein turnover is an essential process in controlling the regulation of the 
cellular environment. It is necessary for a cell to undergo changes in response to 
specific stimuli, to remove damaged or incorrectly folded proteins from the cell, and 
to allow.a cell to adapt to developmental changes. The 26S proteasome is the prime 
mechanism within the cell for the complete breakdown of short-lived intracellular 
proteins. It is a complex pathway composed of many regulatory steps, some of 
which have been described above. In the last decade a plethora of information has 
become available on the proteins involved in this degradation pathway and this has 
revealed a detailed picture of the system. Due to the high evolutionary conservation 
of the proteasome much of this information has been elucidated from studies on 
yeast mutants of these proteins. Whilst providing a basis for the understanding of 
this degradation pathway these studies also reveal whether mutation of one 
component of this pathway can disrupt protein degradation. One aspect which yeast 
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analysis cannot address is whether the proteasome has a role in developmental 
processes. Genetic dissection of this pathway in a number of developing systems, 
mainly Drosophila, have implied that the 26S proteasome may play a prime role in 
regulating development. At present little is known regarding how this system 
functions to regulate development in a mammalian system. It seems highly likely 
that the next stage in proteasome research will be the description of the genetic 
dissection of the mouse proteasome pathway. This will almost definitely reveal a 
new set of functions for the 26S proteasome which had not previously been 
considered. 
1.10 Aims of the Project 
The aims of the studies reported in this thesis were to analyse gene expression 
during development of the mammary gland. It was hoped that by using this 
approach we would identify genes that were involved in controlling the 
differentiation process within the gland. The outcome of this study was the 
identification of a gene that was indeed upregulated during development of the 
mammary gland. The gene identified was a component of a protein degradation 
pathway, which had not previously been considered to play a role in mammary 
gland development. We have shown that this degradation pathway is essential for 
normal functioning of mammary epithelial cells and thus have achieved an aim set 
out at the onset of this project. 
Chapter 2 
Materials and Methods 
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Unless stated otherwise reagents were obtained from Sigma (Poole, United 
Kingdom). 
2.1 DNA Manipulation and Analysis 
2.1.1 Restriction Digest of Plasmid DNA 
Plasmid DNA was typically digested at 37 °C for 2 hours using the 
manufacturers suggested restriction buffer (Boehringer Mannheim, New England 
Biolabs [NEB]) with 3 times excess of the recommended amount of enzyme. Double 
digests were carried out simultaneously provided the salt concentrations in the 
buffers were compatible, otherwise the digest at the lower salt concentration was 
carried out first and the salt concentration subsequently adjusted to meet the 
conditions for the second enzyme digest. PCR products generated containing 5' and 
3' restriction sites were routinely digested overnight with the first enzyme, then 
subsequently with the second enzyme as this PCR generated DNA generally digested 
less efficiently due to shorter flanking sequence at one end of the restriction site. 
2.1.2 Purification of DNA Fragments from A2arose Gels 
Plasmid DNA fragments were resolved on low melting point (LMP) agarose 
gels and the fragment of interest excised from the gel and recovered using 0 Agarase 
(NEB) as described by the manufacturers. IOg DNA was digested and 
electrophoresed in LMP agarose. The DNA was visualised using long-wave UV 
light and the appropriate fragment excised from the gel. This gel fragment was 
heated to 65°C in 1/10 volume of buffer until the agarose was molten and then 
transferred to 40 °C for 1 hour with 2 units of 3  agarase. Following agarose digestion 
the DNA was concentrated by the addition of 1/10 volume of 3M sodium acetate 
(NaAc) and 3 volumes of isopropanol. DNA was pelleted by centrifugation and 
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washed with 70% ethanol to remove salt, air dried and resuspended in ddH 20. 
Approximately 50% of the original digested DNA was recovered using this method. 
2.1.3 Creation of Blunt Ended DNA 
This procedure is dependent on the exonuclease activity of DNA Polymerase 
I. The C-terminal Klenow fragment can be used to fill recessed 3' termini created by 
restriction digestion of plasmid DNA. Conversely, it can also be used to fill recessed 
5' termini. This latter reaction occurs in two stages. Initially the 3'—*5' exonuclease 
activity removes protruding 3' tails from the DNA. This creates a recessed 3' 
terminus which can be blunt ended by the incorporation of nucleotides at this 3' 
terminus. Thus this enzyme can be used to generate blunt ended DNA regardless of 
where there is a 3' or 5' recessed termini. The reaction was as follows:- 
SOOng Insert DNA 
1.5g1 10 x Kienow Buffer 
1.5.il 133 jiM dINIPs 
0.5j.tl Klenow (2U/jsl) 
to 1 5j.tl total volume 
The reaction was incubated at 37 °C for 1 hour and then stopped by heat 
inactivating the enzyme at 75 °C for 20 minutes. The DNA was concentrated by 
precipitation with 1/10 volume of 3M NaAc and 3 volumes of ethanol. Following 
centrifugation of the DNA, the pellet was washed in 70% ethanol, air dried and 
resuspended in 20p1 ddH 20. 
2.1.4 Ligation Reactions 
For cohesive end ligations, approximately 50-1 OOng vector and insert DNA 
were used in a molar ratio of 1:3 in a lOpi reaction containing T4 DNA Ligase 
(Boehringer Mannheim) and reaction buffer. This reaction was incubated at 16°C 
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overnight and 2M1  used to transform E.coli DH5a competent cells. For blunt end 
ligations 300ng DNA was used and the reaction was incubated at 4 °C. 
2.1.5 Transformation of Competent Cells with Plasmid DNA 
E.coli DH5a competent cells (Genotype: F, endAl, hsdR17[rl(,mkl, 
supE44, thi-1, ?L, recAl, gyrA96, relA1,A[argF-lacZYA]U169, $80dlacZA[M15A]) 
{purchased from Life Technologies Inc} were defrosted on ice and 20pi of cells 
were transformed with 2j.t1 of the ligation reaction according to manufacturers 
instructions. The transformation reaction was plated onto LB plates (1% w/v yeast 
extract, 1.5% w/v agar, 0. 1M NaCI) containing ampicillin at a concentration of 
50JAg/ml and Xgal and IPTG (40j.tg/ml and 60j.ig/ml respectively). Transformants 
were selected by blue/white colour selection for the Bluescript and PCRII cloning 
Vectors. These vectors contain a sequence, which encodes the a fragment of the 
lacZ gene into which a polylinker is inserted. The colour selection exploits the a-
complementation process to select recombinant plasmids. Non-recombinant 
plasmids produce a functional a fragment (N terminus) and when the host cells 
produce a co fragment (C terminus) through the lacZ[M1 5A] marker, a functional 13-
galactosidase is produced. When cells are plated on media containing IPTG, which 
inactivates the lacZ repressor, and Xgal, the substrate for 3-galactosidase, the 
colonies are blue. If there is DNA inserted into the polylinker then this disrupts the 
a fragment and a-complementation cannot occur, therefore the recombinant 
colonies are white. For cloning of PCR products into the TA cloning vector 
(Invitrogen) the above procedure was used to transform Topi OF' cells (Genotype F' 
{lacIThiO(Te)} mcrAA [mrr-hsdRM-mcrBC],$80lacZAMl 5A, lacX74, recAl, 
ara, D139A(ara-leu)7697, galU, galK, rpsL(Str5, endAl., nupG). 
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2.1.6 Small Scale Purification of Plasmid DNA 
Plasmid DNA was purified using the alkali lysis method described by 
Sambrook et al, (1989). A 2m1 culture containing SOggIml ampicillin was 
inoculated with a single colony and incubated at 37 °C overnight in a shaking 
incubator. 1 .5m1 of each sample was transferred to an eppendorf tube and 
centrifuged to pellet the bacterial cells. Following removal of the supernatant, the 
pellet was resuspended in lOOjil of ice cold TGE (25mM Tris-HCI pH8.0, 50mM 
Glucose, 10mM EDTA p118.0) and incubated on ice for 10 minutes. 240p1 of 0.2M 
NaOHJ 1% (w/v) SDS was added to lyse the cells. Samples were inverted to mix the 
solution and incubated at room temperature for 5 minutes before addition of 1201A of 
ice cold SM Potassium Acetate (KAc). Samples were incubated on ice for 10 
minutes following inversion to mix. Bacterial cells were centrifuged at 13000rpm 
for 10 minutes, and the DNA containing supernatant was transferred to a fresh tube 
where it was precipitated by the addition of 0.6 volumes of isopropanol. The DNA 
was centrifuged at 13000rpm for 10 minutes and washed in 70% ethanol. The pellet 
was air dried prior to resuspension in ddH 20 containing DNAse-free pancreatic 
RNAse A (20j.xglml). 
2.1.7 LarEe Scale Purification of Plasmid DNA 
Large scale bacterial cultures were purified by a modified alkali lysis method 
(Bimboim and Doly, 1979) and followed by caesium chloride gradient 
centrifugation. A 250m1 culture of LB medium containing ampicillin at 50sgIml 
was inoculated with lml of a pre-culture grown at 37 °C for 8 hours, and incubated at 
37°C overnight in a shaking incubator. The bacteria were pelleted by centrifugation 
at 6000rpm at 4 °C for 10 minutes in a Beckman JA-20 rotor. The cell pellet was 
resuspended in lOmi of ice cold TUE buffer and incubated on ice for 10 minutes. 
Cells were lysed by the addition of lOmls of 0.2M NaOHI1% (wlv) SDS. The 
solution was incubated at room temperature for 10 minutes and chromosomal DNA 
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and protein were precipitated by the addition of 7.5mls of 5M KAc. The solution 
was incubated on ice for 10 minutes followed by centrifugation at 6000rpm in a 
Beckman JA-14 rotor. The DNA containing supernatant was transferred to a fresh 
tube through 6 layers of gauze and DNA was precipitated by the addition of 0.6 
volumes of isopropanol. Plasmid DNA was pelleted by centrifugation at 9000rpm 
for 10 minutes and the pellet washed twice in 70% ethanol. The DNA was air dried 
and resuspended in 2.6mls ddH 20. 
2.1.8 Caesium Chioride/Ethidium Bromide Density Gradient Purification of 
Plasmid DNA 
Purified plasmid DNA (2.6mls) was added to 2.7g Caesium Chloride (CsC1 2) 
and dissolved at room temperature. 220g1 of 10mg/mI Ethidium Bromide was added 
and mixed with the DNA. The solution was then transferred to a Beckman 
Quickseal tube and centrifuged at 70000rpm for 18 hours at 20 °C in a Beckman 
Ti60.5 rotor. Following centrifugation three distinct bands were visualised. The 
closed circular and supercoiled DNA, which corresponded to the lower of the three 
bands, was removed from the tubes using an 18 gauge needle and syringe. The 
ethidium bromide was extracted from the solution by adding an equal volume of iso-
amyl alcohol and vortexing for 1 minute. This was followed by centrifugation at 
13000rpm for 5 minutes. The upper phase containing ethidium bromide was 
removed and the procedure repeated until all ethidium bromide was completely 
removed, requiring a minimum of 6 iso-amyl alcohol extractions. DNA was diluted 
in 2 volumes of ddH20 and precipitated with 3 volumes of ethanol. Centrifugation at 
13000rpm for 15 minutes pelleted the DNA, which was then washed in 70% ethanol 
and resuspended in 250g1 ddH 20. The precipitation procedure was repeated to 
ensure the DNA was free from any contaminating CsC1 2 and the DNA resuspended 
in a final volume of 400p.l.  CsCl 2 plasmid preparations were used when high quality 
pure DNA was required, in particular for transfection into cultured cells. 
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2.1.9 Aparose Gel Electrophoresis of Plasmid DNA 
ig (w/v) of agarose was dissolved in 1 x TAB buffer (40mM Tris-acetate, 
2.5mM EDTA pH7.7) and allowed to cool to 60 °C before addition of Ethidium 
Bromide at a concentration of 1 j.tg/ml. The gel was allowed to set before submersion 
in 1 x TAE running buffer. Each sample was diluted in 1/10 volume of loading dye 
and was electrophoresed at 1 OOV for 2 hours. The gel was visualised under long 
wave UV illumination and photographed. 
2.1.10 DNA Transfer from Aarose Gels 
Plasmid DNA from agarose gels was transferred onto Hybond-N nylon 
membrane (Amersham) using the method described by Southern (1975). DNA was 
denatured in a solution of 1.5M NaCl, 0.5M NaOH for 15 minutes at room 
temperature on a rocking platform. This step was then repeated and followed by 
three washes in neutralising solution (1.5M NaCl, 0.5M Tris p117.5, 1mM EDTA). 
The gel was placed on a wick composed of a sheet of Whatman 3mm paper soaked 
in 10 x SSC (1.5M NaCl, 0. 15M sodium citrate) overhanging the buffer reservoir. 
This was overlaid with a piece of Hybond-N membrane cut to the size of the gel and 
10 pieces of 3mm paper, 5 of which were soaked in 2 x SSC. Air bubbles were 
removed by rolling a glass pipette over the gel, membrane and 3mm paper. Paper 
towels were then placed on top, followed by a glass plate and a weight. This was left 
overnight allowing the DNA to transfer to the membrane by capillary action. The 
membrane was removed and rinsed in 2 x SSC, allowed to air dry and baked at 80 °C 
for 2 hours to fix the DNA to the membrane. If the membrane was not used 
immediately, it was wrapped in Saran-wrap and stored at 4 °C until use. 
2.1.11 Double Stranded DNA Sequencing 
Using a T7 sequencing kit (Promega), double stranded DNA was sequenced 
according to the method of Sanger ci at, (1977). 1.5tg of template DNA in a total 
volume of 32g1 was denatured by the addition of 8j.xl 2M NaOH and incubated at 
room temperature for 10 minutes. DNA templates were then diluted with 1/10 
volume 3M NaAc and 2 volumes of ethanol. This mix was chilled at -20°C for 15 
minutes and precipitated by centrifugation at 13000rpm for 15 minutes. The DNA 
pellet was washed in 70% ethanol, air dried and resuspended in lOgI dH20. The 
DNA template and 2pi primer (1 Opmol) were annealed by the addition of 2jsl 
annealing buffer and incubating for 5 minutes at 65°C, followed by a 10 minute 
incubation at 37 °C. The annealed primer and DNA mix were then left at room 
temperature for a further 5 minutes before commencing the sequencing reactions. 
25R1  of A, (1, C, and T short-run termination mixes were aliquoted into eppendorf 
tubes and pre-warmed to 37 °C prior to addition of the labelling reaction. 6p.l of 
labelling reaction was added to the annealed primer/DNA mix and incubated at room 
temperature for 5 minutes. The labelling mix contained the following components:- 
dATP Labelling Mix 	 3n j.xl 
Diluted T7 DNA Polymerase 	2n jtl (2U/p.l) 
a 35  dATP 	 n M1  (Amersham, specific activity 1000CiImmol) 
Total volume 	 6 M1  where n = number of templates sequenced 
4.5j.tl of labelling mix was added to the pre-warmed termination mixes and 
incubated at 37 °C for 5 minutes. This reaction was terminated by the addition of 5 
jil of stop solution. 
7M Urea gels containing 6% polyacrylamide in 1 x TBE buffer (0, 13M Tris 
HCI, 4mM Boric acid, 0.25mM EDTA) were routinely used for DNA sequencing. 
Sequencing reactions were denatured at 80 °C for 2 minutes prior to loading on the 
gel, and electrophoresed at a constant power of 70 watts in 1 x THE running buffer. 
Gels were fixed by soaking in 10% methanol (v/v), 10% acetic acid (v/v) for 15 
minutes prior to drying at 80 °C for 1 hour. The dried gel was then exposed to 
autoradiographic film overnight (Kodak MRI Film). Approximately 1 50-200bp of 
sequence could be read from a single run. 
2.2 RNA Extraction and Analysis 
2.2.1 Total RNA Isolation from Mouse Tissue 
All plastics used for RNA analysis were double autoclaved and glassware 
was baked at 180°C prior to use. Dissected organs were ground to a powder in liquid 
nitrogen and homogenised in RNAzo1 (Biogenesis) at 2mls per 250mg tissue. 1/10 
volume of chloroform was added to the samples, mixed and incubated on ice for 5 
minutes. Following centrifugation at 13000rpm for 15 minutes at 4 °C, the upper 
aqueous phase was removed and protein and the inorganic lower layer was 
discarded. RNA was precipitated by the addition of an equal volume of isopropanol 
and incubated at 4°C for 15 minutes. This was followed by centrifugation at 
13000rpm for 15 minutes at 4°C to pellet the RNA, which was then washed in 70% 
ethanol, air dried on ice and resuspended in ddH 20. For long-term use RNA was 
stored as an ethanol precipitate at -20 °C. 
2.2.2 RNA Isolation From Cultured Cells 
Confluent T80cm2 flasks of cells (approximately 3 x 10 7 cells) were rinsed in 
PBS and the monolayer harvested by trypsinisation (section 2.4.1). The cells were 
pelleted by centrifugation at 1000rpm for 5 minutes and the supernatant removed. 
On ice the cells were resuspended in 4mls RNAzo1 and the RNA extracted as above. 
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mRNA was isolated from cultured cells using an Invitrogen Micro-Fastlrack 
Kit as described by manufacturers. Briefly, 1 x 106  cells were resuspended in lml 
lysis buffer and incubated at 45°C for 20 minutes to digest protein and RNAses. The 
salt concentration of the samples was adjusted to 0.5M with NaCl and DNA was 
sheared by passing the lysate through an 18 gauge needle three times. One oligo dT 
cellulose tablet was added to the lysate and allowed to dissolve. Once dissolved the 
solution was incubated at room temperature for 20 minutes on a rocking platform. 
The oligo dT cellulose was subsequently pelleted at 13000rpm for 5 minutes, and the 
resultant pellet washed three times in binding buffer. The oligo dT cellulose was 
resuspended in 0.3mls of binding buffer and applied to a spin column. The solution 
was washed three times in binding buffer and the non-polyadenylated RNA was 
eluted from the column by two washes in low salt buffer. mRNA was eluted in 
200 AI elution buffer by centrifugation at 13000rpm for 1 minute. mRNA was stored 
as an ethanol precipitate at —70 °C by the addition of lop'  glycogen (2mglml), 30jil 
2M NaAc, and 600p.tl 100% ethanol. 
2.2.3 Formaldehyde Gel Electrophoresis of RNA 
Both total RNA and poly A RNA samples were electrophoresed on a 0.8% 
(w/v) agarose gel dissolved in 1 x Mops buffer (0.02M 3-N-[morpholinol] 
propanesulfonic acid, 5mM NaAc, 1mM EDTA pH7.0) containing 6% (v/v) 
formaldehyde. 1 0ig of total RNA (or 2ig of nIRNA) was centrifuged at 13000rpm 
for 30minutes at 4 °C to pellet the RNA, which was then washed in 70% ethanol. 
The resultant pellet was dried on ice and resuspended in 30jxi RNA sample buffer 
(15p' Formamide, 5tl 10 x Mops buffer, 8.tl 38% formaldehyde, and 2M'  ddH20). 
1/10 volume of loading dye and 0.5pi of lOmg/ml Ethidium Bromide was added to 
samples prior to denaturing at 65°C for 10 minutes. RNA was then immediately 
loaded onto the gel, which was submerged in 1 x Mops running buffer and 
electrophoresed at 65V for 4 hours. RNA was visualised under long wave UV and 
photographed. 
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2.2.4 RNA Transfer from Formaldehyde Gels 
RNA transfer was similar to that described in section 2.1.10 with the 
following exceptions. No denaturisation or neutralisation of the gel was necessary. 
A capillary transfer was performed using Zetaprobe nylon membrane (BioRad) and 
the transfer buffer was composed of 0.04M. NaOH, 0.5M NaCl. Following transfer 
the membrane was rinsed in 2 x SSC and was baked at 65°C for 2 hours to fix the 
RNA to the membrane. 
2.3 Radiolabelling and Hybridisation Techniques 
2.3.1 Random Priming 
Radiolabelled DNA probes were prepared by the methods described by 
Feionberg and Vogelstein (1984). This procedure exploits the lack of 5'—*3' 
exonuclease activity of Klenow, and therefore incorporates nucleotides 
complementary to 5' DNA overhangs. SOng of linearised double stranded DNA was 
diluted to 24jsl in ddH20 and added to iøii1  of random nonomeric primers (270D 
units/ml) from a Prime-It TI Kit (Stratagene). The DNA was then denatured at 95°C 
for 5 minutes followed by chilling on ice. The following components were then 
added:- 
lOpJ S x dCTP Buffer 
1 jil Klenow fragment of DNA Polymerase I (5U/ml) 
Sjsl a32P dCTP (Amersham, specific activity 3000CiInilvf) 
The reaction was incubated at 37 °C for 30 minutes. Unincorporated nucleotide was 
removed by diluting the probe to lOOsl with ddH 20 and applying to a G50 Sephadex 
column (5' —*3' Inc) according to manufacturer's instructions. Briefly, the column 
was inverted to mix the resin and centrifuged at 1000rpm for 2 minutes to remove 
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the storage buffer from the column. The radiolabelled DNA was then applied to the 
column and centrifuged at 1000rpm for 2 minutes. Unincorporated nucleotides 
remained trapped in the resin and labelled DNA fragments larger than 50bp were 
eluted from the column. The specific activity of the probe was measured by 
quantitation of an aliquot using a scintillation counter. The probe was denatured 
prior to hybridisation by the addition of 1/4 volume 2M NaOH and left at room 
temperature for 2 minutes before addition to the hybridisation solution. 
2.3.2 .Hybridisation of DNA Probes to Nylon Membranes 
The Church and Gilbert (1984) method was followed for hybridisation. 
Membranes were prehybridised at 65°C for 30 minutes in 1 5mls of hybridisation 
solution (0.5M NaPO4 pH7.0, 7% w/v SDS, 1mM EDTA) in a roller oven. Labelled 
DNA probe was added at an activity of I x 106  cpm!ml of hybridisation solution and 
incubated overnight at 65°C. The excess unhybridised probe was removed using a 
range of salt washes. Low stringency washes were performed using two incubations 
in pre-warmed 40mM NaPO 4, 1% SDS at 65°C. If non-specific background was 
high, two further washes in 20mM NaPO 4/I % SDS were performed. The membrane 
was wrapped in Saran-wrap and exposed to X-ray film overnight at -70 °C with 
intensifying screens. 
2.3.3 RNAse Protection Assay 
A Maxiscript In Vitro transcription Kit (Ambion) was used to generated RNA 
transcripts. I jig of cloned plasmid DNA was linearised for transcription from T7 - 
and Spó polymerase promoters. The reactions were set up as follows: 
2j.tl 10 x Transcription Buffer 




1 111  I0mMGTP 
lpl RNAse Inhibitor 
1sg linearised template DNA 
3p.tl 0.1mMUTP 
5M' a32P dUTP (Amersham, specific activity 3000Ci/mmol) 
I j.il SP6 or T7 RNA Polymerase (1OU/pi) 
ddH20 to 20j.tl. 
Reactions were incubated at 37 °C for 30 minutes. I j.tl RNAse-free DNAse I (2U/pi) 
was added and incubated at 37 °C for 15 minutes to remove template DNA. An equal 
volume of gel loading buffer was added to the samples, which were subsequently 
denatured at 90°C for 5 minutes. The reaction was loaded onto an SM. Urea/5% 
acrylamide gel and run for 1 hour at 100 volts. After electrophoresis, the gel was 
wrapped in Saran Wrap and exposed to film for 2-3 minutes. Following 
development of the autoradiogiaph, the full-length transcript was identified as the 
most intense band present. This film was used as a template to cut the corresponding 
area from the gel. The gel slice was diluted in 350p1 elution buffer (0.5M N}l 4Ac, 
1mM EDTA, 0.1% [w/v] SDS) and incubated at 37 °C overnight. The gel fragment 
was removed from the sample and the quantity of radioactive label in the aliquot was 
determined by scintillation counting. 
The RNase Protection Assay was performed using an RPA II Kit (Ambion) 
according to the supplier's instructions. lOp.g total RNA was mixed with 6 x 10 4cpm 
of in vitro transcribed probe. Samples were diluted to 50pJ and ethanol precipitated 
by adding 1/10 volume 3M NaAc and 2.5 volumes of ethanol. Following 15 minutes 
at —20°C, samples were centrifuged at 13000rpm for 15 minutes at 4 °C. RNA was 
washed, air dried and subsequently resuspended in 20M1  hybridisation buffer (80% 
v/v deionised formamide, 40mM PIPES pH 6.4, 400mM NaAc pH 6.4, 1mM. 
EDTA). The RNA and probe suspension was denatured at 99 °C for 3minutes prior 
to hybridisation at 42 °C overnight. 200J.sl of RNase Digestion Buffer (containing 
diluted RNase A and RNase TI. mixtute) was added to the samples and incubated at 
37°C for 30 minutes to digest unprotected single-stranded RNA. 300M'  of RNAse 
Inactivation/Precipitation mixture was added to the samples and vortexed to mix. 
Samples were chilled at —20°C for 15 minutes, prior to centrifugation at 13000rpm 
for 15 minutes at 4 °C. Pellets were resuspended in 8jil of loading dye and denatured 
at 99°C for 3 minutes. Protected RNA fragments were separated on a 5% 
acrylamide/8M urea gel in I x THE running buffer at 250 volts for 3 hours. The gel 
was transferred onto 3mm paper and dried at 80 °C for 1 hour, prior to exposure to 
autoradiographic film at —70 °C overnight with intensifying screens. 
2.4 Culture of Murine Mammary Epithelial Cells 
2.4.1 Passaping and Maintenance of KIM-2 Cells 
KIM-2 mammary epithelial cells (MECs) were grown as a monolayer and 
routinely passaged every 3-4 days. For passaging, media was aspirated from the cells 
which were then rinsed in sterile PBS (Gibco BRL). 2.5mls of prewarmed TEG 
solution (per T80cm2 flask) was added to the cells and left for 1 minute. lomls 
maintenance media was added to the cells to inactivate the trypsin, and the cells 
were harvested using a cell scraper (Costar). KIM-2 cells were routinely passaged as 
clumps of 5-10 cells, which were generated by a minimal pipetting of the cells once 
they were in suspension. Cells were collected by centrifugation at 1000rpm for 5 
minutes. The supernatant was aspirated and the cells were resuspended in an 
appropriate volume of maintenance media and dispersed by gentle pipetting. Cells 
were routinely split 1 in 3 every 3 to 4 days with 1 flask always remaining on 
collagen. Cells were incubated at 37 °C with 5% CO. Media was replaced on the 
cells 24 hours following passaging and thereafter every 2 days. 
Maintenance Media 
1:1 DMEMIFI2(GibcoBRL) 
10% (v/v) FCS 
5 jig/mI Bovine Pancreatic Insulin 
lOng/mi EUF 
5g/ml Linoleic Acid/BSA 
6m1 L-Glutamine (Gibco BRL) 
TEG (Trvnsin EGTA 
NaCl 6.3g 




Tris Base 2.7g 
RiTA 0.4g 
PVA (Polyvinyl Alcohol) 	0. ig 
1% (vi'.,) Phenol Red 	0.9m1 
2.5% (v/v) Tiypsin 	lOOmis (ICN Flow) 
This solution was adjusted to pH7.6, diluted to 1 litre, filter sterilised and stored at 
-20°C. 
Collagen Coated Flasks 
Smls Type I Collagen from Calf Skin was added to 2.8mls 10% (v/v) acetic acid, and 
diluted to 50mls in ddH 20. lOmIs of this solution was added to a T80cm 2 flask and 
incubated at 4°C for at least 24 hours. The collagen solution was aspirated from the 
flask and followed by three washes in PBS. The flask was left to rinse in PBS for 30 
minutes at room temperature, followed by a minimum of three washes in 
maintenance media to remove any residual acetic acid. 
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2.4.2 Induction of Differentiation in KIM-2 Cells 
KIM-2 cells were passaged as described above and grown until reaching 
confluency, whereupon media was changed and left for a further 48 hours before the 
cells were induced to differentiate. Differentiation media was maintenance media 
minus EGF but with the addition of Dexamethasome (1 .tM, Gibco BRL) and ovine 
Prolactin (5g/ml). Cells were treated with prolactin and glucocorticoid for up to a 
maximum of 12 days. Cells were routinely harvested to check functional 
differentiation as measured by the expression of the milk protein fi casein. 
2.4.3 Freezing KIM-2 Cells 
Cells were harvested by trypsinisation from a T80cm 2 flask as described in 
section 2.4.1. The pellet was resuspended in 2mls maintenance media and placed on 
ice. An equal volume of ice cold freeze mix was added drop-wise to the cells whilst 
mixing the contents. This mixture was then aliquoted into four imi aliquots in cold 
freezing vials and placed on -70 °C overnight. The cells were subsequently 
transferred to liquid nitrogen for long term storage. 
Freeze Mix 
60% (vlv) maintenance medium 
20%(vlv)FCS 
20% (v/v) dimethyl sulfoxide [DMSO] 
To defrost cells from liquid nitrogen, the frozen vial was warmed to 37 °C 
until melted. The cells were then diluted in lOmIs maintenance media and 
centrifuged to remove the DMSO. The pellet was resuspended in 5mls media and 
seeded in a T25cm2 flask at 37°C with 5% CO2. 
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2.4.4 Passaging and Maintenance of HC1I Cells 
HCI 1 mammary epithelial cells were grown as a monolayer and passaged 
every 34 days in a similar manner to the KllvI-2 cells (section 24.1). The main 
differences were that HC1 I cells did not require to be passaged on collagen, and they 
could be split as single cells. The maintenance media for HCI I cells was RPM] 
1640 (++) and this was supplemented with the same growth factors as KIM-2 media 
except twice the concentration of EUF was required. HCI 1 cells were differentiated 
in a similar manner as above except the serum concentration was reduced to 3% as 
opposed to 10% for the KlIIvI-2 cells. 
2.4.5 Transfection of KIM-2 Cells 
KIM-2 cells were routinely transfected using 2gg DNA, which had been 
purified twice by CsCl 2 density gradient centrifugation using a lipid based 
fransfection reagent, Fugene (Boehringer). Cells were transfected 24 hours 
following passaging for various lengths of time (maximum of 24 hours). Transfected 
cells were then selected using the appropriate antibiotic, usually geneticin for 14 
days is stable clones were to be generated. The resultant clones were expanded until 
a frozen stock of these cells could be generated. Transfection efficiencies were 
monitored using a plasmid containing a Lac Z gene. Following transfection these 
test transfections were fixed in solution I at room temperature for 10 minutes prior 
to overnight incubation in solution 2 at 37 °C. The number of blue cells were 
subsequently counted to determine transfection efficiencies. 
Solution I (in PBS) 
	
Solution 2 (in PBS) 
2mM MgCl2 
	
5mM Potassium Ferracyanide 
5mM EGTA 
	




2.5 Culture of Murine Embryonic Stem Cells 
Murine embryonic stem (ES) cells were cultured in a manner similar to KIM-2 
mammary epithelial cells. Cells were approximately 60% confluent when passaged, 
this prevented the cells initiating differentiation which occurs when they become 
confluent. Similar to KIM-2 cells, these cells were rinsed in sterile PBS prior to 
incubation in a trypsin solution for 5 minutes at 37°C. Cells were resuspended in a 
single cell suspension prior to re-plating in a larger flask. ES cells were grown as a 
monolayer on gelatinised flasks (0.1% gelatin solution) at 37 °C in 5% CO2 and 
media was replaced every second day following passaging. 
ES Cell Maintenace Media 
BHK2 1 media (Glasgow MEM, Gibco BRL) 
10% Serum (1:1 of FCS and Newborn Serum) 
6ml L-Glutamine (Gibco BRL) 
SOOjsl Recombinant LW (Leukaemic Inhibitory Factor) 
500.zl 0-2mercaptoethanol (13-2M)  solution (1:142 dilution of f3-2M in ddH 20) 
2.6 Cell Cycle and Apoptosis Analysis 
2.6.1 Cell Cycle Synchronisation 
KIM-2 cells were split I in 3 in maintenance media and incubated at 37 °C for 
24 hours. The cells were then treated with the following drugs:- 
a) Hydroxyurea (HXU) which blocks cells late in the GI phase of the cell cycle. 




b) Nocodazole which blocks cells in the G2/M phase of the cell cycle. Nocodazole 
was diluted in DM50 and 50ngIml used to arrest K1M-2 cells. 
Control cells were treated with the appropriate diluent alone and incubated at 37 °C 
for 24 hours (approximately one cell cycle). Following treatment, cells were 
harvested for analysis or resuspended in drug free media. 
2.6.2 Proteasome Inhibition Experiments 
KIM-2 cells at various stages of confluency and differentiation were treated 
with a peptide aldehyde inhibitor of the 265 proteasome, N-carbobenzyoxyl L-
leucinyl L-leucinyl leucinal (MG132). MG132 was stored as a 5mM stock in DM50 
and used at a range of concentrations to inhibit proteasome function. 
2.6.3 Morphological Assessment of Cell Death 
KIM-2 cells were harvested as described in section 2.4.1 and cell pellets were 
fixed overnight in cold 70% (vlv) ethanol in PBS. The cells were then stained with 
the nucleic acid stain acridine orange (Molecular Probes Inc.) according to the 
method of Gregory (1991). Briefly, equal volumes of cells and acridine orange 
(5mg/mI in PBS) were mixed on a microscope slide. Green fluorescence at the 
wavelength 500-525nm was detected. Apoptotic cells were differentiated from 
viable cells by their brightly stained, condensed or fragmented nuclei and the 
percentage apoptotic cells was scored. 
2.6.4 Flow Cytometric Analysis of Cell Death 
Supernatants were removed from the cells and placed in a universal bottle, 
unless apoptosis was not to be analysed in this fraction. Monolayer cells were rinsed 
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in 1MM EDTA (vlv) in PBS. Cells were tiypsinised as normal but were pipetted 
more vigorously to break up large clumps of cells. The cells were pelleted and 
resuspended in ice cold 1% FCS (v/v) in PBS and counted using a haemocytometer. 
1 x 106  cells were placed in an eppendorf tube and centrifuged at 1000rpm for 5 
minutes to pellet the cells. 
The assay was performed using an Apoptosis Detection Kit (R&D Systems) 
which was designed to quantitatively determine the percentage of cells undergoing 
apoptosis. This is achieved by virtue of the ability of apoptotic cells to bind annexin 
V and exclude propidium Iodide (P1). Arinexin V is a phospholipid binding protein, 
which can be used to monitor changes in cell membranes. A key characteristic of 
cells undergoing apoptosis is the flipping of phosphotidylserine (PS) from the inner 
to the outer cell membranes. This makes PS available for binding by Annexin V. 
Cells which are undergoing apoptosis will be bound by Annexin V, whereas necrotic 
cells with ruptured cell membranes will bind both Annexin V and P1, and thus 
apoptotic cells can be distinguished from cellular debris. Cells were resuspended in 
lml of binding buffer and lOOj.d of cells (1 x10 5) were aliquoted into a separate 
eppendorf. Cells were stained with lOjil FITC (Fluorescein isothio-cyanate) labelled 
AnnexinV and 10.tl P1 and vortexed to mix the components. The samples were 
incubated at room temperature in the dark for 15 minutes. 400R'  of binding buffer 
was added to the samples before reading on a Coulter Epics XL flow cytometer at 
488nm for FTTC and 575nm for P1. 
2.6.5 Flow Cytometric Analysis of Cell Cycle Distribution 
Cells were treated as described in section 2.4.1 and fixed in cold 70% (vlv) 
ethanol in PBS for at least 1 hour at 4 °C. 1 x 106  cells were rehydrated in 500 j.xl PBS 
at room temperature for 5 minutes. The nucleic acid stain P1 was added to the cells 
at 5mg/ml and samples were incubated on ice for 10 minutes. 10,000 cells were 
102 
analysed on a Coulter Epics XL flow cytometer at a fluorescence wavelength of 
575nm. Cellular debris was excluded from the analysis by scatter gating. 
2.7 Protein Extraction and Analysis 
2.7.1 Extraction of Protein from Tissue Samples 
Tissues were snap frozen in liquid nitrogen then ground to a powder, which 
was resuspended in imi RIPA buffer. The cells were sheared to release the protein 
by passing through a 21 gauge needle three times. Samples were centrifuged at 
13000rpm for 15 minutes at 4 °C to pellet the debris. Supernatants were transferred 
to fresh eppendorf tubes and aliquoted prior to storage at -70 °C until use. 
RIPA Buffer 
50mM Iris HC1 (pH7.5) 
150mM NaCl 
1% (v/v) Nonidet P40 
0.5% (vlv) sodium deoxycholate 
0.1% (v/v) SDS 
2jig/ml Leupeptin 
1 psg/ml Pepstatin 
Sjig/ml Aprotinin 
I mM PMSF (Phenylmethylsulphonyl fluoride) 
lOO.xM sodium orthovanadate 
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2.7.2 Extraction of Protein from Tissue Culture Cells 
Cells were washed in ice cold 1mM sodium orthovanadate (NaV0 3 ) in PBS 
and then harvested from the flask using 1mM NaVO 3 in PBS to protect phosphate 
groups. Centrifugation to pellet the cells was followed by snap freezing in liquid 
nitrogen for storage. Otherwise the pellet was resuspended in 200R1  (per T25cm 2 
flask) of R[PA buffer and extracted as above. 
2.7.3 Extraction of Protein from S. cerevisiae 
lOml cultures were grown for 48 hours at 30 °C in selective media. Cells 
were centrifuged at 1500rpm for 5 minutes, the supernatant was aspirated and the 
pellet was resuspended in 500.tl RIPA buffer. Glass beads (as section 2.3.3) were 
added to just beneath the meniscus and the protein samples were vortexed for 30 
seconds and then placed on ice for 30 seconds. This procedure was repeated for 15 
minutes to lyse the yeast cells. The supernatant was transferred to a fresh eppendorf 
tube and centrifuged at 13000rpm for 30 minutes at 4 °C to pellet the debris. The 
supernatant was transferred to a fresh tube, aliquoted and stored at -70 °C until use. 
2.7.4 Estimation of Protein Concentration 
Protein concentrations were determined using the Pierce BCA detection 
system. The assay is based on a colour change from green to purple when protein 
reacts with Cu 2+  in an alkaline medium. This gives Cu' which when complexed 
with the salt bicinchoninic acid .(BCA) gives a purple product which can be detected 
at a wavelength of 570nm. The protocol involved diluting a range of bovine serum 
albumin (BSA) protein standards in the appropriate extraction buffer (0.2 - 2mg/mi). 
10 M1  of the standards and lOj.tl of protein samples were pipetted into wells in a 96 
well plate. These were diluted in 200 jil of working reaction, which is composed of 
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50 parts Reagent A with 1 part Reagent B. Samples were mixed by rocking the plate 
on an orbital shaker for 30 seconds followed by a 30 minute incubation at 37 °C to 
allow colour formation. The absorbance was read at 570nm on a Dynatech MRX 
plate reader. Using the BSA protein samples, a standard curve was generated which 
was used to determine the concentration of the test samples. 
2.7.5 Denaturing (SDSIPAGE) Polyacrylamide Gel Electrophoresis 
The method of Laemmli (1970) was used to perform one dimensional 
SDS/PAGE electrophoresis. Using a premixed 30% polyacrylamide solution 
(Scotlabs) a 10% or 15% resolving gel with 3% or 5% stacking gels respectively 
were cast, lOig of protein sample was denatured at 99 °C for 5 minutes, chilled on 
ice and loaded alongside prestained molecular weight markers. Gels were 
submerged in SDS/PAGE running buffer (25mM Tris, 192mM glycine, 0.1% w/v 
SDS) and run at 100 volts through the stacking gel followed by 200 volts through the 
resolving gel. 
2.7.6 Western Blotting 
Proteins were transferred by electrophoresis from the separating gel onto 
either a nitrocellulose filter (Schleicher & Schwell) or a polyvinylidene fluoride 
(PVDF) filter [Gelman Sciences] using a BioRad Protean II Transfer Apparatus. 
Proteins were transferred for 1 hour at 50 volts in transfer buffer (25mM Tris, 
192mM Glycine, 0.01% w/v SDS, 20% v/v methanol). Following transfer the 
separating gel was stained with a 0.2% (v/v) Coomasie solution to ensure even 
loading of protein. 
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2.7.7 Protein Detection 
Nitrocellulose filters were blocked overnight at 4 °C in Tris Buffered Saline 
[10mM Tris HC1 pH7.5, 100mM NaCl, 0.1% (vlv) polyoxyethylenesorbitan 
monolaurate (Tween 20)] (TBST) containing either 5% Marvel dried milk powder 
or BSA. Filters were incubated in primary antibody (diluted according to the 
manufacturer's instructions) in block solution on a shaking platform for 1. hour at 
room temperature. Filters were then washed for 30 minutes in TBST prior to 
incubation in secondary antibody (conjugated to horseradish peroxidase) diluted in 
TBST for 1 hour at room temperature. Filters were again washed for 30 minutes in 
TBST at room temperature on a rocking platform. An Enhanced 
Chemilunilnescence (ECL) detection kit [Amersham] was used to detect the 
antibody-protein interaction on the membrane. ECL reagents emit light at 428nm, 
which can be detected by a short exposure to blue-light sensitive autoradiographic 
film (ECL I-Iyperfilm, Amersham). 
2.8 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
2.8.1 RT-PCR Reaction for Proteasomal ATFases 
RT-PCR reactions were performed using a Gibco BRL Superscript 
Preamplification System for First Stand cDNA sysnthesis. Single stranded cDNA 
was prepared by adding 5p.g of day 15 gestation mammary gland total RNA to l.d of 
random hexamers (SOng/pal). This mixture was denatured at 70 °C for 10 minutes, 
chilled on ice and the following components were added:- 
lp.d RNAse Inhibitor 
2pal 10 x PCR Buffer (200mM Tris HCI pH8.4, 500mM KC1) 
2paI 25mM Magnesium Chloride (MgCl2) 
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1.t1 10mM dNTP mix (dATP, dCTP, dGTP, and dTTP) 
2jsl 0. 1M Dithiothreitol (DTT) 
The reaction was incubated at 25°C for 5 minutes before the addition of 1 p.1 
Superscript II reverse transcriptase (2U/M1) and then incubated at 25°C for a further 
10 minutes. The reaction was transferred to 42 °C for 50 minutes and then terminated 
by heat inactivation of the enzyme at 90 °C for 5 minutes. The template RNA was 
removed from the samples by the addition of 1 j.tl RNAse H (2U/jsl) and incubated at 
37°C for 20 minutes. The PCR reaction was performed using 4.tl of single stranded 
eDNA and adding the following components:- 
5 M1  10 x PCR Buffer 
3sl 25thM MgCl2 
ljil 10mM dNTP mix 
1 IAl 1 OpuM ATPase Primer Pairs 
3 Spul ddH2O 
ipul Taq DNA Polymerase [5U/p.tl] (Boehringer) 
The reactions were overlaid with 30j.tI mineral oil and placed in a thermal cycler and 
the following program run:- 
94°C for 1 mm 
Denature at 94°C for 30 seconds 
Anneal at 60°C for 1 minute 	 30 cycles 
Extend at 72 °C for 2 minutes 
A final 5 minute extension was performed at 72 °C for I cycle only. Negative 
control samples were set up for each PCR performed. These samples consisted of 
the above reaction performed in the absence of eDNA. The following primer pairs 
were used:- 
TBP1 fill length 
5' GGGAATTCCATATGTCCACGOAAGAGATTGTC 3' 
5' CTCCCCCGGGTAGAGGTGTCCCCTAGGC 3' 
TBP1 A375 
5' GGGAATTCCATATGTCCACGGAAGAGATTGTC 3' 
5' GCGCCTAGGAATCTTCAGCTTTTCTGCATCCAC 3' 
TBP1 A475 
5' GGGAATTCCATATGTCCACGGAAGAGATTGTC 3' 
5' GCGCCTAGGAATGTCCACCTCCATGGCCTTCAC 3' 
TBP1 A525 
5' GGGAATTCCATATGTCCACGGAAGAGATTGTC 3' 
5' GCGCCTAGGGATCTCCTGGATATGCTTGTCCAG 3' 
TBP1 PAS 
5' TTCCATCTGTCCACGGAAGAGATTGTC 3' 
5' CTGGTCGACTAGAGGTGTCCCCTAGGC 3' 
TBP1 PACT 
5' CCGGAATTCGCTCAAGATGTCCACGGA 3' 
5' CTGGTCGACTAGAGGTGTCCCCTAGGC 3' 
TBP7 PAS & PACT 
5' ATGCCATGGTGGTCACTATGGAGGAG 3' 
5' CTGCTCGAGCTCACTTGTAAAACTCATG 3' 
SUG2 PAS 
5' TTCCATATGGCGGACCCTAGAGATAAG 3' 
5' CCGCTCGAGTTACACAGGTTTGTAGTCCAA 3' 
FLIIflSUKSI 
5' CCGGAATTCTCATGGCGGACCCTAGAG 3' 
5' CCGCTCGAGTTACACAGGTTTGTAGTCCAA 3' 
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1 Oj.tl of the PCR reaction was electrophoresed on a 1% TAE gel (section 
2.1.9) to check a product of the correct size was present. The remainder of the 
reaction was run on a low melting point gel and the band of interest purified as 
described in section 2.1.2. 
2.8.2 Differential Display RT-PCR 
5g of total RNA was used as template to prepare single stranded eDNA 
using a First Strand cDNA Kit (Pharmacia). Briefly, RNA was diluted to 5R1  in 
sterile ddH20, denatured at 65 °C for 10 minutes and the following components were 
added:- 
lj.il DTT (200mM) 
4M1  8jiM Oligo dT12MN primer 
5p.l Bulk Strand Mix (M-MuLV reverse transcriptase, RNAguard, dNTP mix) 
The cDNA reactions were incubated at 37 °C for 1 hour, followed by heat 
inactivation of the reverse transcriptase at 95°C for 10 minutes. cDNAs were diluted 
to lOOpil and mixed. lOgI of the diluted cDNA reaction was further diluted in 90jal 
ddH20. This dilute cDNA stock was used in the following PCR reaction. 
lOp.! eDNA (approximately 50ng) 
2pJ 20pM dNTP mix 
2gl 8p.M Oligo dT 12MN primer 
2g1 5p.M Random lOmer primer 
2p1 10 x PCR Buffer 
ijil a35S dATP (Amersham, specific activity 1000Ci/mmol) 
0.3j.tl Taq DNA Polymerase (Boehringer, 5U/pl) 
0.7p.l ddH20 
The reactions were overlaid with 30p.l mineral oil and placed in a thermal cycler and 
amplified using the following conditions:- 
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94°C for 2 minutes 
94°C for 30seconds 	1 
40°C for 2 minutes 	 40 cycles 
72°C for 30seconds 
72°C for 5minutes 
The following primers were used:- 
Oligo dT 12MC is an equal mix of T 12AC, T 12CC, and T 120C 
Oligo dT 12MA is an equal mix of T 12AA, T12CA, and T 120A 
Oligo dT 12MG is an equal mix of T12AG, T12CO3 and T12GG 
Sox AGTCAGTCTO 
Rand I GTTCATAAGC 
Rand 5 ACCCCGGTCA 
Rand 12 ACGTCTATAG 
Rand 14 TTCGGCTTGA 
Rand 15 CTGATCGGAC 
Rand 16 GATACCCTGT 
Native 6% polyacrylamide gels in I x TBE buffer were prepared for 
differential display reactions. 8j.xl of the PCR reaction was loaded following dilution 
in loading dye, and the gel run at 250 volts overnight at room temperature. The gel 
was dried at 80 °C for 1 hour and exposed to film overnight. When labelled PCR 
reactions for screening slot blots were required, (X3 5 S dAT? was substituted with 
cz32P dCTP and generally a mix of primer pairs were included in the reaction. 
Otherwise the reaction was identical to that described above. 
2.8.3 Band Excision 
Using the developed autoradiograph, scores were made in the film using a 
sterile scalpel blade on either end of the band to be excised. The autoradiograph was 
110 
overlaid on the dried display gel and used as a template to score the area of interest 
on the gel. This band was subsequently cut from the gel and rehydrated in 100 i 1 
dd}120 at room temperature for 15 minutes. The eluted DNA was denatured at 99 °C 
for 15 minutes prior to the addition of 2•5M1  20mg/ml glycogen, 1/10 volume of 3M 
NaAc and 3 volumes of ethanol. The DNA was stored at --20 °C overnight and 
precipitated by centrifugation at 13000rpm for 30 minutes. DNA pellets were 
washed in 70% ethanol air dried and resuspended in lOjil ddH 20. The DNA was 
then reamplified using the same primer combination as in the original amplification 
procedure. The reaction was performed as follows:- 
4M1  DNA 
4M1  10 x PCR Buffer 
25R1  20jtM Oligo dT Primer 
2.5gsl 20.sM Random Primer 
3.2j.xl 10mM dNTP mix 
0.3j.xl Taq DNA Polymerase 
ddH20 to 40j.xl, and samples were overlaid with 30M1  mineral oil. 
The reactions were transferred to a thermal cycler and amplified using identical 
conditions to the initial PCR reaction. One quarter of the reamplified DNA was run 
on a 1% agarose gel to check the reactions were successful, and the remaining PCR 
reaction was purified using a Qiagen PCR Purification Kit (as per manufacturer's 
instructions) and cloned into an Invitrogen TA (PCR) cloning vector as described in 
section 2,1.5. 
2.9 cDNA Library Screening 
2.9.1 Plating of eDNA Library 
A day 15 gestation mammary gland eDNA library in Lambda Uni-Zap XR 
(Stratagene) provided by Dr Christine Watson, was used according to the supplier's 
III 
instructions. The strains supplied were:- XL1-Blue MRF (genotype A(mcrA) 183, 
A(mcrCB-hsdSMIR-mrr) 173, endAl, supE44, thi-1, recAl, gyrA96, relAl, lac[F' 
proAB, TnlO(tef)]} and SOLR strain {genotype e14-(mcrA), 
A(mcrCB-hsdSMR-mrr)171, sbcC, recB, recJ, umuC::Tn5(kan'), uvrC, lac, gyrA96, 
relAl, thi-1, endAl, AR [F' proAB,faclZM15]  Su(nonsuppressing)). 
50m1 cultures of LB broth supplemented with 0.2% (vlv) maltose and 10mM 
Magnesium sulphate (MgSO 4) were inoculated with a single XL1-blue MRF' colony 
and grown overnight at 30°C in a shaking incubator. Cells were centrifuged at 
2000rpm for 10 minutes and the pellet resuspended in lOmivi MgSO 4 such that 
0D600 was equal to 0.5. These cells were stored at 4 °C for a maximum of 3 days. To 
titre the library, serial dilutions of the phage stock were made in SM Buffer (i.e. l0 
to 10.8  dilutions). 1 j.tl of this diluted phage was added to 200pi of the plating strain 
(XL1-blue MRF cells, 0D600=0.5). These reactions were incubated at 37 °C, shaking 
for 15 minutes to allow the phaje to adhere to the bacteria. 3mls of Top Agar (pre-
warmed to 48 °C) was added to the phage/bacteria solution and vortexed prior to 
pouring onto 90mm NZY plates. Plates were left at room temperature for 15 
minutes to allow the Top Agar to set and then incubated at 37 °C overnight. The 
number of plaque forming units (pfu) was subsequently counted to determine the 
titre of the library. 
LB Broth (per litre) 
10g(w/v)NaCl 
1 Og (wlv) bactotryptone (Difco) 
5g (wlv) yeast extract (Difco) 
Adjust pH to 7.0 with NaOH 
NZY Broth (per litre) 
5g (wlv) NaCl 
2g (w/v) MgSO 4.71-120 
5g (w/v) yeast extract 
lOg (wlv) NZ amine (Difco) 
LB Plates (per litre) 
	
NZY Plates (per litre) 
LB broth with 20g (wlv) bactoagar 	NZY broth with 15g (wlv) Difcoagar 
SM Buffer (per litre) 
5.8g (wlv) NaCl 
2g (w/v) MgSO 4.H20 
50mls (v/v) 1M Iris HCI pH7.5 
Smls 2% (wlv) gelatin 
NZY Top Agar (per litre) 
NZY broth with 0.7% (wlv) agarose 
10 x Pipes Buffer (per litre) 
4.OM NaCl 
0.1M Pipes (pR6.5) 
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2.9.2 DNA Screening Protocol 
For primary screens, phage were plated out at a concentration of 50,000pfu 
per 150mm NZY plate. 5 x 104pfu were added to 600p.1 plating cells (0D 500 = 0.5) 
and incubated at 37 °C for 15 minutes prior to the addition of 6.5mls Top Agar. This 
mixture was poured onto 150mm NZY plates and incubated at 37 °C overnight. 
Plates were subsequently refrigerated at 4 °C for 2 hours to chill, which prevented the 
Top Agar sticking to the nylon membrane (Hybond-N, Amersham). The phage were 
overlaid with nylon filters for 2 minutes to allow transfer of the plaques, and the 
filter pricked with a needle to orientate. Following transfer, the filters were 
denatured by submerging in a solution containing 1.5M NaCl, 0.5M NaOH for 3 
minutes. Neutralisation for 5 minutes followed in a solution containing 1 .5M NaCl 
and 05M Iris HO pH8.0. Filters were rinsed for 30 seconds in 0.2M Tris pH7.5 and 
2 x SSC Buffer, prior to blotting dry on 3mm paper (Whatman). Duplicate lifts were 
taken from each plate and performed as above, with the exception that the second 
filter was left in contact with the plaques for 5 minutes. DNA was fixed onto the 
filters by baking at 80 °C for 2 hours. The agar stock plates were stored at 4 °C 
following the transfer. 
Prehybridisation buffer {2 x Pipes buffer, 50% (v/v) deionised formamide, 
0.5% (w/v) SDS} was pre-warmed to 50°C prior to the addition of denatured salmon 
sperm DNA at 1 OOjsg/ml. Filters were incubated in SOmls of prehybridsation buffer 
at 42°C for 2 hours. A blank nylon filter was hybridised with the phage containing 
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filters to determine background hybridisation levels. Double stranded DNA probes 
were labelled using a Stratagene Prime-It II Kit as described in section 2.3.1. 
Labelled DNA was denatured at 99 °C for 10 minutes and added at a concentration of 
1 x 106  cpm/ml hybridisation buffer. Filters were hybridised at 42 °C overnight in a 
shaking water bath. Following hybridisation, filters were washed in pre-warmed 0.1 
x SSC and 0.1% (wlv) SDS buffer, initially at 50°C and then at 65°C for highly 
homologous signals. Membranes were subsequently blotted on 3mm paper to 
remove the excess liquid and wrapped in Saran Wrap and exposed to film overnight 
at —70°C in a cassette containing intensifying screens. Autoradiographs were 
developed and putative positive colonies identified. False positives were eliminated, 
as they generally did not appear on the duplicate filters for each plate. 
2.9.3 Secondary Screen 
Filters and plates were orientated using the dots and needle holes generated 
during the transfer protocol. The area around the signal on the film was removed 
from the plate using the fine end of a pasteur pipette. The agar plug was placed in 
1 ml SM buffer containing 20xl chloroform. Samples were vortexed and agar plugs 
were tittered as described before. For the secondary screen an identical procedure to 
the primary screen was followed, with the exception that the phage were plated at 
50pfu per 90mm NZY plate, using 200jsl plating cells. The plaque lifts and 
hybridisation procedures were identical to above. 
2.9.4 In Vivo Excision 
Rather than performing a tertiary screen, putative positive colonies from the 
second round screen were excised into pBluescript and a plasmid Southern blot was 
performed as described in section 2.1.10. This option was chosen as individual 
plaques were picked at the end of the second round screen. The excision protocol 
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allows efficient excision of the pBluescript phagemid from the Lambda Zap vector. 
Overnight cultures of both XL1-blue MRF' cells and SOLR cells (grown in LB broth 
only) were grown at 30 °C in a shaking incubator. 1/100 dilutions of both SOml 
cultures were made and grown at 37 °C for 2-3 hours until mid-log phase (0D 600 = 
0.2-0.5). XL1-MRF' cells were centrifuged and resuspended such that 0D 600 = 1.0. 
SOLR cells were grown until 0D600  = 0.5-1.0 and resuspended in 10mM MgSO4 at 
= 1.0. The following components were added to a 50m1 conical tube:-
200p.l of 0D600 = 1.0 XL1-MRF'ceils 
250g1 of phage stock (>10 phage particles) 
lj.xl of ExAssist helper phage (>1 x 10 8 pfulml) 
This mixture was incubated at 37 °C for 15 minutes, prior to the addition of 3mls LB 
broth. A further 2.5 hours incubation at 37 °C with shaking followed. Cells were 
centrifuged at 3000rpm for 15 minutes and the supernatant transferred to a fresh 
tube. The supernatant was subsequently incubated at 70 °C for 15 minutes and 
centrifuged at 3000rpm for 15 minutes. This supernatant contained excised 
phagemid pBluescript packaged as filamentous phage particles, which were stable at 
4°C for up to 1 month. 200.tl SOLR cells were added to 100M1  of the above 
supernatant and incubated at 37 °C for 15 minutes prior to plating 50pi of this 
reaction on LB-ampicillin (Sojiglml) plates and incubating at 37 °C overnight. 
Colonies appearing on these plates contain pBluescript double stranded phagemid 
with the cloned DNA insert. Helper phage could not grow on these plates as they 
were unable to replicate in Su (nonsuppressing) SOLR strains, and do not contain 
ampicillin-resistance genes. Single colonies were picked into 2ml LB-ampicillin 
cultures and grown at 37 °C overnight with shaking. Plasmid DNA was purified as 
described in section 2.1.6. As the cDNA in this library was directionally cloned, the 
restriction enzymes EcoRl and XhoI were used to cut the cDNA fragment from the 
vector and DNA was electrophoresed, transferred and hybridised as described in 
section 2.3.2. Double stranded DNA sequencing (section 2.1.11) was performed to 
identify the clones isolated from the library. 
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2.10 Two Hybrid Analysis 
The genotype of S. cerevisiae strain Y190 used for two hybrid analysis was 
[MATa ga14 ga18O his3 trpl-901 ade2-101 ura3-52 leu2-3, -112 + 
URA3::GAL-+lacZ, LYS2::GAL-*FIIS3 cyW]. 
Y190 pre-cultures were grown in 20mls YPD, containing Adenine Sulphate 
(2mg/mi), over 48 hours at 30°C. 100jsl of this pre-culture was diluted in lOOmis 
YPD containing adenine sulphate and grown until 011) 600 = 0.6-1.0. Cells were 
pelleted at 2500rpm for 5 minutes, and washed in 20mls ddll20. A 5 minute spin at 
2500rpm was followed by a second ddH 20 wash. The cell pellet was resuspended in 
ImI ddH20 and centrifuged at 13000rpm for 5 minutes. The supernatant was 
removed and the pellet washed twice in Lithium Acetate/Tris EDTA (LiAc/TE). 
After the final spin, the pellet was resuspended in a final volume of imI LiAc/TE. 
50p.l of Y190 cells were incubated with lj.tg of each test set of DNA's with 50jsg of 
salmon sperm DNA. Following mixing, 300 jil of 40% PEG in LiAc/TE was added 
to the cell/DNA mixture and the reaction incubated at 30 °C for 30 minutes. A heat 
shock at 42°C for 20 minutes was performed and the reaction was then centrifuged to 
remove the PEG from the samples. Cell pellets were resuspended in lml YPD and 
incubated at 30 °C for 2 hours. 50.il of cells were plated out on selective media and 
incubated at 30°C until sufficient growth of colonies (approximately 5 days). The 
reactions were plated out on selective media as detailed in the following table. 
Co-transformation of the test proteins, if an interaction occurs, should drive 
the expression of both the histidine and lacZ genes. The histidine promoter in Y190 
cells is leaky therefore 3-AT is used to inhibit any residual histidine expression and 
thus reduce false positives. As a consequence, any colonies growing on 3-AT plates 
should represent interacting proteins through the expression of the histidine gene. 
Reactions were also plated on media containing all the necessary supplements to 
allow growth to check the cells had transformed efficiently. Colonies growing on 3-
AT plates were picked and assayed for lacZ expression. These cells were grown on 
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their selective media for 4 days and then overlaid with 3mm paper. Colonies and 
filter paper were left in contact for 5 minutes. Immersion in liquid nitrogen fixed the 
colonies to the filter paper, which was then warmed to room temperature. The 
colony-containing filter was placed onto a piece of 3mm paper soaked in Z Buffer 
and the plates were incubated at 30 °C until colour change was visible. 
Interaction Reaction Media Supplements 
pACT (Activation Domain Vector) alone Adenine, Histidine, and Tryptophan, or 
Adenine, Tryptophan, and 3 Amino- 
Triazole (3-AT) at 25mM and 50mM. 
pAS (DNA Binding Domain Vector) Adenine, Histidine, and Leucine, or 
alone Adenine, Histidine, and 3-AT at 25mM 
and 50mM. 
pACT + pAS ( containing test proteins) Adenine and Histidine, or 
Adenine and 3-AT at 25mM and 50mM. 
SC Media (per litre) 
20g Agar (Difco) 
20g D-Glucose ( Gibco BRL) 
6.7g Yeast Nitrogen Base 
w/o Amino Acids (Difco) 
YDP Media (per litre) 








25mM 3-Amino Triazole (3-AT) 
50mM 3-Amino Triazole (3-AT) 
Z Buffer (per litre) 
16. 1  Na2HPO47H20 
5.5 g NaH2PO47H2O 
0.75gKC1 
0.25g MgS047H20 
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The mammary gland undergoes distinct developmental changes that can be 
divided into the following stages; fetal, postnatal, postpubertal, and adult and these 
are described in section 1.2. The most dramatic changes to the gland occur during 
pregnancy when the gland undergoes cycles of proliferation and differentiation of the 
epithelial component. The sequential activation of milk protein genes has been used 
as a marker to define the distinct stages of cellular differentiation that occur during 
pregnancy (Robinson a al., 1995). Much of the research performed on the 
mammary gland has focussed on the control of milk protein gene expression, in 
particular on the action of prolactin in this process. It is known that prolactin 
activates Stat5a and Sb, closely related transcription factors that bind and 
transactivate milk protein gene promoters. Knock-out mice are available for both of 
these factors and this has led to a detailed knowledge of how these proteins signal to 
result in functional differentiation of the mammary gland. Endocrinologists have 
shown that the presence of prolactin alone is not sufficient to differentiate the 
mammary gland. Oestrogen and progesterone are also required for ductal outgrowth 
(Korach, 1994) and alveolar proliferation (Lydon a al., 1995) respectively. This 
would suggest that mammary gland development requires a complex range of 
components, and the correct temporal expression of these components results in 
functional differentiation. 
The aim of this project was to analyse changes occurring in gene expression 
in the developing mammary gland during pregnancy. We hoped to identify genes 
that were responsible for the early switch from proliferation to differentiation, and 
also for genes controlling the terminal differentiation events in mammary epithelial 
cells. The major interest in mammary gland biology until recently has focussed on 
the regulation of milk protein gene expression. In this study we endeavoured to 
identify some of the genes which acted upstream in this pathway, since the genes 
controlling the induction of differentiation in the mammary gland remain unknown at 
present. Another reason to target our analysis to the genes controlling the 
119 
differentiation process in the mammary gland was the relevance of this event in 
susceptibility to breast cancer. It is stablished that reproductive history in 
combination with other factors can affect the risk of developing breast cancer e.g. 
early first full term pregnancy and multiple pregnancies are associated with a lower 
incidence of breast cancer (Boring ci al., 1993, De Waard and Trichopoulos, 1988, 
Rosner ci al., 1994). Nulliparity, late first full term or interrupted pregnancy are 
associated with a greater risk of disease development (Daling ci al., 1994, Newcomb 
ci al., 1996). These observations suggested that the induction of differentiation can 
protect from neoplastic transformation in the breast. Thus there is a fundamental 
need to identify the factors present during differentiation that confer a protective role 
against breast neoplasia. The aim of this study was to identify genes acting during 
the differentiation process in the mammary gland. The prime aim of the project was 
to characterise the role that any target genes identified played in mammary gland 
development. 
A number of mammary epithelial cell lines were available at the start of the 
study. These cell lines represent valuable in vitro systems on which to model 
mammary development. The cell line chosen for this analysis was HC1 1 mammary 
epithelial cells. HC1 1 cells, grown on plastic with the addition of lactogenic 
hormones, induce expression of the milk protein f3-casein (Ball ci al., 1988). A 
synergistic action of prolactin and glucocorticoid was deemed necessary for high 
levels of 13-casein expression, which has resulted in HC  1 cells being used by a 
variety of groups to study control of f3-casein gene expression. These cells were thus 
thought to be a good model for the developing mammary gland. 
The approach chosen to monitor changes in gene expression in the mammary 
gland was differential display. Liang and Pardee (1992) originally described 
differential display as a method to separate and clone individual messenger RNAs 
(mRNAs) by means of polymerase chain reaction (PCR). The basis of the technique 
was to analyse genes that are differentially expressed in cells under altered 
conditions. The general strategy involved amplifying partial cDNA sequences from 
subsets of mRNA populations. The 3' primers used were designed to anchor the 
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primer to the polyadenylate (polyA) tail present in most mENA species, but these 
primers also contained two additional 3' bases. By probability these primers should 
recognise a subset of the mRNA population e.g. a primer such as T 1 2CA will 
recognise all mRNAs containing UT upstream of the polyA tail. There are twelve 
possible different combinations of the last two 3' bases, omitting T as the 
penultimate base which results in this primer recognising and ampli'ing one twelth 
of the total mRNA present in the cell. The 5' primers used were only lObp long and 
random in sequence. The PCR parameters chosen were of low stringency and 
resulted in amplification of short products (100 to 500bp long) that were resolved on 
a DNA sequencing gel. The PCR reactions were performed in the presence of 
radiolabelled dATP allowing results to be visualised as bands on an autoradiograph. 
This allowed any changes in gene expression to be analysed visually. 
3.2 Differential Display Analysis of UC11 Mammary Epithelial Cell Lines 
The HC1 1 samples used for the differential display analysis had been treated 
in the following manner: a control HC  1 sample, cells treated with dexamethasone 
alone for 24 hours, and cells treated with dexamethasone for 24 hours and then 
treated with prolactin for a further 3 hours. The samples were treated in this manner 
as dexamethasone pre-treatment was thought to prime the cells for prolactin 
treatment e.g. they responded much quicker to the prolactin stimulus when treated in 
this manner. The short 3 hour treatment with prolactin was chosen to target genes 
which were involved early in the differentiation process. The initial displays (Figure 
3.1) showed that very little differences were observed between these treatments, with 
the majority of the bands being evenly expressed in all three samples. This 
suggested that the samples were evenly loaded and any changes that were observed 
may be real. 
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Figure 3.1 HC1 1 Cell Display Gel. Differential display reactions were performed 
on HC1 1 cells which had been untreated (I, Insulin), treated with Dexamethasone for 
24 hours (ID) or treated with Dexamethasone for 24 hours and prolactin for a further 
3 hours (IDP). The reactions containing a35S  dATP were separated on a 5% 
aciylamide gel and exposed to autoradiograph overnight. MA, MG, and MC refer to 
the modified oligo dT primers, and Sox and RI represent the random 10 base pair 
primers. The red dots represent examples of bands excised from the gels for further 
analysis. They are positioned to the right of the band excised and represent clones 
42.1 to 42.3 shown in Figure 3.2. 
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Figure 3.2 shows examples of bands cut from two different display gels. These 6 
bands all had expression profiles which changed with either dexamethasone 
treatment alone and/or prolactin treatment. The expression profiles of these 
transcripts are detailed in Table 3.1. 
The next stage of this technique involved cloning the 3' eDNA fragment into 
a PCR cloning vector. This was achieved by using the autoradiograph as a template. 
The band of interest was scored on the autoradiograph using a scalpel blade and then 
the film was redeveloped to clean the surface of the film. The film was not touched 
with bare hands after this stage as the DNA extracted from the gel was to be 
subjected to a further PCR reaction. The autoradiograph was aligned with the gel 
using Statagene chemiluminescent markers and used as a template to score the area 
of interest on the dried gel. The scored fragment was cut from the dried gel and 
DNA subsequently eluted from the band. The DNA was precipitated in the presence 
of glycogen to enhance recovery. An aliquot of the recovered DNA was amplified in 
a similar manner as the original display reaction using the same primer combination 
as that which amplified the particular band. An aliquot of this reaction was 
electrophoresed on a 1% agarose gel to check the reamplification reaction was 
successful. Figure 3.3a shows the reamplified products from the 6 bands cut from 
the display gels in Figure 3.2. Single bands of the correct size were seen for each of 
these PCR products, although this was not always the case. Occasionally in these 
reactions we would identify smaller fragments than the eDNA fragment cut from the 
gel upon reamplification. When these products were cloned and sequenced they 
were found to represent truncated transcripts of the larger cDNA fragments. It is 
possible that this occurred in the reamplification reaction because the template DNA 
was much more limiting in the second reaction than in the original amplification 
reaction. This was thought to favour binding of the random lObp primer to any 
sequences within the 3' cDNA with which it had a match. Closer analysis revealed 
that some of these truncations had only a 5 or 6bp match to the random lObp primer. 
It is possible that these transcripts were not identified in the initial screen as the 
primer was competed for with sequences to which it had a higher homology. As 
these bands appear to be specific and were related to the original template cDNA, 
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44.2/3 	 - 
Figure 3.2 Products Cut from HCI I Display Gels. These fragments represent 
clones 42.1 to 44.3 which were excised from 2 separate display gels. Cells were 
treated with insulin alone (I) as a control, treated with dexamthasone (D) for 24 
hours, or treated with dexamethasone for 24 hours followed by a 3 hour prolactin 






Figure 3.3 (a) Reamplification products from HC1I Displays. DNA was eluted 
from the dried gel fragments excised from the display gel. This DNA was subjected 
to a PCR reaction, which was identical to the original reaction that generated the 
appropriate lane on the display gel with the exception that radiolabelled nucleotide 
was omitted. An aliquot on the PCR reaction was subsequently run on a 1% Agarose 
gel to confirm the reaction was successful. 
(b) Re-exposure of Display Gel following Band Excision. Following excision of 
dried bands from the gel a long exposure to autoradiographic film (approximately 3 
days) was performed to ensure that the correct band had been excised from the gel. 
This gel represents clones 42.1, 42.2 and 42.3 following band excision. 
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therefore when they occurred they were considered not to be a problem in the 
reamplification procedure. The dried gel from which the bands had been excised 
was re-exposed to autoradiographic film to determine that the correct band and only 
a single band had been excised from the gel (Figure 3.3b). 
The reamplified PCR reactions were purified to remove contaminating 
nucleotide and primers prior to ligation into a PCR cloning vector. The vector used 
was the TA cloning vector PCRII (Jnvitrogen). The PCR products were ligated into 
the PCRII cloning vector and transformed into competent cells. Six colonies were 
chosen from each PCR transformation reaction for subsequent analysis. The clones 
tested were cut with the restriction enzyme EcoRI, which excised the PCR product 
from the vector, to check the size of the products. Double stranded DNA sequencing 
was performed and the resultant sequence compared to sequences within the 
nucleotide and protein databases at BLAST (Altschul es al., 1990). Results from 
sequence analysis are detailed in Table 3.1. Clones 42.1 and 42.3 were identified as 
99% identical to the 3' 180bps of the milk protein gene 3-casein. The primer 
combination that amplified this milk protein had been designed entirely randomly 
and it was not expected to identify this particular transcript. These bands had been 
cut from the lanes containing samples treated with prolactin and therefore 13-casein, if 
expressed anywhere, should be in this sample. These cells were originally selected 
for their prolactin responsiveness, and normally by Northern Blot analysis 13-casein is 
identified after around 4 days treatment with prolactin and dexamethasone. It was 
surprising to detect expression of 13-casein as early as 3 hours after prolactin 
stimulation. This observation validates the use of this technique as we have 
identified a gene product documented to be differentially expressed in the mammary 
gland. These results also suggest that differential display is an extremely sensitive 
technique for detecting changes in gene expression. This particular primer pair 
(oligo dT 1 2MC and Sox) was subsequently used as an internal control for the 
following display reactions. 
42.1 lSObp 99% 	Identical 	to 	3' Induced 	by Yes 	(Slot 	blot 
murine 13  casein Prolactin alone and Northern) 
42.2 210bp 77% 	Homologous 	to Induced by Dex, No (Slot Blot) 
exons 2 and 3 of murine and Prolactin 
c-abl oncogene 
42.3 210bp 99% 	Identical 	to 	3' Induced 	by Yes 	(Slot Blot 
murine 13 casein Prolactin alone and Northern) 
44.1 150bp Unknown! Induced by Dex No 
Novel alone (undetectable by 
Slot Blot) 
44.2 350bp 90.8% 	Identical 	to Induced by Dex Yes (Slot Blot) 
murine 	5cx 	steroid and Prolactin No (Northern - 
reductase expressed in all 
samples) 
44.3 350bp 90.8% 	Identical 	to Induced by Dex Yes (Slot Blot) 
murine 	5ct 	steroid and Prolactin No (Northern - 
reductase expressed in all 
samples) 
Table 3.1. Summary of Clones isolated from HC11 Differential Display 
Reactions. The table details the size of the PCR products, nucleotide sequence 
homology, original expression profile by display, and whether the expression profile 
was confirmed. 
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Band 42.2 was identified to be 77% homologous to exons 2 and 3 of murine 
c-abl. This transcript was isolated in both dexamethasone and prolactin treated 
samples. c-abl is a member of the non-receptor class of protein tyrosine kinases, and 
was originally identified as the cellular homology of v-abl, the transforming 
component of the Abelson Murine Leukaemia virus. c-abi is expressed ubiquitously 
in mammalian cells. It is localised in the cytoplasm in association with the 
cytoskeleton (on actin filaments) and also in the nucleus (McWhirter and Wang, 
1991). c-abl contains an F actin binding site and a sequence specific DNA binding 
domain. This DNA binding activity is lost during mitosis due to the phosphotylation 
of the C-terminal segment that contains the DNA binding motif Overexpression of 
c-abl causes GOIG I cell cycle arrest suggesting that it acts as a negative regulator of 
cell growth. If this transcript represents a mammary specific factor that acts in a 
similar manner to c-abl, then the expression profile observed would fit with a growth 
arrest function. The transcript is only expressed in samples that are being induced to 
differentiate by the removal of EGF and the addition of dexamethasone and prolactin 
to the cells. The removal of EGF from the media eliminates the growth stimulus, 
thus the cells no longer have their proliferative signal. The addition of hormones and 
glucocorticoid induces differentiation and as a consequence the cells may exit the 
cell cycle. These events are similar to those seen when c-abl induces growth arrest, 
therefore we may have identified a gene whose action is to induce growth arrest in 
cells in order to allow the differentiation process to commence. Band 44. 1, which 
was only lSObp long, had no known sequence homology. 
Bands 44.2 and 44.3 were expressed and excised in the samples induced to 
differentiate with dexamethasone (44.2) and prolactin (44.3) and subsequently 
identified as being 90% identical to the steroid 5a-reductase gene. Steroid 5ct-
reductase is an enzyme responsible for the conversion of testosterone to the more 
potent dihydrotestosterone. It is a gene required for the differentiation of the external 
male genitalia (Anderson ci al., 1989). The absence of steroid 5a-reductase activity 
results in a rare form of male pseudohermaphroditism, where the male external 
genitalia differentiate as female structures (Walsh et al., 1974, and Imperato-
McGinley ci al., 1974). The expression of this enzyme is generally restricted to 
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androgen responsive tissues, but it has been found expressed at high levels in the 
female rat liver but not in male rat liver. It has subsequently been described as being 
expressed in the ovary (Anderson etal., 1989). Steroid Sa-reductase is documented 
to play a role in the induction of the differentiation process in the testes. A simple 
explanation for the presence of this enzyme in mammary epithelial cells would be 
that this gene product plays a role in steroid hormone metabolism (Normington and 
Russell, 1992), and the mammary gland is one organ that is extremely responsive to 
hormonal changes. This enzyme plays a role in the metabolism of progesterone, an 
androgen that is highly expressed in the pregnant mammary gland. It may also be 
involved in the differentiation process in the mammary gland, which would correlate 
to the observed expression profile of this transcript. 
Generally, when differential expression of a clone was identified by 
differential display analysis, its expression profile was confirmed by examining 
mRNA expression, usually by Northern Blot analysis or RNAse Protection Assay. 
For the six clones described above a modified slot blot analysis was performed to 
confirm expression profiles. Plasmid DNA was fixed on nylon membranes and 
hybridised with a radiolabelled PCR reaction. This PCR reaction was performed for 
each of the RNA samples used in the display reactions and included all the primer 
combinations used to generate all of the excised clones. The results of this analysis 
are summarised in Table 3.1. Slot Blot Analysis confirmed that the f3-casein 
transcript was present only in the samples treated with prolactin. This result 
confirmed what was previously known about this transcript, that 13-casein was 
prolactin responsive (Ball et al., 1988). The expression profile observed by display 
for clones 42.1 and 42.3 was identical to that observed by Slot Blot analysis. Clone 
42,2, with high homology to exons 2 and 3 of murine c-abl, was shown to be present 
in all three samples by Slot Blot Anlaysis. This result differed from that seen by 
differential display, where this transcript was originally thought to be present in only 
the dexamethasone and prolactin treated samples. No signal was observed for clone 
44.1 by Slot Blot Analysis. In contrast, clones 44.2 and 44.3 appeared to be 
differentially expressed as confirmed by Slot Blot analysis. Northern hybridisation 
was performed on HC1 1 cell RNA using clone 44.3 (steroid 5a-reductase) and 
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showed a weak signal in all three samples. This result conflicted that observed by 
Slot Blot where this clone was observed to be differentially expressed. 
The results on the j3-casein transcript would suggest that this Slot Blot 
technique could be used to confirm differential expression. On further analysis it 
would appear that this modified Slot Blot method was only adequate for identifying 
genes which are relatively abundant. It was used to confirm 13-casein expression 
correctly but this transcript accounts for around 20% of the total mRNA within the 
cell by late pregnancy. For transcripts of lower abundance this method was less than 
adequate. This may be due to the problem with the labelling technique. The method 
involved performing a PCR reaction containing all of the primers used to generate 
the bands excised from the display gels. Effectively each lane on the display gel was 
recreated in the labelling reaction e.g. in this case where 6 transcripts were to be 
analysed 4 different sets of primer combinations were used. This resulted in 4 lanes 
of the display gels being recreated in one reaction, which suggested that the 
particular transcript of interest would be a extremely small proportion of the total 
eDNA present. This may have resulted in difficulty in detecting transcripts that were 
not particularly abundant in the original starting RNA population. The Slot Blot 
method was chosen for an initial screen because it allowed the examination of all 6 
clones in one reaction, as opposed to hybridising 6 Northern Blots. This was of 
importance in the display reactions as a vast number of clones can be generated very 
quickly and much of the time involved with this technique is that of confirming 
differential expression. In retrospect, it was apparent that this screening method had 
its limitations, and could not empirically confirm differential expression e.g. in the 
case of clones 44.2 and 44.3. As the relative abundance of the majority of the bands 
excised from the differential display gels is unknown, it may be prudent to perform 
Northern Analysis on these clones for a more definitive answer. 
The studies using RNA from BC 11 cells had revealed a small number of false 
positives identified in this analysis. Taking clone 42.2 as an example, we 
demonstrated by Slot Blot analysis that this clone was not differentially expressed. 
In general we exposed the differential display gels to autoradiographic film for a 
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maximum of 3 days. This resulted in a strong signal being observed for the vast 
majority of the bands present. Re-exposure of differential display gel #42 for a 
longer period resulted in the possibility that a very weak band may have been present 
in the untreated insulin sample. This observation confirmed the results obtained 
using the screening method. Although this transcript was present in the untreated 
control sample, by display and Slot Blot this appeared much weaker than that 
observed in the dexamethasone and prolactin treated samples. This result led to the 
observation that there may be some subtle changes in the expression of genes, which 
could be overlooked when two or three samples were compared side by side. This 
could be overcome when analysing a time-course of samples, where gene expression 
could be compared over S or 6 samples. This may also eliminate the problem of 
false positives, as any change in gene expression observed throughout 6 samples is 
more likely to be reproducible than changes observed between only 2 or 3 samples. 
In general, a less complex system is preferred for use in differential display 
reactions e.g. if an in vitro cell culture model was available, this was the preferred 
template RNA for differential display as opposed to whole organs. This was thought 
to be due to the assumption that when using a whole tissue for analysis some 
differences may appear due to different populations of cells present in the tissue 
examined. This was the original reasoning behind using a mammary epithelial cell 
line as a model for differentiation changes occurring during pregnancy in the 
mammary gland. As a result of the initial display reactions working well in the cell 
lines we chose to analyse mammary gland tissue in the differential display reactions. 
The mammary gland is different from most other organs in that it contains only 
epithelial cells and stroma and in this respect should not represent a problem for use 
in differential display. Examining differentiation changes in the mammary gland 
itself was a more relevant approach to this question. Although the mammary 
epithelial cell lines available at this time could differentiate and express 13-casein, 
they were unable to mimic terminal differentiation. This is marked by the expression 
of WAP in the mammary gland, and none of the available cell lines express this milk 
protein, therefore they may not be quite as relevant to mammary gland differentiation 
as originally assumed. 
131 
3.3 Differential Display Analysis of Murine Mammary Gland During 
Pregnancy. 
Differential display analysis was performed on samples from virgin through 
to late gestation mammary glands. Mammary glands were collected from 
C57BL6ICBA mice at non-pregnant, day 10 gestation, day 13 gestation, day 15 
gestation, and day 18 gestation time points. The strain of mice used had a gestation 
period of approximately 21 days. Differential display analysis was performed in an 
identical manner to those performed on HC1 1 mammary epithelial cells. Figure 3.4a 
shows display analysis on mammary gland samples and represents samples that were 
performed in duplicate. Each set of reactions was performed entirely independently 
and comparison of the corresponding lanes showed >95% accuracy in the 
reproduction of banding patterns. Resolution of these samples showed that the vast 
majority of the bands were common within a set of 5 samples. These observations 
suggested that performing the display reactions on a developing tissue would not 
result in changes observed which were due to changes in proportions of cell 
populations in the mammary gland. Figures 3.4b and 3.4c represent bands that were 
cut from a range of differential display gels for further analysis. All of these bands 
were excised and reamplified in a manner described in section 3.2. Figure 3.5 shows 
the results of these reamplifications. Truncated products were obtained for a range 
of these clones, and sequence analysis confirmed in most cases that where two PCR 
products were obtained these represented overlapping fragments of the same cDNA5. 
The reamplified PCR products were cloned into the PCRII cloning vector and the 
plasmid DNA from the resultant colonies sequenced. Table 3.2 summarises the data 
obtained on these clones. 
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Figure 3.4b Products Cut from Mammary Gland Display Gels. These fragments 
represent 5 clones that were excised from the display gel shown in Figure 3.4a. The 
display gel was performed on cDNA extracted from the mammary glands of mice 
from virgin until late gestation. The arrow represents the band excised for clone 
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Figure 3.4c Products cut from Mammary Gland Display Gels. These fragments 
represent 4 clones cut from a range of display gels performed on eDNA prepared 
from virgin mammary glands through to day 17 gestation mammary glands. Clones 
102.7 and 124.5 are expressed highly from virgin through until day 10 gestation. In 
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Figure 3.5 Reamplitied Products from Mammary Gland Displays. DNA was 
eluted from the dried gel fragments and subjected to a further PCR reaction. This 
second reaction was identical to the original reaction which generated the appropriate 
lane on the display gel with the exception that radiolabelled nucleotide was omitted. 
An aliquot of the PCR reaction was subsequently run on a 1% Agarose gel to confirm 
that the reaction was successful. 
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Clone 72.1 was identified as 100% identical to murine 13-casein. This 
reaction was performed as an internal control for the PCR reactions. We had 
previously identified f3-casein using this particular primer pair (oligo dT12MC and 
Sox) in HC1 1 cells. The expression pattern observed for this clone, increasing 
gradually throughout gestation, was identical to that which we expected to see for 
this milk protein, and this was confirmed by Northern Blot analysis (Figure 3.6). 
The mammary gland begins to express f3-casein from around day 10 of gestation, and 
this expression increases as the gland develops towards the lactation period (Ball €1 
al., 1988). We identified a band for this transcript in the control non-pregnant 
sample by differential display, which was not expected. Generally, virgin mammary 
glands are thought not to express 0-casein, but it has been observed in vitro that 
embryonic mammary glands are able of responding to lactogenic hormones in 
culture. These glands produce a casein-like material which comigrates with 
authentic casein (Ceriani, 1970). It is possible that no one has previously used a 
method as sensitive as differential display to analyse mammary gland mRNA, hence 
f3-casein has never been detected this early. These studies using embryonic 
mammary glands suggest that this result was not as strange is it had first appeared. 
Another reason that these mammary glands express [3-casein may be due to the fact 
that the mice used had been previously mated, but were not pregnant. The change in 
circulating hormone levels caused by mating may have resulted in some small 
changes in the mammary gland e.g. may have acted to stimulate the gland in a way 
similar to an early pregnancy signal. 
Clones 72.4, 72.6, and 72.8 were all excised from the same lanes as clone 
72.1 (3-casein). Comparison of these primer combinations (oligo dT 12MC and Sox) 
in Figure 3.4a shows that a high proportion of the bands present in these lanes appear 
to decrease as the gland develops during pregnancy. These three clones were chosen 
for further analysis to determine if the banding pattern was real or an artefact due to 
the high expression of -casein in late gestation mammary gland. Sequence analysis 
revealed no major homologies of any of these clones with sequences in the databases 
searched. Northern Blot analysis revealed that expression could be detected for two 
of the three clones. Results from both of these clones showed that the expression 
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Figure 3.6 mRNA Expression of Clones isolated from Mammary Gland Display 
Gets. Total RNA was isolated from the mammary glands of C57/CBA mice at 
various stages of gestation e.g. non-pregnant represent that which were mated but 
failed to become pregnant, or day 10, 13, 15 or 18 of gestation. The strain of mice 
used had a 21 day gestation period. 1 Ogg RNA was electrophoresed prior to blotting 
on nylon membranes. Each membrane was hybridised against radiolabelled cDNA 
prepared from the excised bands from the display gels. Membranes were washed 
and exposed to autoradiographic film prior to being hybridised with an 
oligonucleotide against 28S ribosomal RNA to allow quantitation. The second panel, 
which is the loading control for clone 72. 1, represents the 18 and 28S RNA stained 
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72.1 1 SObp 100% 	Identical 	to Increase from day 10 Yes (Northern) 
3 'murine 	-casein onwards 
72.3 22 Sbp 99% 	Identical 	to Increase from day 10 Yes (Northern) 
murine TBP 1 onwards 
72.4 175bp Unknown! Increased up to thy No (Northern) 
Novel 10 then decreased 
72.5 175bp Unknown! Increased on days 10 Yes (RPA) 
Novel and 13 
72.6 200bp Unknown! Increased up to day No (Undetectable) 
Novel 10 then decreased 
72.7 250bp Unknown! Increased on days 10 Yes (Northern) 
Novel and 13 
72.8 250bp Unknown! Increased up to day No (Northern) 
Novel 10 then decreased 
72.9 275bp Unknown! Increased on day 13, Yes (Northern) 
Novel peaks 	on 	day 	15, 
then off in day 18 
102.7 250bp Unknown] Increased in virgin, No (Undetectable) 
Novel and days 5 and 10 
124.1 1 OObp Unknown] Present on day 	10 No (Undetectable) 
Novel only 
124.3 1 5Obp Unknown! Present 	in 	virgin No (Undetectable) 
Novel only 
124.5 250bp Unknown! Increased in virgin, No (Undetectable) 
Novel and days 5 and 10 
Table 3.2 Summary of Clones Identified in Mammary Gland Differential 
Display Reactions. The table summaries the clones excised, their size, expression 
profiles, and whether they were confirmed to be differentially expressed. 
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profile was constant throughout gestation, in conflict with the pattern observed on the 
display gel. These results can be explained by the fact that f3-casein represents 
around 15-20% of all the niRNA present in the cell by late gestation. As this 
transcript is so abundant, it was assumed that 13-casein was binding the majority of 
the primer present in the mid to late gestation samples resulting in what appeared to 
be a decrease in a high proportion of transcripts in these particular samples. 
Clone 72.3 had an expression profile by differential display that appeared to 
increase in expression from day 10 gestation onwards as the gland develops during 
pregnancy. Sequencing revealed this clone to be the mouse homologue of Tat 
Binding protein 1 (TBP1). TBP1 was originally identified as a protein that interacts 
with the Human Immunodeficiency Virus (WV) Tat Transcactivator (Nelbock etal., 
1990). TBP1 was described as binding to lilY Tat and specifically repressing Tat 
mediated transactivation. More recently, TBP1 has been described as a member of a 
family of Mg2 dependent ATPases, which play a role in capturing ubiquitinated 
proteins targeted for degradation (Dubiel ci' al., 1992). These ATPases function as 
part of the 26S proteasome and yeast mutation studies have shown that expression of 
one of these proteins is essential for cell cycle progression (Gordon et al., 1993). 
The expression profile for clone 72.3 was confirmed by Northern Blot analysis 
(Figure 3.6) and showed a ten-fold increase in expression by mid gestation. This 
result paralleled that observed by differential display. 
Clone 72.7, which peaked in expression on days 10 and 13 gestation, had no 
known sequence homology when compared to the databases. This expression profile 
was confirmed by Northern Blot analysis (Figure 3.6). Clone 72.9, present on day 13 
and peaking on day 15 gestation, again showed no identifiable sequence homology. 
Northern Blot analysis confirmed the expression profile observed by differential 
display for clone 72.9 (Figure 3.6). 
Clone 72.5 had an expression profile that peaked on days 10 and 13 of 
gestation. No sequence homology was obtained for this clone. Northern Blot 
analysis was performed using this 3 'cDNA, and no signal was observed. As a more 
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sensitive method for detecting mRNA expression, an RNAse Protection Assay 
(RPA) was performed. To optimise the system, we performed an RPA with clone 
72.1 (0-casein) as the expression profile of this clone was well known. Results 
showed the correct expression profile for f3-casein (Figure 3.7a) and thus the assay 
was performed using clone 72.5 (Figure 37b). The RPA confirmed a similar pattern 
to that observed on the differential display gel, with high expression on days 10 and 
13 gestation. 
None of the clones represented by 3' cDNA fragments 102.7, 124.1, 124.3, 
and 124.5 had any identifiable sequence homology when screened against both 
nucleotide and protein databases. Clone 124.1 appeared to be represented by a single 
PCR reamplification product, but when sequenced revealed that there was an equal 
proportion of three different cDNAs present. Although there are reports that one 
band represents one gene in these display gels (Guimarares et al., 1995), other 
groups have reported that one band may represent additive products of distinct 
eDNA fragments (Li ci al., 1994, Callard et al., 1994). Approximately 20 individual 
clones were sequenced for clone 124.1 and it became apparent that none of the three 
transcripts identified were represented more frequently than any of the others. 
Northern Blot analysis was performed for these three cDNAs as well the other clones 
and no signal was detected for any of these excised bands. RPAs were subsequently 
performed for each of these clones, again yielding no discernible results. The 
detection problems were not as a result of the quality of the template RNA used in 
these reactions as 18S ribosomal RNA probes were used for both Northern and RPA 
analysis and these produced signals. In order to confirm whether the banding 
patterns we observed represented PCR artefacts, we prepared fresh RNA samples 
and repeated the differential display reactions. Identical results were obtained from 
this second display gel suggesting that these bands did indeed represent differentially 
expressed cDNAs, which are probably of extremely low abundance. More recently, 
polyA RNA was prepared from mammary epithelial cells that were induced to 
proliferate, differentiate, or undergo apoptosis. Northern Blot analysis revealed no 
signals for any of these clones. 
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Figure 3.7a Optimisation of RNase Protection Assay. An RNase Protection 
Assay was performed using clone 72.1 (3-casein) to optimise the system for use with 
mammary gland RNA. Sense and anti-sense transcripts were generated from clone 
72.1 and hybridised to RNA from mice at different stages of gestation (gest). The 
same samples were also hybridised with an oligonucleotide generated against 18S 
RNA as a loading control. The reactions were performed in the presence of 32 P 
dUTP and exposed to autoradiographic film overnight. The control samples are 
represented by probe alone and undigested yeast RNA hybridised to clone 72.1 (-ive 

















Figure 3.7b Expression Profile of clone 72.5. An RNase Protection Assay was 
performed on clone 72.5 (200bp long) as no signal had been detected by Northern 
hybridisation. Sense and anti-sense transcripts were hybridised to RNA from the 
mammary gland of mice at different stages of gestation (gest), lactation (lact), and 
involution (Inv). Reactions were performed in the presence of 32P-dUTP and 
exposed to autoradiographic film overnight. The control samples are represented by 
probe alone and undigested yeast RNA hybridised with clone 72.5 (-ive control). 
These samples were exposed for 3 hours. 
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The clones which appeared novel in sequence when originally compared with 
the nucleotide and protein databases have been recently re-entered. No additional 
matches with any of these sequences were found. It would appear that the clones 
with undetermined sequence homology may represent novel genes expressed at 
specific stages in the mammary gland. Although these clones contained putative 
open reading frames, no signal could be detected by Northern Hybridisation or 
RNAse protection Assay for each of these clones therefore it remains to be shown 
whether they do indeed represent cDNAs of very low abundnace. 
3.4 Discussion 
The results presented in this chapter demonstrate the optimisation of the 
technique of differential display for analysis in a mammary epithelial cell line and 
also with mammary gland tissue. The initial studies performed using HC 11 cells 
confirmed that this technique was capable of identifying differentially expressed 
genes. 13-casein, a milk protein known to expressed following prolactin treatment in 
an in vitro mammary gland model, was identified in the appropriate prolactin treated 
sample. In vivo, 13-casein was detected at high levels in the mammary gland from 
day 10 gestation onwards. This expression profile minors that documented for f3-
casein during pregnancy (Ball et al., 1988). These results validate the use of this 
technique to detect differentially expressed genes. 13-casein is a highly abundant 
gene in differentiated mammary epithelial cells. The detection of genes in the HC 11 
cells (clone 44. 1), and in mammary gland (clones 102.7, 124.1, 124.3 and 124.5) 
whose expression profile cannot be confirmed by conventional Northern 
Hybridisation and/or RPA suggests that differential display has the ability to amplify 
genes of low abundance in the cell. The advance from cell lines to using a whole 
organ system for differential display has allowed the isolation of genes that show 
more subtle changes in expression during pregnancy. For example clone 72.3, which 
gradually increases in expression as gestation progresses, may not have been isolated 
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if only one or two samples were being compared side by side. When analysing two 
samples side by side there is a tendency to overlook changes such as this in 
preference for genes which are switched on or off in one of the samples. The use of 
a time course of mammary development has allowed the detection of more subtle 
quantitative changes in gene expression, which themselves may be just as important 
to mammary gland differentiation as genes which either switch on or off in response 
to differentiation. 
The description of differential display in 1992 has taken the analysis of 
cDNA expression one step forward. Until then the only techniques available for 
identifying differentially expressed genes were differential screening and subtractive 
hybridisation, both of which have limitations. These techniques are both time 
consuming, cumbersome, and show high levels of false positive results. Differential 
screening involves screening an appropriate cDNA library, plated in duplicate with 
radiolabelled single stranded cDNA from two different populations of cells (Watson 
and Demmer, 1994). Most of the plaques will hybridise equally to both probes, but 
some will show a difference in signal strength. These clones represent differentially 
expressed cDNAs. The major problems associated with this technique are that 
successive rounds of screening are required to eliminate false positives. Plaques are 
required to be screened at low densities to differentiate between signals therefore 
only a small number of clones can be screened at one time. The major drawback of 
this technique is that rare RNAs are poorly represented in the cDNA probe resulting 
in weak hybridisation signals. As a consequence there are difficulties in observing 
any differences between replica filters, and a problem in distinguishing these weak 
signals from background hybridisation levels. cDNAs of very low abundance 
(<0.1%) were found to be very difficult to clone using differential screening and 
subtractive hybridisation was originally thought to be the preferred technique for this 
group of low abundance cDNAs. Subtractive hybridisation is a more complex 
procedure to perform. It is based on producing single stranded eDNA from a treated 
population of cells. This cDNA is hybridised to purified mRNA from a related cell 
population e.g. untreated cells, and the resulting single stranded unhybridised eDNA 
purified from the hybridised molecules (Watson and Margulies, 1993). These should 
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represent cDNAs that are more abundant in one population of cells. Again this 
technique has its limitations, the major one being that it is biased towards abundant 
transcripts. Modifications in this technique have been developed and these involve 
biotinylating common sequences and removing them using streptavidin prior to 
hybridisation. As the technique is based on hybridisation, the efficiency of this step 
dictates the number of false positives generated e.g. where the hybridisation is poor a 
high proportion of clones will be isolated that are common to both cell populations. 
A common problem with both of these techniques is the inability to isolate very rare 
cDNAs from these screens. Differential display appears to have overcome the vast 
majority of the problems associated with the existing cDNA screening methods. As 
it is PCR based, it has the ability to identify and amplify transcripts of low 
abundance. Analysis using this technique was not biased towards transcripts that 
were of higher abundance. In this study we identified the milk protein 3-casein, 
which itself represents around 15-20% of the mRNA present in the cell by late 
gestation. This is one of many milk proteins expressed within the mammary gland, 
but was the only one that was identified in this study. 13-casein was identified using 
only one of the four available oligo dT primers and one of the thirty random lObp 
primers. In a situation whereby gene expression was to be analysed then these 
primer pairs could be avoided and the problem overcome. Differential display 
affords a major advantage over the existing techniques because it is not time 
consuming to perform; From the stage of ha -Ong the population of RNA prepared 
ready for use, to excising bands from the gel can take as little as 3 days. This allows 
rapid screening of a high proportion of cDNAs within a relatively short time scale. 
The prime advantage offered by using differential display to screen cDNAs is that a 
time course of samples can be compared side by side as opposed to the earlier 
techniques which were limited to comparing two populations. This allowed the 
analysis of quantitative changes in gene expression and also decreases the chances of 
producing false positive cDNAs. 
Many modifications of the differential display technique have been described 
recently. These include modifications to the oligo dT primers e.g. the use of three 
one base anchored oligo dT primers which reduces the number of reverse 
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transcription reactions needed for each RNA sample and minimises the redundancy 
and under-representation of certain RNA species due to degeneracy of the primers 
(Liang et al., 1994). Zhao and co-workers (1995) in addition to Diachenko and 
colleagues (1996) described the use of longer random primers (25-29mers). These 
longer primers allowed the use of optimal nucleotide concentration and a higher 
stringency PCR. Thermostable Taq DNA Polymerase has allowed longer PCR 
products which were said to result in more reproducible differentially expressed 
bands. These adaptations were in part combining the techniques of differential 
display and RNA fingerprinting. Lohmann and colleagues (1994) chose to perform 
display reactions on horizontal polyacrylamide gels and visualised by silver staining, 
which allowed them to overcome problems associated with excising DNA from a 
dried polyacrylamide gel. This also resulted in the removal of radiolabelled 
nucleotides from the display reactions. Chen and Peck (1996) took this adaptation 
one step further by transferring the PCR products onto a nylon membrane and 
staining with dioxygenin to detect cDNA bands. In contrast to this other researchers 
had sensitivity problems and thus switched from using 35S radiolabelled nucleotide to 
32P (Trentmann et al., 1995) or to 33P (Tokuyama and Takeda, 1995). Other 
modifications to the technoque involved adapting primers in such a way as a 
facilitate use in a screening protocol e.g. Yeatman and Mao (1995) devised a method 
whereby PCR products could be used directly in an ribonuclease protection assay as 
well as for use in automated sequencing. In general, the majority of these 
refinements were subtle changes in the original strategy designed to overcome 
problems that individual groups had encountered with the technique. The only 
modifications we chose to perform from the original technique described in 1992 
were the use of four oligo dT primers containing one fixed and one degenerate base 
at the 5 'end as opposed to twelve individual oligo dT primers containing two fixed 5' 
bases, and the use of non-denaturing polyacrylamide gels. We did not attempt to 
make any further modifications to the technique, as it appeared to be working 
optimally within the system we chose to analyse. Differential display has become a 
widely accepted and utilised cDNA screening technique in the last 5 years and it only 
requires examination of the literature to see how widely used this technique has 
become for the analysis of gene expression. The model systems within which 
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differential display has been used are described in Table 3.3. 
The study of expression patterns of a gene within different tissues is normally 
performed by Northern Blot analysis or RPA, and these were the methods we chose 
to use for analysis of the clones isolated by differential display. However, these 
techniques are not adequate for the detection of a very low abundance message. 
Although RPA is approximately ten fold more sensitive than Northern Blot analysis, 
it still has some limitations in detection. By definition differential display results in 
the cloning of mRNAs of very low abundance (Liang and Pardee, 1992). Generally, 
the option at this stage would be the preparation of polyA selected mRNA and then 
Northern Blot analysis. However this is not always an option, and is dependent on 
the availability of tissue. Indeed, one of the major advantages conferred by using 
differential display was the ability to perform the reactions with just 5g of total 
RNA, with no need to purify and enrich for mRNA. Therefore the major proportion 
of the starting material for differential display is required for the screening reactions. 
In our display reactions we excised four bands which we could not detect by either of 
these methods. As the availability of both mammary glands and mice were limiting, 
we prepared an enriched mRNA population from mammary epithelial cells grown in 
culture, and screened this with the clones. These results were inconclusive, which 
does not automatically mean that these clones were artefacts. The banding patterns 
for each of these clones was repeated in differential display reactions generated using 
a different starting RNA population, which would suggest that the clones did 
represent coding RNAs. The inability to detect a message in mRNA enriched cells 
may be due to these transcripts not being expressed within the mammary epithelial 
cell population. The detection problem appears to be a major stumbling block with 
this technique and is not a problem distinct to this particular study. An adaptation of 
conventional RPA has been described to overcome this problem. The technique was 
described by a research group who encountered similar problems with detection of 
clones isolated from differential display. They had incorported PCR into the RPA 
reactions, using the original differential display primers to generate sense strand 
cDNAs, which could then be hybridised against in vitro transcribed cDNA clones 
(Woo et al., 1995). The result was a more sensitive RPA. A semi-quantitative 
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%U. • 
NIH-3T3 	cells 	stimulated Delayed-early gene related to Donohue etal., 1994 
with FGF-1 aldose reductase 
Aortic smooth muscle cells 3 clones, one of which has Nishio ci al., 1994 
(Glucose Induction) homology 	to 	human 
elongation factor-2 
NIH-3T3 cells induced with 3 	clones 	identified, Hsu etal., 1993 
FOF- 1 phosphofructokinase, 	fatty 
acid synthase, and 
Ca2 ATPase 
Osteoblast-like cells induced Stathmin Kumar and Flaugen, 1994 
with vitamin D3 
Squamous 	carcinoma 	cell Elongation factor 15 Jung etal., 1994 
line induced with ionising 
radiation 
Mammary 	epithelial 	cells Maspin, which has tumour Zou etal., 1994 
compared 	vs 	mammary suppressing activity 
carcinoma cells 
Chronic cardiac rejection 5 	genes 	upregulated 	in Utans el.  al., 1994 
transplanted 	hearts, 	2 	of 
which are novel 
Mammary 	epithelial 	vs 3 novel clones, expression Liang etal., 1992 
breast cancer cells pattern 	of 	only 	one 
confirmed 
Human 	epithelial 	ovarian 3 novel genes Mok ci al., 1994 
cancer 
p53 induced apoptosis 10 clones, only 3 known Amson ci al., 1996 
Thymocytes 	induced 	with 2 clones, one of which is Chapman etal., 1995 
dexamethasone novel 
Preimplantation 	mouse 4 clones, 3 novel Zimmermann etal., 1994 
embryo 
Table 3.3 Systems used for Differential Display Analysis. The table details the 
tissue examined and the cDNAs identified using this technique. 
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RT-PCR method may be used to confirm expression. Technically this is a very 
demanding technique and not suitable for screening a high number of clones, 
although it would appear to be more likely to detect expression than any of the 
preceding techniques. The problems with detection are not only limited to 
confirming expression. Identical problems may be encountered when obtaining full 
length cDNAs. The conventional method involves screening a cDNA library if an 
appropriate one is available. If the clone to be screened cannot be detected by the 
standard mRNA detection methods, it seems extremely unlikely that these cDNAs 
will be represented in the library at a level high enough to isolate full length clones. 
Another option would be to use a PCR based method for generating full length 
cDNAs, 5'—*3' RACE (Rapid Amplification of cDNA Ends). This technique again 
in very demanding to perform and itself is wrought with technical difficulties. 
Overall, it would appear that differential display is the leading technique for the 
analysis of changes in gene expression. In particular it is demonstrated to amplify 
very rare cDNAs, which may not be detected by conventional mRNA screening 
methods. It is highly probably that further development of differential display will 
itself result in speeding up the development of novel screening techniques for the 
detection of very rare cDNA transcripts. This will allow the realisation of the full 
potential of this tool for analysis of gene expression. 
3.5 Future Directions In The Analysis of Gene Expression 
Since the start of the studies reported in this thesis a number of different 
approaches for the analysis of gene expression have been developed. These are 
described in the following section and advantages over the current techniques are 
discussed. 
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3.5.1 Serial Analysis of Gene Expression (SAGE) 
Serial Analysis of Gene Expression (SAGE) allows quantitative and 
simultaneous analysis of a large number of transcripts (Velculescu et al., 1995). The 
method is based on the production of eDNAs containing biotinylated linkers. These 
3' cDNAs are subsequently digested with a restriction enzyme that recognises a 4bp 
sequence, and the resultant digested fragments are purified using streptavidin beads. 
The purified cDNA pool is then divided into two aliquots and each population is 
annealed to a linker; this linker contains a primer site and a restriction site for a class 
2 restriction enzyme. Class 2 restriction enzymes cut 9bp downstream from their 
recognition sequence. This 9-13bp sequence tag contains sufficient information to 
uniquely identify the 3' end of a cDNA. It has been proven that a sequence as short 
as 9bp can distinguish approximately 260,000 transcripts given a random nucleotide 
distribution at the tag site. The second stage of this technique involves ligating the 
two cDNA populations and performing a PCR to amplify these products. This 
amplified reaction is then ligated to concatenate the 9-13bp sequence tags; this 
allows the efficient analysis of transcripts in a serial manner by sequencing multiple 
tags within a single clone. It has been estimated that approximately 60,000 tags 
required to be sequenced to make this technique powerful enough to give 
representative results. When two populations are compared side by side the ratio of 
tags between these two cell types are analysed and this leads to expression patterns 
deduced from the abundance of these individual tags. These 9-1 3bp tags of interest 
can then be screened against EST (expressed sequence tag) databases for any 
homolgoy and the EST can be obtained and used to generate a full length cDNA. In 
this manner SAGE can be used to examine expression profiles between normal and 
cancer cells (Zhang etal., 1997), and may lead to identification of transcripts that are 
more abundant in cancer cells as compared to normal cells or vice versa. The major 
advantage this technique offers is the rapid analysis of thousands of transcripts 
within the cell in a relatively short time scale. This is obviously highly dependent on 
the rate of sequencing of the tags. Recently two papers have been published 
describing the use of SAGE to analyse changes in colorectal cancer (Zhang et al., 
1997) and to identify genes involved in p53-induced apoptosis (Polyak et al., 1997). 
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This technique appears to represent an advance in technology for the analysis of gene 
expression patterns. The major difference between the available techniques is that 
SAGE analysis quantitatively compares the expression profiles of a large number of 
transcripts within the cell. As SAGE is still a relatively new technique, it is difficult 
to determine whether it will replace differential display as a method for analysing 
gene expression changes. This clearly is dependent on whether SAGE is actually 
simple and rapid to perform, and on whether the technology to perform this analysis 
becomes commonly available. 
3.5.2 Microarray Analysis 
In the last few years a revolutionary new technology for measuring the 
expression of all genes in an organism has been described. The development of this 
technique was facilitated by technical advances which allow DNA fragments to be 
arrayed at high densities on a solid support for use in hybridisation experiments 
(reviewed in Johnson, 1998). The human genome mapping project has also provided 
the basis for this technique; it is estimated that all of the human genome will be 
sequenced within the next 5 years. This has resulted in a vast number of EST's being 
available to screen against. Two different methods for arraying DNA have been 
developed. In one, cDNA fragments generated by PCR are spotted onto poly-lysine 
coated glass slides. In the other, short (-25 base) oligonucleotides are synthesised on 
a glass surface. Both of these methods pack thousands of DNA fragments into a very 
small area: the current oligonucleotide chip displays all 6000 yeast genes on four 
1.28 x 1.28cm chips; the DNA fragment microarrays fit the same information onto a 
single 1.8 x 1.8cm glass slide. The cDNA microarrays are generated by fixing 
unlabelled DNA fragments to the slide and probing with a complex mixture of 
labelled cDNAs or mRNAs. The labelled cDNAs represent the two populations to 
be compared and are labelled with different fluorochromes. The hybridised array is 
analysed using sophosticated microscopy and software that allows the quantitation of 
signal intensity. The major advantage of arrays over existing techniques is the 
significant increase in sensitivity. The small area occupied by the array results in 
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Figure 3.8 Summary of Differential Display Results. This diagram summarises 
the expression profiles of the clones examined in the mammary gland. WDNM1, j3-
casein, WAP, and ct-lactalbumin are all milk proteins expressed at specific stages in 
gestation in the mammary gland. Clones 72.1 and 72.3 represent the eDNAs for 13-
casein and Tat Binding Protein 1 respectively, whereas the remaining clones appear 
novel in sequence. 
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reducing the volume of the hybridisation solution and greatly increases the 
concentration of the probe. The use of a glass surface for hybridisation results in a 
smaller background hybridisation signal than the use of porous membranes. Both 
oligonucleotide and DNA microarrays permit very sensitive detection of gene 
expression: an mRNA present at a level of less than one molecule in 100,000 can be 
detected using this approach. An additional advantage of the microarray approach is 
that specific gene arrays can be prepared e.g. an array which encompasses all of the 
genes known to be expressed in the human mammary gland is available. The 
technology required to run this system is currently outwith the means of most 
laboratories, but commercial services are becoming available which may result in 
this technology becoming widely available. It is clear that microarray analysis 
represents a very powerful tool for the future of gene expression studies. The major 
advantage that both microarray and SAGE offer is the ability to screen thousands of 
EST's in one reaction. Should these techniques become widely used they will 
greatly enhance our knowledge of biological pathways. 
The results described in this chapter demonstrate the use of differential 
display as a tool to identify changes of gene expression in the developing mammary 
gland. All of the genes identified in this study show changes at particular points in 
mammary development, which are key developmental junctures. This is 
demonstrated in Figure 3.8 where the expression profiles of the genes are compared 
to stages at which known genes become active. For example, clones 102.7, 124. 1, 
124.3 and 124.5 are all present in the early stages of mammary development when 
the gland undergoes a massive proliferation. Clones 72.5, and 72.7 are expressed at 
the stage when the mammary gland begins to differentiate (around day 10) as marked 
by the expression of J3-casein. Clone 72.3 is expressed highly throughout the 
differentiation period in the gland, and the expression clone 72.9 peaks on clay 15, 
the stage at which the mammary gland is thought to terminally differentiate as 
marked by the onset of expression of WAP. As these clones are all expressed at 
significant developmental stages in the mammary gland we suggest that these genes 
may represent key regulators of these process. 
Chapter 4: 
Analysis of TBP1 Expression in the Mammary Gland and 




In chapter 3 it was demonstrated that the expression profile of clone 72.3 
(TBP 1) increased ten fold by day 10 gestation, and that this was maintained until late 
gestation (thy 18). As the majority of the remaining clones had no known sequence 
homology and in some cases the expression profiles could not be confirmed, it was 
decided to concentrate the remainder of this study on analysing the function of TBP1 
in the developing mammary gland. 
TBPI was originally described as a protein that was capable of interacting 
with the REV Tat transactivator and functioning as a transcriptional repressor. 
Nelbock and colleagues (1990) originally isolated TBP1 by screening a Xgtll fusion 
protein library prepared from Jurkat T cell cDNA with biotinylated Tat protein, and 
the TIBP1 isolated in this manner was found to be predominantly nuclear in 
expression with highest expression in human cells. More recently TBP1 has been 
isolated from a variety of species e.g. rat (Rivkin ci' al., 1997), Plasmodium 
falciparum (Hirtzlin et al., 1994), Dictyostelium discoidcum (Cao and Firtel, 1995), 
and yeast (Goyer, 1992). It is now widely accepted that TBP1 function is 
predominantly an ATPase activity associated with the ubiquitin dependent 
degradation pathway (described in section 1.6.1). TBP1 is one member of a family 
of ATPases, which have been assigned as members of the AAA family [AlPases 
Associated with a variety of cellular Activities] (Confalonieri and Duguet, 1995). 
The key feature of this family of proteins is a highly conserved module of 230 amino 
acids (the ATPases module) present in one or two copies in each protein. Despite 
extensive sequence conservation, the members of this family fulfil a very diverse 
range of cellular functions. These include cell cycle regulation, peroxisome 
assembly, 26S proteasome function, vesicle-mediated transport etc. It is 
hypothesised that these proteins may operate through two groups of distinct non-
overlapping functional activities: (i) ATP-dependent proteasome function, and (ii) 
ATP-dependent anchorage of proteins. The six ATPases involved in proteasome 
function all contain a single ATPase module. As there had previously been some 
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controversy over TBP 1 function, the aim of the studies described in this chapter was 
to determine whether the expression profile examined was one for TBP 1 alone or 
that of the 26S proteasome. We therefore examined the expression of 26S 
proteasome components in a mammary epithelial cell (MEC) line, KIM-2. KIM-2 
cells were derived from the mammary gland of a mid-pregnant mouse expressing a 
temperature sensitive mutant of SV40 T antigen (tsA58) driven by the ovine 3-
lactoglobulin (BLG) milk protein gene promoter (Gordon, 1997). Mammary explant 
cultures were used to isolate stable cell lines that are now routinely used as a model• 
system of mammary gland differentiation in our laboratory. KIM-2 cells 
functionally differentiate, as marked by the induction of the milk protein j3-casein, in 
a similar manner to the existing mammary cell models. However, this cell line has 
retained the ability to express a late differentiation marker whey acidic protein 
(WAP) when cultured on plastic. No mammary model currently available will 
express WAP when cultured on plastic and KIM-2 cells have been used in this study 
as they provide a good in vitro model with which to study mammary epithelium 
development. 
4.2 Upregulation of 26S Proteasome Components in the Developing Mammary 
Gland 
The results generated by differential display analysis in chapter 3 documented 
a ten fold increase in expression of TBPI at day 10 gestation, which was maintained 
until day 18 gestation. Examination of the expression of TBP 1 in a wide range of 
other tissues showed that the level of TBP1 expression was low in the majority of 
other tissues tested, and this was comparable to the virgin mammary gland (Figure 
4. la). This observation suggested that the level of TBP1 was increased in mid to late 
gestation mammary gland relative to other tissues. The presence of TBP1 in the 
testes showed a relatively high level of expression with the presence of three 
transcripts. This result has been confirmed in the laboratory of Dr C Gordon (pers. 
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Figure 4.1 (a) Expression profile of TBP1 mRNA in a range of tissue samples. 
Total RNA was extracted from each of the tissues and 10ag electrophoresed, prior to 
blotting onto a nylon membrane. RNA was hybridised with radiolabelled clone 72.3, 
which represents the 3' 200bp of TBP1. The first panel represents TBPI expression 
in the virgin and day 10 gestation mammary gland, followed by a range of RNA 
from either male or female organs. 
(b) Expression profile of TBPI Protein in the Developing Mammary Gland. 
Total cellular protein was extracted from mammary glands at different stages of 
gestation (Gest), lactation (Lact), or involution (Inv). 1 Otg protein was analysed by 
western blot using antibodies specific to 26S proteasome subunits, S. pombe S4 and 
20S (kindly received from Dr. C. Gordon), and murine MSS1 (kindly received from 
Prof. J. Mayer). Although the antibodies used in this study were raised against 
specific ATPases subunits more than one band was commonly present on the 
developed blot. It was therefore assumed that the if a band was present at the correct 
size that this corresponded to the protein of interest. This may not have been the case 
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comm.) suggesting that the TBP1 expressed in the testes has alternatively spliced 
transcripts. The high levels of TBPI in the testes may simply be due to a high basal 
rate of transcription that is often observed in the testes. A tissue like testes with a 
high rate of transcription may require elevated levels of degradation machinery to 
remove short lived proteins e.g. transcription factors which require a fast turnover. 
The ATPases associated with proteasome function are believed to be 
predominantly involved in protein degradation, but other functions have been 
described for these proteins. In the main these tend to be assigned to a 
transcriptional function. To determine if the expression profile of TBP1 identified in 
the developing mammary gland was related to its function as a component of the 
ubiquitin-dependent protein degradation pathway, we examined the expression of 
related ATPases and of the 20S core of the proteasome in the mammary gland. 
Western blot analysis showed a corresponding increase in the expression of the 
ATPases MSS1 and S4 (Figure 4.1b). In contrast to this the level of the 20S 
proteasome a subunits appeared to be evenly expressed through gestation and early 
lactation. A decrease in the 20S proteasorne was observed early in involution 
(Figure 4.1b). These results show that the high expression of these regulatory 
components of the 26S proteasome are maintained throughout lactation, and would 
suggest that the increase in TBP I expression that was originally observed by 
differential display corresponds to an overall increase in the 26S proteasome. The 
antibody analysis on these ATPase subunits is limited due to the cross-reactivity of 
these antibodies with non-specific proteins. 
4.3 Induction of TBP1 Expression During Mammary Gland Development is not 
Lactogenic Hormone Dependent 
The expression profile observed by both differential display and Northern 
Blot analysis showed an increase in TBPI expression around day 10 gestation. This 
is the stage when the mammary gland begins to express the milk protein (3-casein for 
the first time, signifying an early differentiation event. To address the question as to 
163 
whether the increase observed in TBP 1 expression was dependent on differentiation 
and lactogenic hormones, we switched to using an in vitro mammary gland model. 
The MIEC line KIM-2 cells were chosen for this analysis as these cells can be 
induced to differentiate with the addition of the lactogenic hormones, prolactin and 
dexamethasone to their growth media. Figure 4.2a shows the morphological 
appearance of KllvI-2 cells that have been induced to differentiate. After two days in 
culture these cells express the milk protein 13-casein, and by four to six days they 
begin to express a second milk protein, WAP. This cell line was chosen for use over 
the HC II cells that had been used for differential display analysis because KIM-2 
cells have the ability to express WAP and are thus the most relevant in vitro model 
available for examining mammary gland development. Unfortunately, these cells 
were not fully characterised at the start of this study otherwise they would have been 
used for the differential display analysis. KIM-2 cells were induced to differentiate 
over a twelve day period and samples were collected for RNA analysis. 
Hybridisation of these samples with TBPI revealed no induction in expression of 
TBP1 with differentiation of KIM-2 cells (Figure 4.2b). Protein levels of the core 
20S proteasome were also examined in KIIvI-2 cells and a similar result was obtained 
(Figure 4.2c). No changes in the level of the core 20S proteasome were observed 
regardless of the differentiation status of the cells. These results suggested that the 
increase in TBP 1 expression observed in the developing mammary gland was not 
occurring as a response to lactogenic hormones and also that the core of the 
proteasome is not hormonally regulated. Figure 4.2c also shows f3-casein protein 
expression in these samples to confirm that the cells were functionally differentiated. 
Taken together these results suggest that there is an increase in the 26S proteasome 
as the mammary gland begins its differentiation process, and that this increase is not 
dependent on stimulation with lactogenic hormone. We have shown that MECs 
express TBP 1, but do not act to upregulate its expression. A specific antibody 
against TBPI would allow determination of which cells in the mammary gland 
express TBP1. This may enlighten our knowledge as to the function of an 
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Figure 4.2a Morphological Appearance of KIM-2 Mammary Epithelial Cells. 
(i) Phase contrast of proliferating KIM-2 cells grown in maintenance media (MM) 
containing insulin and EGF. (ii) Phase contrast of confluent KIM-2 cells grown in 
MM, where a typical epithelial cobblestone morphology can be observed. (iii) Phase 
contrast of KIM-2 cells that had been differentiated for 12 days in the presence of the 
lactogenic hormones prolactin and dexamethasone. KIM-2 cells form domes or 
mammospheres when grown in the presence of lactogenic hormones on plastic. (iv) 
Higher resolution of differentiated KIM-2 cells. Myopeithelial cells can be observed 
on the surface of the mammospheres. 
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Figure 4.2 (b) Expression of TBPI mRNA in KIM-2 Mammary Epithelial Cells. 
KIM-2 cells were grown to confluency and induced to differentiate over a 12 day 
period in the presence of dexamethasone and prolactin. Samples were harvested at 
various stages during this process and total RNA extracted from the cells. 1 Otg 
RNA was electorphoresed prior to Northern Hybridisation with a radiolabeled cDNA 
corresponding to the 3' 200bp of TBPI. The membrane was exposed to 
autoradiographic film overnight prior to stripping and probing with a cDNA 
corresponding to murine f3-actin as a loading control. 
(c) Expresison of the 20S Proteasome in KIM-2 Mammary Epithelial Cells. 
KIM-2 cells were induced to differentiate in the same manner as above. Samples 
were harvested and total cellular protein exptracted from these cells. 1Og protein 
was subjected to western blot analysis using a mixture of antibodies directed against 
the 20S proteasome subunits [S. pombe 20S antibody (from Dr. C. Gordon) and an 
ICN human 20S alpha subunit antibody]. The lower panel represents 1O.tg protein 
from the same cells subjected to western blotting using a murine 3-casein antibody 
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4.4 Screening of a Day 15 Gestation eDNA Mammary Gland Library For a Full 
Length TBP1 cDNA. 
As the murine homologue of TBP 1 had not previously been cloned, we chose to 
use the 3' 200bp eDNA fragment of TBP 1 obtained by differential display to screen 
a day 15 gestation cDNA mammary gland library. The library had been prepared 
from a C57BL6/CBA strain of mouse by Dr C. Watson using a Stratagene Uni-Zap 
XR Kit. Following plating of the library, a mixed probe was used to screen the 
primary plaques. This was a mixture of radiolabelled cDNA fragments from clones 
72.9 and 72.3 (TBP1). Hybridisation revealed two types of signal on the filters, a 
stronger and a weaker hybridisation signal (Figure 4.3a). Thirty six plaques were 
picked from the primary screen, containing a mixture of both types of signals. 
Approximately 50-100 pfu per plate were plated for the second screen and four lifts 
were taken from each plate as this screen was performed using both probes 
individually to differentiate between the signals observed. Hybridisation revealed a 
high number of positive plaques for TBPI but no positive plaques for clone 72.9 
(Figure 4.3b). Although the signals overlapped on duplicate filters at the stage of the 
primary screen and were weaker than the TBP1 signals, it appears that they were not 
related to clone 72.9. From the secondary screen with TBPI 26 plaques were 
obtained, which included 12 mixed and 14 single plaques. At this stage it was 
decided to excise all of the single plaques into pBluescript (described in section 
2.9.4). Of the 14 clones excised, 13 of these gave colonies following excision. 
Rather than perform a tertiary screen, a plasmid DNA Southern Blot was performed 
as all of the clones excised represented single plaques. The blot was hybridised with 
the radiolabelled 3' TBPI cDNA fragment used to screen the library originally. The 
results are shown in Figure 4.3c and show that of the 26 colonies screened, two 
contained no inserts and only one of all the clones contained an insert that did not 
hybridise to TBP 1. Full length TBP I clones of approximately 1.4kB were obtained 
from this screen as well as a range of smaller clones. 
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Figure 4.3 Screening of a Day 15 Gestation Mammary Gland eDNA Library for 
Full Length TBP1. (a) This panel represents the primary library screen, where 
plaques from a day 15 gestation mammary gland library (kindly provided by Dr. C. 
Watson) were screened with a radiolabelled probe containing a mixture of two 
cDNA fragments. The 3' 200bp of clones 72.3 (TBP1) and 72.9 were used to screen 
the library. Membranes were hybridised with this • probe overnight prior to 
autoradiography for 3 hours. The arrows represent the clones picked for secondary 
screening. Two types of signal were detected, strong signals (black arrows) and 
weak signals (blue arrow). 
Secondary Screen Using TBP1 eDNA Fragment. Positive plaques from the 
primary screen were re-plated prior to fixation on nylon membranes. Duplicate 
filters were prepared to screen with individual cDNAs on this screen. The example 
shown represents a membrane hybridised with the 3' 200bp of TBP1 and is a 3 hour 
exposure to autoradiographic film. The arrows represent the two plaques picked for 
subsequent analysis. 
Plasmid Southern Blot Using TBPI eDNA Fragment. Positive plaques picked 
at the secondary screen were excised from the phagemid into the plasmid vector 
pBluescript. This DNA was transformed into competent cells and resultant colonies 
picked for analysis. Duplicate colonies were examined for each of the 13 plaques 
excised. Plasmid DNA was purified and 5j.tg was subjected to Southern. Blotting 
onto nylon membrane. The membrane was hybridised using the 3' cDNA fragment 
of TBP1 generated by differential display and the membrane was exposed to 
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The library was plated out in duplicate for a second time to re-screen with clone 
72.9. The possibility existed that no positive plaques were obtained for this 
particular clone as TBP1 appeared to be much more abundant in the library than 
clone 72.9. Thus it was decided that screening for this clone individually might 
allow the detection of plaques related to this cDNA which might previously been 
overlooked due to the intensity of signal for TBP1. In concert with this, clone 72.7 
was screened against this library. Clone 72.9 peaked in expression on day 15 
gestation and could be detected by Northern Blot analysis thus it was probable that 
this clone should be represented in a day 15 gestation cDNA library. Clone 72.7 
peaked in expression on days 10 and 13 of gestation. Northern Blot analysis showed 
that this clone was expressed on day 15 gestation, albeit at lower levels than on days 
10 and 13. Radiolabelled cDNA probes for both of these clones were screened 
against the library plaques and weak hybridisation signals were evident for both 
clones. Putative positive plaques were picked and plated out for a secondary screen. 
This second round screen showed that the plaques picked were not authentic positive 
signals, but background hybridisation. From this, it would appear that these cDNAs 
are not represented in this particular mammary gland cDNA library. This is assumed 
to be due to the low abundance of these particular clones. 
Double stranded sequencing was performed on the cDNA fragments isolated 
from the library screen with TBP1. Figure 4.4a is a linear map showing some of the 
fragments obtained from the library and their position relative to full length TBP 1. 
Fortunately, the fragments we had generated from the screening were overlapping in 
such a manner that they allowed TBP1 (134 lbp) to be fully sequenced. Comparison 
of murine TBP 1 to the nucleotide and proteins databases revealed 89% homology at 
the nucleotide level to human TBP 1 and at the amino acid level this corresponded to 
99% identity (Figure 4.4b). Only two amino acid changes were observed between 
murine TBPI and all but the initial 26 amino acids of human TBPI. These were an 
isoleucine (I) to valine (V), and alanine (A) to arginine (R) change from human to 
mouse sequences respectively. The Ito V change represents a conserved amino acid 
substitution. The murine TBP1 obtained in this study was 134 lbp long, which 
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Figure 4.4a Linear Map of TBPI Library Screen Fragments. These clones are 
represented as linear maps of the TBP1 fragments generated from screening a day 15 
gestation mammary gland cDNA library. The clones detailed above were used to 
obtain the full length sequence of TBP1. 
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published for human TBP1 (Nelbock ci aL, 1990). The same group later published a 
longer sequence for human TBP1 (Ohana ci al., 1993). Rescreening of the Xgtl 1 
fusion protein library resulted in the isolation of a 439 amino acid human TBPI. 
This sequence was seen to contain two ATU codons upstream of the initial proposed 
ATO start. The three full length murine clones obtained from the library screen were 
all 404 amino acids long with an ATU start at position 49. One ATG codon was 
found upstream but this was not in frame and would have only resulted in a protein 
of 21 amino acids. Only 10 of the remaining 18 codons 5' of the ATG start in the 
murine sequence matched with the human sequence. All of the mismatched codons 
were at the most 5' end of the murine TBP1 sequence. These results would suggest 
that the TBP1 expressed in the mammary gland corresponded to a protein of 404 
amino acids. It would be of interest to examine the TBP1 form present in human 
breast tissue to determine if this truncation is a murine or a mammary tissue-specific 
event. It is possible that one of the other transcripts detected within the testes by 
Northern analysis maybe identical to this longer form of TBPI cloned by Ohana and 
colleagues (1993). 
Murine TBP1 was 78% identical to the yeast TBP1 sequence suggesting that 
these proteins were very highly evolutionarily conserved. The high level of 
conservation in these ATPases is also seen in the components of the 205 proteasome. 
In eukaryotics, the 205 core is composed of seven different a and seven different f3 
subunits. These subunits are very similar to those in Thermoplasina acidophilurn, an 
archaebacterium that has only one a and one 3 subunit (Rubin and Finley, 1995). In 
Thermoplasma, ultrastructurally the 20S proteasome is almost indistinguishable from 
eukaryotic 20S particles. There is also sequence similarity between the a and 
subunits families, suggesting that all subunits were derived from one single ancestral 
gene early in evolution (Peters, 1994). 
Structurally the 6 ATPases associated with proteasome function all contain 
certain conserved sequence motifs. There are highlighted in Figure 4.4b and include 
a highly conserved functional ATPase module. Within this region there are 4 
conserved sequences which are present in ATP- and GTP-binding proteins and ATP- 
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dependent DNA/RNA helicases. The nucleotide binding site or P-loop is a structure 
common to ATP- and GTP-binding proteins. The consensus sequence of the P-loop 
consists of a glycine rich sequence followed by a conserved lysine and a serine or 
threonine e.g. GXXXXGK[TS], where X denotes any nucleotide. In different 
protein families P-loops often have distinct features. For example in TBP1 this 
sequence is GPPGTGKT, which is also conserved within TBP7, MSS1, and SugI 
(Ohana ci al., 1993). The conserved lysine (K) residue was thought to be the most 
important residue in this motif as it confers the conformation of the P-loop and also 
directly interacts with the 3- and y- phosphates of the bound NTP (Saraste ci al., 
1990). Two other regions show characteristics of GTP-binding proteins and the last 
region of homology highlighted has conservation with domain VI of a subfamily of 
DNA/RNA helicases. (Pause ci al., 1993). Another common feature of these 
proteins is a conserved carboxy-terminal cysteine residue (Cys 361 ). The function of 
this cysteine residue is unknown, but may have an as yet undefined catalytic 
function. The above conserved sites are all clustered within 100 amino acid residues 
from each other, and within the 6 ATPases they all begin around 250 amino acid 
residues from the amino terminal. The sequence conservation between the ATPases 
is markedly higher within the carboxy terminal of the proteins, whereas the structural 
homology is lowest at the amino terminal region (Lucero c/ al., 1995). The N 
terminal amino acids of these proteins show the presence of a conserved leucine 
zipper-like structure, which may mediate protein-protein interactions. This structure 
is detailed in Figure 4.4c, and shows the heptad repeats within TBP1 and TBP7. 
Leucine is the most common amino acid at every seventh position, but methionine, 
isoleucine, and valine can appear as substitutes (Fu, 1992). There is a suggestion that 
this region of the protein may be involved in substrate recognition (Reehsteiner c/ al., 
1993). 
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Figure 4.4 (b) Comparison of Amino Acid Sequence of Human (H), Murine (M) 
and Yeast (Y) TBP1. Amino acid sequences were aligned using the Fasta program. 
The boxed region represents the highly conserved ATPase module. A highly 
conserved cysteine residue in represented by the yellow box. The blue boxed regions 
represent the putative nucleotide binding sites and the green box represents the 
helicase-like domain. 
(c) Conserved Luecine-Zipper like Structure in TBP1. Comparison of human 
TBP1 and TBP7, and routine TBPI amino-terminal regions. A highly conserved 
leucine-zipper like structure is found in these proteins. The hydrophobic amino acids 
forming the heptad repeat of the zipper are boxed, and the charged amino acids are 
depicted by "+" and "-" signs. Whilst leucine is the most common amino acid at 
even seventh position, methionine, isoleucine and valine are suitable alternatives. 
GIQPPKGVLM 	YPPtTGflj. LARACAAQTK ATFLKLAGPQ IMNHKEKFENL MNHKEKFENL GIQPPKGVLM 	IPPGTGK* LARACAAQTK ATFLKLAGPQ MKRADKFENL GIRAPKGALM 	YbP-a~r=itgt LARACAAQTN ATFLKLAAPQ 
LVQMFIGWA KLVRDAFALA 	KEKAPSIIFI KA FDSEKAGDPE 
LVQMFIGA KLV1DAFALA 	KEKAPSIIFI __KA FDSEKAGDRE 
LVQMYIGEGA KLVPDAFALA 	KEKAPTIIFI KA FDSEKSGDRE 
VQRTMLELLN QLDGFQPNTQ 	VKVI 	TNRV tILnPALç?rGRrDcIEFP 
VQRTMLELLN QLDGFQPNTQ 	VKVI TNRV LDPAL RS GRLDCIEFP 











MTBP1 N 	 STEEl VQRTPLLDSE IKIMKSEVLR 
F-{TBP1 H STEEl IQRTRLLJJSE IKIMKSEVLR 
YTBP1 HATLEELDAQ TLPGDDELDQ EILNLSTQEL QTRAKLLDNE IRIFRSELQP 
NTBP1 VThELQZHKD KIKENSEKIK VNKTLPYLVS NVIELLDVDP N]EED 
HBP1 VTHELQZMKD KIKENSEKIK VNKTLPYLVS NVIELLDVDP NDQEED 








QRKGKCAVI K TSTRQTYFLP V IGLVDAEKL KPNDLVGVNK 
QRKGKCAVIK TSTPQTYFLP VIGLVDAEKL KPNDLVGVNK 
TAVGKAAVVK TSSRQTVFLP MVGLVDPDKL KPNDLVGVNK 
TEDYSRVKAM EVDQRPEQY SDIGGLDKQI QELVEAIVLP 
TEDYSRVKAM EVDERP EQY SDIGGLDKQI QELVEAIVLP 
SEFYSRVKAM EVDEKP Efl SDVGGLDKQI EELVEAIVLP 
MTBP1 PNEEARARI MQIHSPKMNV SPDVNYEELA R&rDDFNGAQ CKAVCVEAGM 
HTBP1 PNEEARARI NQIHSRKMNV SPDVNYEELA PCTDDFNGAQ cKAVCVEAGH 
YTBP1 PSEDSPAOI LQIJ-{SRKMTT DDDINWQELA RTDEFNGAQ LKAVTVEAGM 
MTBP1 IALPRGATEL THEDYMEGIL EVQAKKKANL QYYA 
HTBP1 IALPRGATEL TI-rEDYMEGIL EVQAKKKANL QYYA 
YTBP1 IALRNGQSSV KHEDFVEGIS EVQARKSKSV SFYA 
(c) 
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HTBP7thY s R v K KID Q Q B LB FOE V Q BE 	D E  K 
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4.5 Two Hybrid Analysis of Three ATiPases of the 26S Proteasome 
Biochemical studies have revealed that the 19S cap or regulatory complex is 
composed of 15 subunits, and that at least 6 of these proteins are thought to have an 
ATPase activity (Dubiel etal., 1992). The assumption made from these studies was 
that an active 26S proteasome must contain all 6 ATPases. Studies from Ivianduca 
sexta have thrown confusion on this theory, as it appears that there may be a change 
in ATPase composition as the tobacco horn moth undergoes programmed cell death 
(Dawson et at, 1995). An increase in the ATPases MSS1, TBP7 and 54 was 
detected, whilst TBP1 protein levels remained unchanged in the abdominal motor 
neurones and muscles during eclusion. The explanation for a change in proteasome 
subunit composition centred on a regulatory reprogramming which was thought to 
facilitate the degradation of newly ubiquitinated proteins. No other studies have 
reported a change in ATPase subunits with development. Despite this evidence, the 
major focus of proteasome research is based on the assumption that the 26S 
proteasome must contain all 6 ATPases for full function. Studies in yeast have 
shown that disruption of one of these ATPases, S4 causes a defect in mitosis (Gordon 
et al., 1993). This phenotype was shown to be a consequence of the disruption of 
protein degradation as an increase in ubiquitinated proteins was observed. These 
results suggested that S4 was essential for proteasome function. The aim of the 
following work was to gain an insight into the organisation of the regulatory 
complex. To achieve this we cloned two additional murine ATPases, Sug2 and 
TBP7 by PCR and performed a yeast two-hybrid assay. 
The study of protein interactions is of prime importance as these interactions 
play a critical role in the vast majority of biological processes. For example, the 
identification of interactions between viral oncoproteins and cellular tumour 
suppressor proteins, between components of signal transduction pathways, and 
between proteins involved in the regulation of the cell cycle have greatly increased 
the understanding of cellular functions. Two-hybrid analysis has been invaluable in 
studies to define regions of proteins that are responsible for specific interactions e.g. 
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SH2 and SH3 domains (Bartel and Fields, 1995). The yeast two-hybrid system is a 
genetic based assay for detecting protein interactions in vivo. It can be used to detect 
interactions between two known proteins or to screen libraries with a target protein, 
and was developed by Fields and Song in 1989. The assay exploits the observation 
that many transcriptional activators contain two independent domains, one 
containing a specific DNA binding activity and the other recruiting the 
transcriptional machinery (activation domain). The close proximity of these two 
domains is deemed sufficient to active transcription. The observation that several 
transcription factors have undetectable DNA binding activity and also that they were 
thought to act via protein-protein interactions led to the foundation of this technique. 
In the two-hybrid system, two fusion proteins are generated, one is a fusion of the 
DNA binding domain of a transcription factor and a test protein X. The other is a 
fusion between the test protein Y and an activation domain. Plasmids encoding these 
fusions are introduced together into a Saccharomyces cerevlsiae strain that contains 
one or more reporter genes with upstream binding sites for the DNA binding domain 
present in the first hybrid. If the test proteins X and Y interact then the 
transcriptional activator is brought in close proximity to the DNA binding site and 
results in expression of the reporter gene (Figure 4.5a). The protein interactions 
successfully detected by this system include those found in a variety of subcellular 
compartments e.g. the nucleus, cytoplasm, and mitochondria. The most commonly 
used DNA binding domains are from the yeast transcription factor Gal4p and the E. 
coil repressor lexA. Gal4p and the herpes simplex virus VPI6 protein are the 
preferred activation domains chosen for use with this system (Bartel and Fields, 
1995). 
The two-hybrid vectors used in this study are outlined in Figure 4.5b. These 
vectors, pAS2 and pACTII represent the DNA binding and activation domain vectors 
respectively. The recipient cells have different auxotrophic markers and the 
plasmids harbour the corresponding wild type genes e.g. leucine for pAS2 and 
trypotophan for pACTII. The pAS2 vector contains the coding region of the Ga14 
amino-terminal region (residues 1-147) driven by a constitutive yeast alcohol 





DBD 	 LacZ 
 
Y— AD TC 
LacZ 
 
X 	Y - 	 Activation TC 
DBD 	 WL C Z 
Promoter 	Reporter Gene 
Figure 4.5a Basic Two-Hybrid System. (a) A hybrid consisting of a DNA binding 
domain (DBD) fused to protein X is unable to activate transcription of a reporter 
plasmid because it lacks an activation domain. (b) A hybrid consisting of an 
activation domain (AD) fused to protein Y fails to localise to the reporter gene. (c) If 
both hybrids are expressed in the same cell and protein X and Y interact, the 
activation domain and transcription complex (TC) are anchored to the DNA binding 
site and the reported gene is expressed. 
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the Ga14 carboxy-terminal region (residues 768-881) in addition to a nuclear 
localisation signal placed in frame with the Ga14 sequence. The vectors used in this 
study had a haemaglutinin (HA) epitope inserted between the Ga14 sequence and the 
multiple cloning site. This allowed detection of the expressed tagged fusion proteins. 
The reporter genes assayed in this test were HIS3, which allows growth selection and 
LacZ, whose activity was detected by a colourimetric assay. The fusion proteins to 
be analysed required cloning in frame with the Ga14 sequences and thus were 
generated by PCR amplification. As murine sequences for TBP7 and Sug2 were not 
available the human sequences were used to design primers to amplify the coding 
regions of these genes. Murine TBP1 was also amplified by PCR within the coding 
region to facilitate cloning. Restriction sites were incorporated into either end of the 
PCR products for cloning into the multiple cloning site. Each ATPase was cloned 
into both DNA binding domain and activation domain vectors to allow conformation 
of an interaction in both directions e.g. if TBP in pAS interacted with TBP7 in 
pACT, then TBP7 in pAS should also interact with TBP1 in pACT. In some cases, 
the ATPases had to be amplified twice as different restriction sites were required for 
the pAS2 and pACTII vectors. In general, only three primers were designed for each 
ATPase as the pAS vector contained a Sail restriction site that was placed on the 3' 
end of the amplified ATPase. This Sal I site when cleaved could be ligated to the 
corresponding XhoT site in the pACT vector. This resulted in only the 5' primer 
requiring different restriction sites for each vector and thus reducing the number of 
primers required. Figure 4.5c shows the resultant amplified PCR products. Sug2 
was amplified from both human and murine cDNA because the murine homologue 
of Sug2 had not yet been identified and we were unsure how highly conserved the 5' 
sequence was around the ATG start site between the human and mouse protein. 
Initially the only Sug2 sequence available was that of S. cerevisiae and we were 
unable to generate murine Sug2 from the primers designed from yeast Sug2. Latterly 
the human sequence was published and this was used for more successful 
amplification. The PCR products were cloned into both a PCR cloning vector (TAIl) 
and the two-hybrid vectors. The murine ATPase MSS1 cloned into pAS2 and 
pACTII was kindly received from Dr Gordon McGurk. The transformed colonies 
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Figure 4.5 (b) S. cerevisiae two hybrid vectors. pAS-CYH2 contains the Ga14 
DNA binding domain and pACT!! contains the Ga14 Activation domain. PCR 
products were preferentially cloned into either 5' Ndel or NcoI sites and to the 3' 
Sail or XhoI restriction sites. 
(c) Two Hybrid PCR products. PCR products were generated from day 15 
gestation mammary gland cDNA using primers designed to generate 5' and 3' 
restriction sites on these ATPases. An aliquot of the reaction was run on a 1% 
agarose gel to check the reaction was successful. The -ive control is an amplification 
reaction performed in the absence of template cDNA. 
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1 MADPRDKALQDYRKKLLEHKE IDGRLKELREQLKELTKQYEKSENDLKAL 
51 QSVGQIVGEVLKQLTEEKFIVKATNGPPYVVGCRRQLDKSKLKPGTRVAL 
101 DMTTLTIMRYLPREVDPLVYNMSHEDPGNVSYSE IGGLSEQIRELPEVIE 
151 LPLTNPELFQRVGI IPPKGCLLYGPPGTGKTLLARAVASQLDCNFLKVVS 
201 SSIVDKYIGESARLIREMFNYARDHQPCI IFMDEIDAIGGRRFSEGTSAD 
251 RE IQRTLMELLNQMDGFDTLHRVKMIMATNPPDTLDPALLRPGRLDRKIH 
301 IDLPNEQARLDILKIHAGPITKHGEIDYEAIVKLSDGFNGADLRNVCTEA 
351 GMFAIRADHDPVVQEDFMKAVRKVADSKKLESKLD'ZKPV 
Figure 4.5d Sequence of Murine TBP7 and Sug2. Murine TBP7 and Sug2 coding 
eDNA sequences were amplified for use in the Two Hybrid Assay. Automated 
sequencing of these cDNAs were performed by Oswel DNA Services. The upper 
sequence is TBP7 and the lower sequence Sug2. Translation was performed using 
the Blast database (http:\\.www.ncbi.nlm.nih.gov) and sequence homologies were 
compared. 
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Each clone to be used in the two-hybrid analysis was sequenced to determine that no 
errors had been introduced during the PCR amplification. The amplification was 
performed in the presence of high fidelity Taq DNA polymerase, which is a proof-
reading enzyme designed to reduce the number of errors introduced by PCR into a 
sequence. Figure 4.5d shows the amino acid sequences of murine TBP7 and Sug2. 
They show 87% and 85% identity to their human counterparts respectively. 
Once PCR products were cloned into the appropriate vectors, they were 
subsequently transformed individually into the S. cerevisiae strain used for the 
interaction assay, Y190 cells. These clones were grown on synthetic complete (SC) 
plates containing all the nutrients required for growth e.g. adenine, histidine, and 
either leucine or tryptophan depending on the vector. The resultant colonies were 
picked and grown in liquid culture for 48 hours, and protein subsequently extracted. 
Western Blot analysis was performed using an HA antibody to detect tagged fusion 
proteins (Figure 4.6a). These results showed that all the fusion proteins were 
expressed although not at high levels in some cases. One striking observation from 
this analysis was that the constructs expressed in the activation domain vectors 
appeared to be expressed at a higher level than those in the DNA binding domain 
vectors. The observed difference was not due to any difference in the constructs 
because in the case of TBP7 the same PCR product was cloned into both pAS and 
pACT vectors. The pAS vector must contain some intrinsic property that results in 
lower expression of fusion proteins in comparison to identical constructs expressed 
in the pACT vector. 
The yeast reporter strain used for the interaction assays was Yl 90, which had 
a leaky HIS3 reporter gene (Emilsson et al., 1993). This required the addition of the 
competitive inhibitor 3-aminotriazole (3-AT) in the medium, which inhibits any 
basal HIS3 activity. The test proteins were simultaneously transformed into the 
reporter strain and plated out on selective media. Growth on 3-AT plates was 
analysed approximately 7 days later. As a result of using growth selection as one of 
the reporters, the growth observed on 3-AT plates, relating to his colonies was slow. 
Colonies were re-isolated on selective plates, allowed to grow for a further 4-5 days 
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and then tested for 3-galactosidase activity. If the his phenotype observed was due 
to the restoration of Ga14 activity via protein interaction, then the LacZ reporter gene 
should be induced. In addition to testing the bait proteins against each other, they 
were also tested alone and with two unrelated proteins, SNF1 and SNF4, which were 
used as a positive control for interaction. SNF 1 is a member of a protein kinase 
family and is essential for the transcription of glucose-repressed genes in response to 
glucose starvation, and SNF4 is the activating subunit of SNF1 (Jiang and Carlson, 
1997). Results from the interaction assay showed that the transformation reaction 
was efficient as detected by the number of colonies on plates containing no selective 
pressure. On four separate occasions when the assays were performed, the results 
suggested that TBP1 in pAS could activate transcription alone (Figure 4.6b). Most 
of the results obtained were with TBP1 pAS interacting with other bait proteins. 
TBP 1 in pAS was seen to drive LacZ expression on its own, in conjunction with an 
unrelated protein SNF4, with TBP1 pACT, with Sug2 pACT, with MSS  pACT, and 
with TBP7 pACT. Since all of these results could be due to TBP1 pAS activating 
transcription on its own, it therefore cannot be assumed to represent an interaction. 
A weak interaction was observed between the ATPases Sug2 pAS and TBP1 pACT, 
but could only be observed in one direction and could not always be detected. It is 
occasionally the case with this assay that a real interaction can only be demonstrated 
in one direction. The reasoning for this is unclear but may be due to the hybrid 
protein not being stably expressed in yeast. It is also a possibility that if one protein 
is more highly expressed than another, as is the case for proteins expressed in the 
pACT vector, that this alter the dynamics of the interaction. This may result in a bias 
towards homodimerisation of the more abundant protein if its physiological 
interaction with the lesser expressed protein is normally of low affinity. The results 
presented in this thesis may provide evidence suggesting that some of these ATPases 
could play a transcriptional role in the cell. TBP1 in the presence of a DNA binding 
domain appeared to be able to activate transcription of a reporter gene either on its 
own or more strongly with unrelated proteins. The results generated for these 
ATPases by two-hybrid conflict with previous results that suggested TBP1 and TBP7 
could heterodimerise (Ohana et al., 1993). More recent biochemical studies have 
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TBPI pAS + SNF4 pACT 
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Figure 4.6 Two Hybrid Analysis. (a) Whole cell extracts were prepared from S. 
cerevisiae Y190 cells expressing the two hybrid bait proteins. 10 jig protein was 
subjected to SDS/PAGE analysis and subsequently blotted. Membranes were probed 
with a Haemaglutinin antibody (Sigma) and detected using ECL (Amersham). The 
—ive control is represented by Y190 cells alone. (b) Results of Two Hybrid 
Interactions Assays. In all cases 4 clones stained with Z Buffer have been shown, 
except Sug2 pAS + TBPI pACT (where 8 clones are shown). The +ive control 
repesents an interaction between the yeast protein SNF 1 and SNF4. 
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TBP1 	 TBP7 	
(Ohana et al, 1993) 
TBP1 TBP1 human ATPases 
Sugi - 	54 	—MSS1 (Gordon et al, 1993) 
S. cerevisiae ATPases 
TBP1 pAS transactivated alone, following TBP1 results 
all with TBP1 pACT construct 
TBP 1 	40ow—TBP7 
Sug2 	 TBP7 
Sug2 	Z)4.MSS1 -4iii 	TBP7 
TBP1 	 '-Sug2 
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54 	 '—MSSl 
	(Richmond eta!, 1997) 
S. Cerevisiac ATPases 
Sugi 	 —TBP7 
Sug2 	 —TBP1 
	
(Very strong interaction) 
TBP1 -*(s TBP7 
Figure 4.7a Summary of Two Hybrid Results. (a) Interactions that were known 
prior to the start of this study. Blue arrows represent positive interactions and grey 
arrows no detectable interaction. Both of the studies in this section were performed 
using the yeast 2 hybrid system. (b) Results generated in this thesis. TBP1 cloned 
into the DNA binding domain vector could activate transcription alone. The only 
other interaction which was detected was between TBP1 and Sug2 and this was a 
weak interaction which could not always be observed. (c) Nitrocellulose binding 
assay results determined that Sug2 and TBP 1 interacted strongly and that the other 4 
ATPases did not interact with either of these proteins. 
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(Richmond et al., 1997). This group have shown by nitrocellulose binding assay that 
TBP1 and TBP7 do not interact, and that TBP1 and Sug2 strongly interact with one 
another but not with any other ATFases. Figure 4.7a summaries the results of the 
two hybrid analysis presented in this thesis and other available data on interactions 
between proteasome ATPases. 
4.6 Discussion 
The results presented in this chapter determined that the original increase in 
TBP 1 expression that was observed by differential display was related to an overall 
increase in the 26S proteasome. Until recently it was unclear whether all 6 ATPases 
were actually a functional part of the 26S proteasome. This was due to a number of 
these ATPases being assigned functions relating to transcriptional control e.g. TBP1 
was described as a transcriptional repressor (Nelbock et al., 1990), and Sugl as a 
transcriptional mediator (Fraser etal., 1997, Weeda etal., 1997, and Swaffield etal., 
1995). Biochemical purification of the proteasome complex revealed that 6 ATPases 
were part of the regulatory complex, and this led to the reclassification of these 
ATPases as components of the proteasome. The results in the mammary gland 
suggest that the increase in TBP1 expression observed was very likely related to 
TBP1 function within the 265 proteasome. The results also showed a similar 
increase in expression of two other ATPases, 54 and MS SI although there was no 
change in the level of the core of the proteasome during this time. These results fit 
the predicted model for proteasome assembly; it is hypothesised that assembled 20S 
proteasomes sit within the cell and become functional when they are bound by a 195 
regulatory complex or an uS activator complex. At present there is some debate as 
to whether 20S proteasomes alone can degrade proteins; degradation by this complex 
has been observed in vitro but it is unclear whether this process occurs in vivo. 
These results suggest that there is no change in these particular ATPases as the 
mammary gland undergoes its differentiation process. Dawson and colleagues 
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(1995) observed changes in the ATPase composition of the proteasome as the 
tobacco horn moth underwent developmental changes. These results were 
interpreted to suggest that the proteasome could change its regulatory subunit 
composition dependent on the developmental process occurring. From the results 
presented in this chapter, this would appear not to be true for the mammary gland. 
Three ATPases were examined in the mammary gland during proliferation, 
differentiation and lactation and the composition appeared to remain constant. In the 
case of one ATPase MSS 1, the level appeared to decrease early in involution, but 
this was probably due to less protein in this particular lane on the gel. Unfortunately, 
this antibody was a gift and we did not receive enough to repeat this result which 
therefore cannot be confirmed. 
The increase in expression of the 26S proteasome components observed in 
the mammary gland was determined not to be dependent on lactogenic hormones. 
Studies in MECs showed no change in the expression of TBP1 regardless of whether 
the cells were undifferentiated, or induced to differentiate over a 12 day period. The 
expression profile of TBPI in the mammary gland increased at the stage when the 
gland first starts to differentiate around day 10 gestation. The NEC used in this 
study, and all other available NEC lines, are derived from mid pregnant mice. In the 
case of KlItv4-2 cells, they were derived from day 12.5-13 gestation mice. It is 
possible that we observed no increase in T13P1 expression in this cell line as it was 
derived in vivo just beyond the stage when we first observed the increase in 
expression. These results determined that TBP1 was expressed in mammary 
epithelial cells. The expression profile of TBP1 in other mammary cell 
compartments remains unknown at present. Currently there are no antibodies 
available against TBPI that are specific enough to give a definitive result. The 
availability of such an antibody may shed more light on the function of an increase in 
the 26S proteasome in the developing mammary gland. An antibody against TBP1 
would allow the examination of expression of this protein in the developing 
mammary gland, within the specific cellular compartments and would also allow us 
to examine its role during proliferation and apoptosis. This would produce a more 
definitive role for this ATPase during gland development. A problem with the 
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majority of antibodies raised against these ATPases, all polyclonal antibodies, is that 
these proteins are so highly conserved that many of the antibodies are not very 
specific. In retrospect, it would have been useful to produce an antibody against 
TBP1 or perform in situ PCR to determine the expression of TBP1 in the 
myoepithelial and stromal compartments of the mammary gland. The expression 
peak in TBP1 and the 26S proteasome commences when the mammary gland starts 
to differentiate. This is also the stage when the gland first produces the milk protein 
13-casein. It is documented that by late gestation the mRNA for f3-casein accounts for 
around 15-20% of the niRNA in the cell (Ball etal., 1988). Following lactation the 
process of involution commences probably as a consequence of the accumulation of 
milk protein in the lumen. This protein acts in an autoregulatory loop to inhibit 
further milk protein synthesis (Feng et at, 1995). Exactly how this process is 
bypassed during gestation is unclear. It is possible that because milk protein is not 
secreted until the very late stages of gestation then this feedback loop is not 
functional early in pregnancy. If this were the case then it would result in an 
accumulation of 0-casein intracellularly. How this protein is removed from the cell 
is unclear. There are very few studies where degradation of milk protein has been 
examined. O'Hare and co-workers (1986) suggested that casein degradation was 
dependent on the lysosomal degradation system and that this degradation was highest 
when casein synthesis and secretion was least, and vice versa. These studies were 
performed using mammary explant cultures and therefore may not be directly 
relevant to the in vivo situation. In addition they do not entirely agree with our data 
as our increase was observed at the stage when the mammary gland begins to 
produce milk protein. More recently the proteasome has been described as 
containing a proteolytic activity capable of degrading 0-casein. Inhibition of the 
three major activities of the 20S proteasome with a serine protease inhibitor had been 
observed to stimulate a caseinolytic-like activity in bovine pituitary or lens 
proteasomes (Pereira et al., 1992). This proteolytic activity was seen to cleave 13-
casein into a 21kDa intermediate, which was then further processed to smaller 
peptides. This study demonstrated that under certain conditions the 26S proteasome 
has the ability to degrade milk protein. The caveat remains that this study was 
performed in vitro using purified 20S proteasomes, and many proteins can be 
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degraded in this situation. Whether these in vitro substrates are actually degraded in 
the same manner in vivo and with the 26S proteasome remains unknown. It may be 
possible that the increase in proteasome function observed in the mammary gland is 
due to degradation of milk protein, but other more probable theories exist. At the 
particular stage in development when TBP1 expression increases the mammary 
gland gains a specialised function and as a result a complex process of changes in 
gene expression and regulation are required. The increase in proteasome function 
may be a prerequisite for a cell to survive when it gains a more specialised function. 
It may be required to remove proteins that are cell type specific and thus allow the 
gland to switch from a proliferative state to differentiation. This functional 
progression may also result in an increased metabolism within the cell, which would 
require an increase in the systems that act to regulation the levels of protein 
production and degradation in the cell. Indeed the observation of downregulation of 
the 20S proteasome early in involution fits with this theory. It would seem highly 
probable that the proteasome may become a lesser requirement as the mammary 
gland is commencing its remodelling program. The major proteases involved in 
gland remodelling are the matrix metalloproteinases and the caspase, Interleukin- 1 13 
converting enzyme (ICE). It may also be assumed that following later stages in 
involution may show an increase in expression of the proteasome as the gland begins 
to proliferate to repopulate the fat pad. The further examination of proteasome 
function in range of developing tissues is required to determine if this is a general 
phenomenon or one that is specific to mammary gland development. Until recently, 
the major focus of proteasome research has been on the biochemical characterisation 
of the complex, and the study of yeast mutants of this pathway. When the bias of 
research transfers to examining proteasome function in mammalian systems, then the 
role of the 26S proteasome in developing tissues may become clearer. 
Within this chapter two-hybrid analysis was performed on three ATPases to 
determine their organisation in the 19S regulatory complex. The results generated 
from this work initially appeared inconclusive. The assay was performed on three 
ATPases, TBP1, TBP7, and Sug2and no definitive interactions were observed 
between any of these proteins, which was unexpected. TBP1 in conjunction with the 
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Ga14 DNA binding domain was able to activate transcription alone, or with unrelated 
proteins in this assay. Therefore most of the results observed by this analysis related 
to the interaction of TBP1 pAS with each of the proteins tested. One weak 
interaction that could be intermittently detected was between Sug2 and TBP 1, 
although this could only be confirmed in one direction due to TBP1 in the DNA 
binding domain vector transactivating alone. The failure to detect any interactions in 
this study was unexpected as it had been previously determined that the yeast 
homologue of S4 and murine MSS  interacted using this assay (Gordon et at, 1993) 
and therefore it was assumed that interactions could be detected between ATPases 
using this system. The underlying hypothesis at the start of this analysis was that all 
6 AlPases may sit in a ring structure in the cap complex. Therefore it seemed 
probable that some of these ATPases should interact with one another. The results 
produced from the interaction assay may simply be a technical problem with the 
assay. The major technical problem associated with this technique is that the hybrid 
proteins are targeted to the nucleus, and the interactions may be dependent on post-
translational modifications that take place in the endoplasmic reticulum, such as 
glycosylation and disulphide bond formation (Allen et al., 1995). These 
modifications may not occur in this system, but this should only limit the use of two 
hybrid for screening against extracellular proteins and plasma membrane receptors. 
Proteins that cannot fold correctly in the cytoplasm or that require other 
modifications e.g. phosphorylation or acetylation by non-yeast proteins may also not 
be suitable for use in a two-hybrid screen. Sometimes interactions that occur 
commonly in vivo fail to be detected when tested using the two-hybrid system. The 
reason for this remains ambiguous, but may be due, in some cases to high level 
expression of the fusion protein being toxic to the reporter strain. Another reason for 
failing to detecting a signal is that the fusion proteins may not be stably expressed in 
yeast. The failure to detect an interaction in this study was a consequence of using 
the two-hybrid system for analysis, as recent biochemical studies have detailed 
interactions between ATPases that we could not conclusively detect. Technically, all 
the fusion proteins were expressed, although not at very high levels, therefore 
toxicity of the fusion can probably be eliminated. As interactions have been detected 
using yeast homologues of ATPases with this type of analysis, then it is possible that 
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the failure to discover any interactions using the murine ATPases was due to some 
modification requirement from a protein that is not expressed in yeast. Clearly a 
biochemical analysis is required to address this question. 
Previous work with human TBP 1 has shown that TBP1 can interact with both 
itself and with TBP7 (Ohana et al., 1993). The two-hybrid system used above was 
slightly different from the one used in this study e.g. TBPI was fused to a Ga14 DNA 
binding domain (amino acids 1-147, identical to that in pAS) and tested against 
TBP7 fused to a herpes virus VP 16 activation domain. Mutation studies revealed 
that the first 100 amino acids of TBP1 were essential for interaction. Ohana and 
colleagues (1993) did not detect any transactivation activity from human TBP1 fused 
to the Ga14 DNA binding domain in the yeast two hybrid study. In contrast to this, 
they detected a transctivation activity for human TBP I fused to Ga14 DNA binding 
domain co-transfected with a Ga1UAS-driven thymidine kinase or HIV promoter. This 
transactivation potential was seen to be promoter specific e.g. TBP 1 -Gal4 DNA 
binding domain did not drive strong expression of a mouse mammary tumour virus 
(MMTV) promoter. This transactivation potential was abolished by mutation of the 
P-loop and the helicase-like domain. The observation that human TBP 1 does not 
activate transcription in yeast in the above study conflicts with the data generated in 
this study. The Gal4-DNA binding domains used were identical in both systems 
therefore the inability to detect binding in this study may be due to a technical 
problem with the particular yeast vectors and reporter strain used for the assay, or it 
is equally possible that TBP1 does display a transactivation potential. The results 
generated from biochemical studies are more concrete. These studies involve 
synthesising radiolabelled proteins from a reticulocyte lysate and performing a 
nitrocellulose binding assay, and have shown that 54 binds to MSS1, TBP7 binds to 
Sugi, and Sug2 binds to TBP1 (Richmond etal., 1997). This study confirmed the 
previous work suggesting S4 and MSS1 interacted (Gordon et al., 1993). These 
results from the biochemical assay determined that TBP1 and Sug2 associate tightly 
with one another but did not interact with any of the other ATPases analysed in this 
study. This is thought to suggest that these two subunits may be localised elsewhere 
in the regulatory complex. The interactions observed in the Richmond study suggest 
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that we may only have expected to observe an interaction between Sug2 and TBP1. 
The biochemical binding assay failed to detect an interaction between TBP1 and 
TBP7, similar to the results described in this thesis. These data conflict with those 
published by Ohana and colleagues (1993) who suggested that human TBPI and 
TBP7 interacted using a yeast two hybrid assay. Richmond and co-workers (1997) 
addressed the question of whether all 6 ATPases can sit in a hexameric ring in direct 
contact with the proteasome a subunits. They suggested that a hexameric ring of 
approximately 45kDa proteins would extend beyond the edges of the central cylinder 
of the proteasome, and that this is difficult to visualise given the published crystal 
structure of the proteasome (Peters et al., 1993, Groll ci' al., 1997). Thus the concept 
of a ring of 4 central ATPases, with a further two located more peripherally may be 
the preferred model (Figure 4.7b). At present no further details on ATPase 
arrangement in the regulatory complex is available therefore there is still some 
confusion on whether all of these ATPases sit in a hexameric ring structure, the 
preferred theory previous to the publication of this work, or whether there is a central 
compartment of 4 ATPases. 
The premise at the start of the two hybrid analysis was that all six ATPases 
sat in a ring structure within the 19S regulatory complex. The rationale behind the 
two hybrid analysis described in this chapter was based on a previous publication 
detailing an interaction between TBP1 and TBP7 (Ohana ci' al., 1993). If this 
assumption had proved to be correct then we expected to be able to orientate all six 
ATPases in the complex from these studies. The inability to detect any interactions 
in this thesis has been validated with a recent publication from the laboratories of 
Richmond and colleagues (1997), and the elucidation of the crystal structure of the 
20S proteasome (Groll et al., 1997). From this later work it is now apparent that no 
interactions occur in any of the proteins examined herein with the exception of TBP 1 
and Sug2. More comprehensive studies are required to resolve the biochemical 
structure of this complex. 
Recent data has also served to heighten the debate as to whether these 
ATPases merely function as components of the proteasome or whether they can play 
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Figure 4.7b Theories on the structure of the 19S regulatory complex. 
Original theory was based on all 6 ATPases forming a ring structure. (ii) Face on 
view of proposed structure of 26S proteasome with 6 ATPases sitting in a ring. 
The second theory is based on the observations from the crystal structure of the 
yeast 20S proteasome. It indictates that if all 6 ATPases sat in a ring this would be 
too large to sit on top of the 20S core. (ii) Richmond and colleagues (1997) proposed 
that 4 ATPases sit in a central ring with two outlying ATPases. 
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a transcriptional role. In general it is assumed that some of the transcriptional 
phenotypes observed in yeast strains mutant in ATPase subunits may by due to a 
proteasomal defect. For example, the proteasome may be involved in proteolytically 
processing or degrading a transcription factor. Inhibition of this pathway may result 
in either an inhibitory effect on transcription where this complex is involved in 
activating a transcription factor, or in the stimulation of transcription where the 
proteasome is involved in degrading a transcription factor. Data from studies with 
TBP1 and Sugi suggest that if any of these proteins play a transcriptional role, then 
these are the two most likely candidates. Ohana and colleagues (1993) showed a 
stimulatory activity of TBPI on a variety of different promoters. Sugi has been 
shown to contain an ATPases activity that was stimulated by synthetic RNAs and 
mRNA-type RNAs (Makino etal., 1997). This would suggest that Sugi may play a 
role in RNA metabolism as well as proteolysis. Again this effect may be due to the 
possibility that some mRNA-binding proteins undergo conformational changes 
induced by interactions with mRNAs, which may be targets of SugI proteasome 
mediated proteolysis. Fraser and colleagues (1997) have suggested that Sugi 
exhibits a 3'-+5' DNA helicase activity, and this was confirmed with the 
identification of Sugi interacting with the XPB subunit of the repair/transcription 
factor TFJIH (Weeda et at, 1997). Only a small proportion of cellular Sugi was 
identified bound to the nucleotide excision repair helicase XPD in complex with 
TFIIH. These data have pointed to a more universal role for Sugl, and suggested a 
link between the basal transcription initiation/repair factor and the cellular machinery 
implicated in protein remodelling and degradation. Given that the six ATPases 
involved in protein degradation are highly structurally conserved, then I suggest that 
it is highly probably that other ATPases may play a transcription role in the cell. 
Paramount to the study of a transcriptional role is the differentiation between the 
proteolytic and transcription effect. At present, there is scepticism around any 
transcriptional function as this response may represent a function of disruption of 
protein degradation. Assigning functions to the different regions contained within 
these proteins should lead to a better understanding of the structure and function of 
the 26S proteasome, and also of any additional roles these ATPases may play. 
Chapter 5: 
Analysis of the Effect of a Proteasome Inhibitor 




The aim of the studies reported in this chapter was to determine the effect that 
inhibition of the ubiquitin dependent 26S proteasome pathway had on KIM-2 
mammary epithelial cells. We have previously observed that levels of the 26S 
proteasome increase in the mammary gland during the later half of gestation. It is 
well documented that the mammary gland responds to a massive proliferative signal 
in the early stages of pregnancy and it was hypothesised that the increase in the 26S 
proteasome may be essential for the maintenance of a low level of apoptosis during 
pregnancy. To address this question we examined the effect that proteasome 
disruption had on a mammary epithelial cell line undergoing proliferation. A 
synthetic peptide aldehyde inhibitor was used to block proteasome function. The 
recent interest in ubiquitin-dependent protein degradation has led to the identification 
of several hydrophobic peptide aldehydes which act to block peptidase sites within 
the 20S proteasome and thus can be used to study this pathway (Rock et al., 1994). 
These inhibitors include N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal (ALLnL), N-
acetyl-L-leucinyl-L-leucinyl-methional (ALLM), N-carbobenzyoxyhL-leucinyl -L-
norvalinal (MGi 15), and N-carbobenzyoxyl-L-leucinyl-L-leucinyl-leucinal 
(MGI32). These peptides bind in the active sites formed by two related 
neighbouring 0 subunits. The three amino acids of the inhibitor (PI-P3) are in 
extended conformation and form hydrogen bonds with sites on either side of the 
hydrophobic central channel. This blocks the active site flanking residues Va120, 
Thr2 I, and Met22 and on the other side of the hydrophobic cleft 11e45, A1a46, G1y47, 
Leu48, and Va149 (Ditzel et al., 1997). Crystallographic studies revealed that the 
inhibitors bind in a 0 sheet conformation between an extended loop between the 13 
strands S2 and S3 of the 13 subunits. ALLnL and ALLM also function in inhibiting 
calpains which are cysteine proteases, and therefore are more commonly referred to 
as calpain inhibitor I and calpain inhibitor II respectively. Their inhibitory activity 
on calpains is similar whereas calpain inhibitor II has a stronger inhibitory effect on 
the 20S proteasome than does calpain inhibitor I. In contrast to this MGi 15 and 
MGI32 have more specific effects on proteasome inhibition, and these effects are at 
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least 3 fold more potent that those of the calpain inhibitors (Rocket al., 1994). 
The vast majority of the initial studies analysing these aldehyde inhibitors 
focused on the inhibitory effect on the 20S proteasome itself Recently it has been 
shown that these inhibitors are less potent against the 26S proteasome. This was 
thought to be due to the active sites of the proteasome being less accessible when 
they are incorporated into the 26S proteasome although it has been shown that these 
peptides clearly inhibit the 26S proteasome function in vitro. They have been 
observed to block the presentation of ovalbumin on IvIHC Class I which has been 
shown to require ubiquitin conjugation (Michalek et al., 1993). These peptide 
aldehyde inhibitors have been demonstrated to have no obvious toxicity to cells as 
treatment at high concentrations for several hours shows no obvious necrosis within 
the cell population treated. They are also documented to be able to enter mammalian 
cells and inhibit proteasome function in vivo in a reversible manner. Initial studies of 
these inhibitors in yeast showed that following removal of M0132, the degradation 
of pulse-labelled proteins returns to normal rates (Lee et al., 1996). This reversible 
effect also argues that the reduction of proteolysis observed with these inhibitors is 
due to inhibition of the proteasome and not to a toxic action of the inhibitor. Lee and 
colleagues (1996) noted in yeast that the inhibitory effect of MG132 was lost after 5 
hours incubation. This was reversed by the addition of more inhibitor suggesting 
that these peptides were metabolised much more rapidly in yeast, as they are known 
to block degradation for longer periods in mammalian systems. 
More recently a newer class of compound has been described which acts to 
block proteasome function. The antibiotic lactacystin, which is cleaved to the more 
potent 13-lactone has been attributed with blocking the three major activities of both 
the 20S and 26S proteasome (Craiu et al., 1997). Unlike some of the peptide 
aldehyde inhibitors, 3-lactone does not inhibit any other protease pathways and its 
effects are irreversible. 13-lactone binds in close proximity to the N-termini of all 14 
13  subunits (Ditzel et al., 1997) and blocks the degradation of proteins with similar 
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kinetics to M0132. Dick and co-workers (1997) have shown that only 13-lactone can 
enter cultured mammalian cells, therefore the conversion of lactacystin to f3-lactone 
is rate limiting for its inhibitory effects. The availability of these inhibitors has 
proven a useful tool in the analysis of the regulation of proteolysis within the cell and 
more generally has expanded our knowledge on a number of processes in which the 
rapid turnover of proteins plays an important regulatory role. 
In this chapter 1 have used the peptide aldehyde inhibitor MG 132 to 
specifically block proteasome function in mammary epithelial cells. The effects of 
proteasome inhibition were analysed by morphological assessment of cell death by 
staining cells with acridine orange and examination by fluorescence microscopy. 
Apoptotic cells are generally distinguished by characteristic morphological and 
biochemical changes such as cell shrinkage, chromatin condensation, cell 
fragmentation and chromosome DNA cleavage at internucleosomal sites (Ellis etal., 
1991). A flow cytometric Annexin V assay was performed to specifically quantitate 
the proportion of cells undergoing apoptosis following proteasome inhibition. 
Annexin V binds to phosphatidylserine (PS) which flips from the inner to the outer 
surface of the cell membrane early in the apoptotic cascade. By counterstaining cells 
with propidium iodide, which will only enter if the cell membrane is disrupted, 
apoptotic and necrotic cells can be distinguished. This assay can therefore be used to 
detect cells undergoing one of the early changes characteristic of apoptosis. 
Apoptotic changes within a cell are a transient event taking between 15 minutes to 1 
hour (Wyllie et al., 1980). After a few hours, apoptotic cells undergo a later non-
specific deterioration as their membrane permeability increases. At this stage the 
apoptotic cells cannot be distinguished from cells undergoing primary necrosis. As a 
consequence of this, I analysed apoptotic changes at specific time points to quantitate 
the apoptotic events occurring at each particular time. 
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5.2 Induction of Apoptosis by Proteasome Inhibition 
Proteasomes contain a number of distinct proteolytic activities: these include 
a chymotrypsin-related activity, a trypsin-related activity, and a peptidyiglutamyl-
peptide hydrolysing activity. The peptide aldehyde inhibitor of the proteasome, 
MG132 selectively inhibits the chymotrypsin-like activity of the complex resulting in 
inhibition of this degradation pathway (Rock et al., 1994). To investigate the role of 
the proteasome in apoptosis, we examined the effect of MG 132 as well as other 
protease inhibitors on KIM-2 mammary epithelial cells. Figure 5.1 provides 
evidence that inhibition of the proteasome in mammary epithelial cells (NEC) 
induced apoptosis. The results shown were determined from morphological analysis 
of acridine orange stained cells; apoptosis was identified by the presence of 
cytoplasmic shrinkage, and nuclear fragmentation. The cysteine/serine protease 
inhibitor Leupeptin, the aspartic protease inhibitor Pepstatin, and the serine protease 
inhibitor PMSF, did not induce apoptotic cell death at high concentrations over a 24 
hour period (Grimm et al., 1996, Sadoul et al., 1996, and Drexler, 1997). The 
lysosomal cathepsin inhibitor, E64d ester did not induce apoptosis in NEC. In 
contrast to this, calpain II inhibitor (ALLM) induced a low level of apoptosis (12%) 
at a high concentration (lOOj.tM) over the course of the experiment. 2M of MG132 
induced >25% death over an identical time period. ALLM is well documented to 
cross-react with the proteasome in addition to calpains (Rock et al., 1994). E64d, 
which has cross-reactive inhibitory activity on calpains did not induce apoptosis 
therefore it seems highly likely that the death observed with high concentrations of 
ALLM treatment is due to its inhibitory activity on the 265 proteasome rather than 
the inhibition of calpains. Figure 5.2 shows MG 132 treated KIM-2 cells stained with 
acridine orange, showing the characteristic features of apoptosis. In the following 
experiments KTIM-2 cells were routinely treated with 5jiM M0132 unless otherwise 
stated. Titration of MG 132 demonstrated that there was no major difference in the 
level of death induced by either 2iM or 5jsM MG132, and no enhanced necrotic 
effects were observed at the higher concentration as shown by an Annexin V assay, 
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Figure 5.1. Effect of a range of protease inhibitors on KLM-2 mammary 
epithelial cells. The protease inhibitors PMSF, Leupeptin, Pepstatin A, E64d, 
Calpain II Inhibitor, and MG132 were added to media at various concentrations for 
24 hours. Cells were harvested and fixed for staining with acridine orange. The 
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Figure 5.2 Effect of Proteasome Inhibition on KIM-2 Mammary Epithelial 
Cells. (a) KIM-2 cells grown to confluence were treated with a range of 
concentrations of MG 132 for 24 hours. As a positive control cells were also serum 
and growth factor starved (low serum) to induce apoptosis. Cells were harvested and 
fixed prior to staining with acridine orange. Cell death was assessed morphologically 
by flourescence microscopy. The results represented are the mean of three individual 
experiments ± sem. 500 cells were counted for each sample presented. (b) Acridine 
orange stained KIM-2 cells were assessed for apoptosis by the presence of 
cytoplasmic shrinkage and nuclear condensation. Examples of apoptotic cells are 
identified by the letter A's. 
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the principles of which are described below. As previous groups had published 
treatments of cells in culture with concentrations of between 20MM and 50MM 
M0132, we chose to use the higher concentration (5MM) of inhibitor to ensure we 
were inhibiting protein degradation at as effective a level as possible. 
A flow cytometric Annexin V assay was performed to allow a faster and 
more accurate quantitation of apoptosis following inhibition of the 26S proteasome. 
This assay also allows the processes of apoptosis and necrosis to be distinguished. 
Examples of flow cytometry data are shown in Figure 5.3a. Annexin V and P1 
staining are shown for a control and MG132 treated sample. The lower left quadrant 
displays the viable unstained cells, with the upper left being PT positive (necrotic) 
cells. The lower right quadrant contains Annexin V (apoptotic) positive cells, with 
the upper right quadrant containing dual stained cells (necrotic and late apoptotic 
cells). When this assay is performed over a range of time, the population of 
apoptotic cells can be seen to later become positive for PT as well as Annexin V. 
KIM-2 cells are grown as a monolayer and thus are harvested from the flask by 
trypsinisation. This process results in the rupture of a number of cell membranes, 
increasing the background level of Annexin V and P1 positive cells. This can be seen 
in the control sample where 7.4% of the cells are staining for both Annexin V and PT. 
By contrast the level of dual staining increases to 25.7% in the M0132 treated 
sample suggesting that this population now contains cells which are necrotic, in 
conjunction with cells which are showing signs of late apoptosis. Figure 5.3b shows 
data from KIM-2 cells treated with MG132, and harvested over a 24 hour time 
period. These results show that apoptotic cells can be observed within 4 hours of 
M0132 treatment. The death response observed appeared to be bi-phasic e.g. a peak 
in apoptotic cells was observed within the first 8 to 10 hours and then another 
between 18 and 20 hours. This may be a function of the MEC progression through 
particular stages of the cell cycle. This result also showed an increase in the 
proportion of double stained cells with time, suggesting that cells which had 
undergone apoptotic responses later began to stain positive for PT as well as Annexin 
V. 
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Figure 5.3a. Flow Cytometric Annexin V assay. Examples of control and MG132 
treated samples. Cells were treated with either DMSO or 511M MG132 for 24 hours. 
Samples were harvested and 10 5 cells stained with Annexin V (AV) and Propidium 
Iodide (PT) using an R&D Systems Apoptosis Detection Kit. The data is shown as 
the percentage viable cells (no stain, in the lower left quadrant), Annexin V positive 
(apoptotic, in the lower right quadrant), PT positive (necrotic, in the upper left 
quadrant), and Annexin V and P1 positive (necrotic and late apoptotic, in the upper 
right quadrant). The data is subsequently expressed as the percentage of Annexin V 
positive cells e.g. 12.7% for controls and 34.1% for cells treated with 5j.iM MG132. 
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Figure 5.3b Annexin V time-course on KIM-2 Cells. KIM-2 cells were grown to 
confluence and treated with 5jiM M0132 over a 24 hour period. Samples were 
harvested and an Annexin V assay was performed. The results shown are the mean 
of three experiments ± sem, and are expressed as the percentage of Annexin V 
positive cells. 
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Figure 5.4a. Can Proteasome Inhibition protect from Apoptosis? Confluent 
KIM-2 cells were treated with fill maintenance media containing 5PM MG132 at 0, 
1, 2, 3, 5, and 8 hours or in media containing only 3% FCS. All samples were 
harvested at 24 hours and used as controls for either treatment alone. Test samples 
were induced to die by treatment with 3% ECS for 24 hours. At time 0, 1, 2, 3, 5, 
and 8 hours into the serum starvation, SjsM MG132 was added to the cells. Samples 
were harvested at 24 hours and an Annexin V assay was performed. Results shown 
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At present it appears that the response to proteasome inhibition may depend 
on the system chosen for analysis. Recent results have suggested that proteasome 
inhibitors are capable of inducing cell death in some systems e.g. in lymphoma cells 
(Tanimoto et al., 1997), Molt 4 cells (Shinohara et al., 1996), neurons (Lopes et al., 
1997), and HL60 cells (Drexler, 1997), whilst other results suggest that inhibition of 
the proteasome can prevent apoptosis e.g. in thymocytes (Grimm et al., 1996), and 
sympathetic neurons (Sadoul et al., 1996). In KIM-2 cells we have shown that 
proteasome blockage induces an apoptotic response. In order to address whether 
proteasome inhibition could also play a protective role in mammary epithelial cells, 
KIM-2 cells were serum and growth factor (OF) starved to induce an apoptotic 
response. These cells were also treated with 51.tM MG132 at the onset of serum and 
CF withdrawal and up to 8 hours following this death stimulus. Annexin V staining 
determined that MGi 32 could not protect from apoptosis induced by GF withdrawal 
(Figure 5.4a). This experiment was repeated using a lower concentration of MG132 
(1.5j.xM) which induced less death and a similar result was obtained (Figure 5.4b). 
The effects on death observed with both treatments appeared to be additive. These 
experiments suggested that the proteasome is not involved in degrading and/or 
processing a protein that is essential for driving apoptosis induced by GF and serum 
starvation. 
6.3 Induction of Apoptosis by Proteasome Inhibition Displays Cell Cycle 
Dependence 
The differences observed in response to proteasome inhibition were thought 
to be due to differences in the cell cycle status of the cell lines examined. To address 
this question KIM-2 cells at different stages of confluence were treated with MGI 32 
and death assessed morphologically by acridine orange staining. Cells were treated 
in this manner to represent samples that contained progressively less cells actively 
traversing the cell cycle. Cells were treated 4, 24, 48, 72, and 120 hours following 
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passaging with MG132 over a 24 hour period. By 72 hours KIM-2 cells were 
reaching confluence. These results showed that in cells treated 4 hours following 
passaging, MG132 treatment over 24 hours induced 50% death (Figure 5.5a). The 
level of death observed decreased as the cells became more confluent, and this 
remained at a minimum of around 20% in the samples treated from 72 hours 
onwards. These results showed a baseline level of 20% apoptosis in cells that were 
almost entirely confluent. This would suggest that the apoptosis induced by 
proteasome inhibition had a dependency on the cells being within the cell cycle. 
This was shown not to be the case for serum and growth factor starvation of the cells. 
10-15% death was observed with this death stimulus regardless of the confluence 
status of the cells. To further this observation Annexin V staining was performed on 
KIM-2 cells that had been differentiated for 12 days in the presence of prolactin and 
dexamethasone and thus should be effectively out of cycle. Death was seen to occur 
in these cells although at a much lower level than that observed in undifferentiated 
cells (Figure 5.5b). These results together suggest that cell proliferation is a major 
component of the sensitivity to proteasome inhibition although not the sole 
determinant, as a low level of death was observed in both differentiated and 
confluent cells. These results could also explain the previous conflicting results; 
apoptotic death induced by proteasome inhibition can be observed in actively 
proliferating cells as opposed to terminally differentiated cells. 
To determine if the apoptotic response observed as a consequence of 
proteasome inhibition was entirely dependent on a cell traversing the cell cycle, we 
performed experiments that involved blocking NEC in either GuS phase with 
Hydroxyurea, which inhibits the production of bases for DNA synthesis, or G2/M 
with the spindle poison Nocodazole. The blocking effect of these drugs were 
optimised for KIM-2 cells revealing that 1mM Hydroxyurea treatment for 24 hours 
resulted in approximately 65-70% cells in 01/S phase. Nocodazole treatment 
(SOng/ml) blocked approximately 75% of cells in G2/Mitosis. Cells were blocked 
for one cell cycle (approximately 24 hours) and then medium was replaced with fresh 
medium containing either more Hydoxyurea or Nocodazole supplemented with 5jsM 
MG132. The rationale of this experiment was to determine if apoptosis could be 
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induced in a cell population that was not actively progressing through the cell cycle. 
Unfortunately, the results obtained were not conclusive. Hydroxyurea is relatively 
toxic to the cells if left in contact for 48 hours even at concentrations as low as 1mM. 
This resulted in an enhanced level of background death precluding analysis of any 
real response, which could not be differentiated from the toxic effect of the drug on 
the cells. In contrast to this, Nocodazole was not toxic to the cells when left in 
contact for 48 hours, but the kinetics of blockage changed from 24 hours to 48 hours. 
At 24 hours we generally obtained 75% G2fM phase block, but at 48 hours this had 
reduced to 49% suggesting that there was some leakage from this G2/N4 block. The 
Annexin V assay showed approximately 40-50% cells were in the early stages of 
apoptosis (Figure 5.5c). As only approximately 50% of the cells had remained 
blocked in 02/M this may suggest that the death observed was from the cells that 
were no longer effectively blocked. These drugs did not block 100% of the cells and 
therefore it was difficult to interpret these results. 
The results described above suggested that the effect of proteasome inhibition 
is dependent on cell cycle status. This was not unexpected as the proteasome is well 
documented to be involved in degrading proteins involved in cell cycle control. 
Experiments were therefore performed to determine if KIM-2 cells were undergoing 
apoptosis from a specific point in the cell cycle as a consequence of MG132 
treatment. To achieve this cells were synchronised at particular stages of the cell 
cycle prior to treatment with MG132 and apoptosis analysed over a 24 hour time 
period. Figure 5.6a shows the morphological appearance of synchronised cells. 
Cells treated with ITydroxyurea and therefore blocked in late 01 appeared more 
elongated than unsynchronised control cells. In contrast to this, Nocodazole 
treatment caused a more dramatic change in the cells. KIM-2 cells rounded up and 
some detached from the plastic when blocked in 02/mitosis. Upon removal of these 
drugs and culture for 24 hours in drug free medium, the cells morphologically 
appeared very similar to unsynchronised control cells suggesting that these 
treatments were reversible and had no long-term toxic effects to the cells. Cells 
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Figure 5.5 (a) Apoptosis Analysis in a Proliferating Cell Population. KIM-2 cells 
were passaged and treated with either vehicle alone (DMSO), serum and growth 
factor starved (3% FCS), or 5jiM MG132 at 4, 24, 48, 72, and 120 hours after 
passaging. Cells were treated for 24 hours and an Annexin V assay performed. 
Results are shown as the percentage of Annexin V positive cells, and are expressed 
as the mean of three experiments ± sem. 
(b) Effect of Proteasome Inhibition on Differentiated KIM-2 Cells. KIM-2 cells 
were differentiated for 12 days in the presence of dexamethasone and prolactin prior 
to a 24 hour treatment with either 5M MG132 or serum and growth factor 
withdrawal (3% FCS). Cells were harvested and an Atmexin V assay performed. 
Results are expressed as the mean of three experiments ± sem and expressed as the 
percentage of Annexin V positive cells. 
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Figure 5.5c Effect of Proteasome Inhibitor on KIM-2 Cells which are not 
actively Progressing the Cell Cycle. (i) KIM-2 cells were cultured for a full 24 
hours following passaging prior to treatment with 50nglml Nocodazole. Cells were 
harvested and fixed prior to staining with Propidium Iodide and analysis on a Coulter 
Epics flow cytometer. The examples shown represent unsynchronised KIM-2 cells, 
and either 24 or 48 hours synchronisation with Nocodazole. 
(ii) KIM-2 cells were synchronised in 021M phase for 24 hours using SOng/mI 
Nocodazble. At 24 hours cells were either treated with addition of Nocodazole 
alone, or Nocodazole supplemented with 5jtM M0132 for a further 24 hours. As 
controls, cells were treated with either Nocodazole or MG132 alone for 48 hours. 
KIM-2 cells were harvested and an Annexin V assay performed. Results are shown 
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were blocked for 24 hours (approximately one cell cycle) and then the drug was 
removed and replaced with either maintenance medium (MM) or MM supplemented 
with M0132. Cells were harvested and stained with Annexin 'V for apoptosis 
analysis or fixed and stained with Propidium Iodide (P1) for cell cycle analysis. 
Results for cells blocked in 01/S phase showed that apoptosis was detectable within 
2 hours of MG132 treatment, and this increased dramatically by 4 hours. In contrast 
to this, cells that had been blocked in 02/Mitosis did not begin to show a dramatic 
increase in Annexin V staining until 12-16 hours after treatment with MG132 (Figure 
5.6b). Analysis of the cell cycle kinetics demonstrated that in cells released from a 
01 synchronisation, M0132 treatment caused an accumulation of cells in the 01/S 
phase of the cell cycle. The cells appeared to be unable to progress any further than 
S phase (Table 5.1) compared to control cells (Table 5.3). The cell cycle profiles of 
these cells are shown in Figure 5.6c. KIM-2 cells synchronised in 02 prior to 
proteasome inhibition appeared to progress through 02/M but at a much slower rate 
than cells which were released from block into maintenance media (Tables 5.2 and 
5.4, and Figure 5.6c). The MG132 treated cells did not begin to accumulate in UI/S 
phase until 10-12 hours following the onset of treatment. This corresponds to the 
onset of apoptosis in these cells. Similar to 01 synchronised cells, 02 synchronised 
cells were unable to progress any further than Ui/S phase of the cell cycle. Taking 
the cell cycle and apoptosis results together it would appear that the 26S proteasome 
is implicated in functioning during mitosis as MG132 treated cells were less efficient 
at traversing this stage of the cell cycle than control cells. These results also detailed 
an absolute requirement for proteasome function at the 01/S phase of the cell cycle 
as the cells appeared to arrest and undergo apoptosis either during or following this 
stage in the cell cycle. 
To ensure that KI1\4-2 cells were able to enter S phase prior to undergoing 
apoptosis we examined the levels of the cdk inhibitor p27'". p27 is elevated late in 
01 and is one of a number of restriction points controlling the 01/S phase transition. 
Its association with the cyclinE/cdk2 complex catalyses its degradation by the 26S. 
proteasome (Vlach et al., 1997). It was assumed that if the cells were reaching this 
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Figure 5.6a. Cell cycle synchronisation of KEM-2 Cells. Phase contrast light 
microscopy of (1) unsynchronisecl proliferating KIM-2 cells, (ii) Proliferating KIM-2 
cells synchronised in GuS phase with 1mM Hydroxyurea for 24 hours, (iii) KIM-2 
cells released from a Hydroxyurea block in full maintenance media for 24 hours, (iv) 
Proliferating KIM-2 cells synchronised in G2/Mitosis with SOng/mi Nocodazole for 
24 hours, (v) KIM-2 cells released from a G2/Mitosis block into full maintenance 
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Figure 5.6b. Apoptosis induced from a GuS phase arrest in KIM-2 cells treated 
with proteasome inhibitor. KIM-2 cells were passaged normally, and 24 hours 
later blocked with Hydroxyurea (1mM) or Nocodazole (50ngIml) for 24 hours 
(approximate cell division time). Cells were washed to remove the blocking drugs 
and then treated with 5MM MG132 for a range of times. Cells were harvested and an 
Annexin V assay performed. Control samples are represented by apoptosis levels in 
cells treated with either of the blocking drugs for 24 hours and subsequently released 
into full maintenance media for a further 24 hours. Results shown are expressed as 
the percentage of Annexin V positive cells. The data is the mean of three 
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Figure 5.6c Effect of Proteasome Inhibition on Cell Cycle Distribution of KIM-
2 Cells. KIM-2 cells were passaged normally and 24 hours later blocked in 6-1/S 
phase with 1mM hydroxyurea, or in 02/M phase with 50ng/ml Nocodazole. The 
blocking drug was then removed from the cells and they were subsequently placed in 
full maintenance media (MM) alone or supplemented with 5 j.tM MG 132 for a further 
24 hours. KIM-2 cells were harvested and fixed prior to staining with propidium 
iodide for cell cycle analysis. Flow cytometry was then performed using a Coulter 
Epics cytometer. Three individual experiments were performed and the results 
shown are representative of these. 
1mM Hydroxyurea 24 Hours 	 1mM Hydroxyurea 24 Hours + 
	
1mM Hydroxyurea 24 Hours + 
MM for a further 24 Hours MM + 5jiM MG132 for a 
further 24 Hours 
50ng/ml Nocodazole 24 Hours 	50ngIml Nocodazole 24 Hours + 
	
50ng/ml Nocodazole 24 Hours + 
MM for a further 24 Hours 	 MM + 5 RM MG132 for a further 
24 Hours 	 I', 
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Table 5.1. Cell Cycle Analysis of KIM-2 Cells Synchronised in GuS Phase 
Prior to Treatment with Proteasome Inhibitor. KIM-2 cells were synchronised in 
01/S phase and subsequently treated with 5jxM MG132 as described in Figure 5.6b. 
Cells were harvested and fixed prior to staining with Smglml Propidium Iodide. 
Results shown are the mean of three experiments, and are expressed as the 
percentage of cells which showed a Pre-GI DNA peak, 01, S phase, or G2/N4 phase 
DNA profiles. 
Table 5.2. Cell Cycle Analysis of KLM-2 Cells Synchronised in G2/Mitosis Prior 
to Proteasome Inhibition. KIM-2 cells were blocked in 02/Mitosis and 
subsequently treated with 5jiM MG132 as described in Figure 5.6b. Cells were 
harvested, and fixed for flow cytometry analysis. 106  cells were stained with the 
nucleic acid stain Propidium Iodide. Results shown are means of three independent 
experiments, and data is shown as the proportion of cells showing a Pre-GI DNA 
peak, 01, S phase, or 02/M phase DNA profile. 
225 










0 Hours 4.7 (0.275) 69.6 (0.715) 10.2 (0.560) 10.7 (0.233) 
2 Hours 8.8 (0.178) 56.0 (0.872) 12.2 (0.338) 13.3 (0.753) 
4 Hours 11.9 (0.328) 58.3 (1.103) 13.2 (0.153) 7.1 (0.491) 
6 Hours 14.4 (0.451) 55.3 (0.752) 16.2 (0.145) 5.3 (0.176) 
8 Hours 16.6 (0.513) 53.1 (0.826) 16.4 (0.317) 7.3 (0.409) 
10 Hours 19.1 (0.289) 50.6 (0.565) 15.7 (0.437) 7.1 (0.176) 
12 Hours 30.9 (0.682) 33.5 (0.592) 21.1 (0.202) 8.0 (0.178) 
14 Hours 34.9 (0.882) 31.5 (0.447) 23.1 (0.676) 4.4 (0.405) 
16 Hours 35.3 (0.589) 27.9 (0.512) 26.1 (0.115) 5.9 (0.384) 
18 Hours 40.6 (0.373) 25.4 (0.379) 21.6 (0.328) 4.8 (0.120) 
20 Hours 42.1 (0.366) 19.0 (1.143) 24.5 (0.406) 5.6 (0.251) 
22 Hours 44.0 (0.571) 21.5 (0.722) 25.0 (0.361) 2.9 (0.360) 
24 Hours 40.5 (0.918) 23.8 (0.586) 25.3 (0.233) 2.0 (0.528) 










0 Hours 1.2 (0.187) 9.3 (0.315) 7.2 (0.088) 73.3 (0.529) 
2 Hours 4.0 (0.226) 15.3 (0.283) 7.8 (0.145) 54.1 (0.731) 
4 Hours 4.2 (0.311) 14.9 (0.342) 8.5 (0.260) 54.5 (0.484) 
6 Hours 4.5 (0265) 17.9 (0.256) 7.7 (0.273) 52.5 (0.375) 
8 Hours 4.5 (0.377) 20.7 (0.314) 9.0 (0.404) 50.9 (0.384) 
10 Hours 5.8 (0.447) 20.8 (0.531) 11.6 (0.251) 49.4 (0.435) 
12 Hours 11.3 (0.553) 17.9 (0.784) 11.2 (0.448) 44.3 (0.405) 
14 Hours 14.3 (0.722) 20.8 (0.569) 12.7 (0.215) 38.0 (0.617) 
16 Hours 16.7 (0.871) 23.4 (0.617) 14.4 (0.375) 32.8 (0.721) 
18 Hours 19.5 (0.673) 21,1 (0.332) 16.3 (0.470) 31.0 (0.762) 
20 Hours 22.5 (0.455) 21.3 (0.474) 14.8 (0.669) 29.9 (0.811) 
22 Hours 24.9 (0.524) 23.8 (0.514) 13.4 (1.117) 28.0 (0.589) 
24 Hours 27.7 (0.379) 24.1 (0.616) 21.9 (0.346) 26.8 (0.437) 
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Table 5.3. Cell Cycle Analysis of KIM-2 Cells Synchronised in Cl/S Phase 
Prior to Release into Maintenance Medium. KI1\4-2 cells were synchronised for 
24 hours with 1mM Hydroxyurea. Following drug removal, cells were incubated in 
maintenance medium alone for the times shown. Cells were fixed and stained with 
Propidium Iodide for cell cycle analysis. Results detailed are the means of three 
experiments, and are presented at the proportion of cells in Pre-GI, GI, S phase, or 
in G2IM phase. 
Table 5.4. Cell Cycle Analysis of KIM-2 Cells Synchronised in G21 Mitosis 
Prior, to Release into Maintenance Medium. Cells were synchronised in 
G2/Mitosis for 24 hours using 50ng/ml Nocodazole. Following drug removal, cells 
were incubated in maintenance media alone for the times shown. Cells were fixed 
and stained with Propidium Iodide for cell cycle analysis. Results shown are the 
mean of three experiments, and are presented as the proportion of cells in Pre-GI, 




(±sem) (±sem) (±sem) 
0 Hours 13.2 (0.352) 67.9 (0.315) 142 (0.348) 7.4 (0.233) 
2 Hours 7.1 (0.482) 70.4 (0.525) 10.2 (0.378) 7.9 (0.208) 
4 Hours 7.2 (0.511) 63.2 (0.441) 18.7 (0.642) 6.4 (0.233) 
6 Hours 6.8 (0.283) 53.2 (0.477) 17.8 (0.674) 16.5 (0.066) 
8 Hours 12.6 (0.364) 48.6 (0.539) 19.2 (0.633) 12.6 (0.251) 
10 Hours 13.6 (0.572) 42.6 (0.488) 26.7 (0.404) 10.6 (0.176) 
12 Hours 13.6 (0.489) 33.6 (0.992) 35.9 (0.665) 13.6 (0.240) 
14 Hours 23.8 (1.153) 34.0 (0.716) 26.3 (0.491) 10.1 (0.375) 
16 Hours 18.2 (0.769) 41.6 (0.843) 23.9 (0.328) 8.9 (0.378) 
18 Hours 22.4 (0.837) 41.7 (0.641) 20.9 (0.768) 7.2 (0.120) 
20 Hours 22.4 (0.586) 46.9 (0.763) 18.5 (0.384) 8.9 (0153) 
22 Hours 23.2 (0.618) 45.8 (0.568) 18.0 (0.550) 10.7 (0.264) 
24 Hours 21.1 (0.459) 47.3 (0.761) 18.1 (0.296) 11.9 (0.208) 
0 Hours 8.1 (0.158) 15.1 (0.281) 9.7 (0.260) 66.4 (0.519) 
2 Hours 9.9 (0.413) 36.5 (0.457) 14.8 (0.503) 32.2 (0,923) 
4 Hours 9.5 (0.356) 41.8 (0.378) 11.6 (0.218) 31.7 (0.895) 
6 Hours 9.4 (0.245) 41.7 (0.672) 11.0 (0.328) 30.7 (0.321) 
8 Hours 10.6 (0.359) 49.2 (0.525) 10.1 (0.378) 24.4 (0.578) 
10 Hours 9.9 (0.418) 51.4 (0.871) 12.5 (0.352) 21.0 (0.721) 
12 Hours 8.2 (0.238) 50.3 (0.762) 15.3 (0.173) 20.4 (0.204) 
14 Hours 7.6 (0.279) 47.7 (0.414) 14.3 (0.703) 19.9 (0.608) 
16 Hours 10.7 (0.562) 46.2 (0.337) 18.3 (0.438) 17.0 (0.536) 
18 Hours 10.3 (0.518) 47.4 (0.179) 18.9 (0.433) 16.2 (0.260) 
20 Hours 11.3 (0.316) 45.8 (0.456) 18.2 (0.776) 17.4 (0.173) 
22 Hours 11.9 (0.541) 50.2 (0.913) 17.2 (0.883) 15.7 (0.233) 
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Figure 5.7 p27 k  Expression in KIM-2 Cells treated with Proteasome Inhibitor. 
KIM-2 cells were treated with Hydroxyurea (1-IXU) at 1mM. Nocodazole (Noc) at 
50ng/ml, or vehicle alone (control) for 24 hours. Cells were washed to remove the 
drug and subsequently treated with either maintainance media (MM) alone or MM 
supplemented with 51.iM MG132 for an additional 24 hours (Upper panel). 
Conversely, KIM-2 cells were grown to confluence and treated over a 24 hour period 
with 5jtM MG 132 (Lower panel). Whole cell extracts were prepared and I Og 
protein was subjected to SDS/PAGE analysis. This was followed by western blotting 
using a p27 monoclonal antibody (Transduction Laboratories). The p27 positive 
control was 5tg protein from HeLa cells stimulated with EGF (Transduction 
Laboratories). The lower panel represents a longer exposure to autoradiographic film 
that that shown in the upper panel. 
(a) 
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Figure 5.8 a and b Effect of Proteasome Inhibition on Mammary Epithelial 
Cells and Jurkat T Cells. (a) HC1 I mammary epithelial cells were grown to 
confluence and treated with a range of concentrations of MG132 for 24 and 48 
hours. Cells were harvested and fixed prior to staining with acridine orange. Cell 
death was observed morphologically by fluorescence microscopy and the data shown 
are the mean of three experiments ± sem, where 500 cells were counted for each 
sample presented. (b) Jurkat T cells were treated with either 2tM MG132 or 
lOmJ/cm2 of UV irradiation for 24 hours. Cells were harvested and fixed prior to 
staining with acridine orange, The results shown are the mean of three experiments 
± sem, where 500 cells were counted for each sample presented. 
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Figure 5.8c Accumulation of tJbiquitinated protein in Mammary Epithelial 
Cells following Proteasome Inhibition. KIM-2 and HCI 1 mammary epithelial cells 
were incubated with various concentrations of MG 132 for 24 hours. Whole cell 
extracts were prepared and 1Opg protein analysed by western blotting using a 
polyclonal ubiquitin antibody (DAKO). The +ive control sample is 5.tg purified 
ubiquitin protein (Sigma). Additional controls for cell death are represented by cells 
that were serum and growth factor starved (-serum, -(iF). 
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5.4 Induction of Apoptosis by Proteasome Inhibition is p53 Dependent 
Many apoptotic pathways within the cell require the tumour suppresser 
protein p53. Results with HC 11 cells suggested that functional p53 may be required 
for the induction of apoptosis by proteasome inhibition. To address this question in 
KIM-2 cells, we temperature switched the cells to 33 °C to complex SV40 T Antigen 
(Tag) to p53. This can be achieved because KIM-2 cells were generated from 
transgenic mice carrying a temperature sensitive Tag driven by a milk protein gene 
promoter to direct expression to the mammary gland. At 33 °C, Tag complexes with 
p53, the retinoblastoma gene product (Rb), and another Rb family member p107 
resulting in a cell population with no functional p53 or Rb (Schreier and Gruber, 
1990). This allows continual passaging of the cell line due to immortalisation. KIM-
2 cells were routinely cultured at 37 °C, a semi-permissive temperature because it was 
assumed that the Tag was partially active at this temperature. This was due to the 
observation that mice carrying high copy numbers of the transgene developed 
tumours (Gordon, 1997). In contrast to this, at 39 °C the Tag is not functional due to 
a conformational change and subsequent degradation of this protein. This results in 
Tag being unavailable for binding to p53, Rb, and p107 and as a consequence the 
cells are no longer immortal. At 39 °C, KIM-2 cells can only be grown for 3 to 4 
days in culture before the cells spontaneously senesce. The experiment performed 
involved passaging cells and allowing them to grow at 37 °C for 48 hours. The cells 
were then switched to 39 °C for a frill 24 hours before treatment with M0132 for an 
additional 24 hours. KIM-2 cells, which were switched to 33 °C were passaged for 
14 days prior to treatment. At 33 °C and 37°C, MG132 treatment was continued for 
up to 96 hours and the cells analysed for apoptosis by Annexin V expression (Figure 
5.9a). These results showed that cells at 33 °C were resistant to apoptosis by 
proteasome inhibition. Serum and growth factor starvation was included as a control 
in this group of treatments. This controlled for the slower onset of death at 33 °C. 
The delay in onset of death was approximately 48 hours and this treatment induced 
15-20% apoptosis regardless of the temperature. At 37 °C, KllvI-2 cells are immortal 
due to "leaky" expression of Tag, which would suggest that some of the p53 is 
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complexed to Tag at this temperature. If this is the case then we should expect to see 
enhanced death by proteasome inhibition at 39 °C. This hypothesis was confirmed, 
only 10% non-apoptotic cells (unstained with either propidium iodide or Annexin V), 
as determined by Annexin V assay, were remaining in the culture following a 24 
hour treatment period at 39 °C. This compared to approximately 65% non-apoptotic 
cells observed at 37°C. These results further suggest a role for functional p53 in the 
apoptotic response induced by proteasome inhibition. To determine whether KIM-2 
cells cultured at 33 °C still responded like mammary epithelial cells, we induced these 
cells to differentiate with lactogenic hormones. Figure 5.9b shows 13-casein 
expression in KIM-2 cells cultured at 37°C over a 12 day period. Cells at 33°C were 
differentiated for a full 12 days. This result confirmed that cells cultured at 33°C 
were still prolactin and dexamethasone responsive. When we compared the level of 
j3-casein expression it was obvious that cells at 33°C did not express as much of this 
milk protein as the equivalent cells at 37°C. f3-casein expression in 12 day 
differentiated cells at 33°C was equivalent to 4 days differentiation at 37°C. These 
results suggest that KIM-2 cells at 33°C were still responding to prolactin like 
mammary epithelial cells, although they were no longer as responsive as their 
counterparts at 37°C. 
Overexpression of p53 is sufficient to induce apoptosis in response to a range 
of insults (Evan etal., 1995). It was assumed that p53 levels may have been elevated 
in KIM-2 cells following proteasome inhibition as this protein has also been found to 
be a substrate of the 26S proteasome (SchefTher etal., 1990). An elevation in p53 
protein alone could represent the apoptotic signal following MG132 treatment. We 
therefore examined the level of p53 protein in cells treated with MG132. At 24 
hours the levels of p53 protein are similar in control cells and cells treated with 
MGi 32, suggesting that there is no long term accumulation of p53 in these cells 
(Figure 5.10). The p53 expression over a 24 hour period of MG132 treatment was 
also seen to remain constant suggesting that KIM-2 mammary epithelial cells are not 
undergoing apoptosis as a consequence of the perturbation of p53 expression. 
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Figure 5.9a. Comparison of Apoptosis induced by proteasome inhibition in 
KIM-2 cells grown at 33 °C, 37°C, and 39°C. KIM-2 cells were cultured at 33 °C 
for 14 days prior to treatment, and at 39 °C for 48 hours prior to treatment. Cells 
were treated with vehicle alone (DM30), serum and growth factor starved (3% 
FCS), or with 5MM  M0132 over 24 hour period for a maximum of 96 hours. Death 
was initially assayed over a 72 hour period. The 96 hour timepoints represent any 
additional apoptosis after 72 hours as medium was replaced on the cells at this stage. 
Cells were harvested and lO cells were analysed for cell death using an Annexin V 
assay. The data shown are a representative of the mean of three independent 
experiments, and are expressed as the percentage of Annexin V positive cells ± sem. 
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Figure 5.9b 3-casein  Expression in KIM-2 Cells Cultured at 33°C. KIM-2 cells 
were differentiated at 37°C for up to 12 days in the presence of dexamethasone and 
prolactin. KIM-2 cells transferred to 33°C were cultured at this temperature for at 
least 14 days prior to the induction of differentiation. Whole cell extracts were 
prepared and lOpg protein subjected to SDS/PAGE analysis. Western blot analysis 
followed using a murine polyclonal 13-casein antibody (kindly provided by Dr. B 
Binas). The uninduced sample represents KIM-2 cells which were grown to 
confluence but did not receive a differentiation stimulus. The +ive control sample 
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Figure 5.10 Effect of Proteasome Inhibition on p53 levels in KIM-2 cells. The 
upper panel represents KIM-2 cells that were treated with either Hydoxyurea (HXU) 
at 1 mM, Nocodazole (Noc) at 50ng/ml, or vehicle alone (control) for 24 hours. Cells 
were washed to remove the drug and subsequently treated with 5tM MG 132 for an 
additional 24 hours. The lower panel represents cells that were grown to confluence 
and treated for up to 24 hours with 5iM MG 132. Whole cell extracts were prepared 
and 10tg protein was subjected to SDS/PAGE analysis. Western blotting following 
using a polyclonal p53 antibody (CM5 clone). The —ive control is differentiated 
KIM-2 cells, which express less p53 as these cells are not actively progressing the 
cell cycle. The +ive control samples are KIM-2 cells treated with 1 OmJ/cm 2 of UV 
irradiation. 
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To test the hypothesis that p53 was essential for apoptosis induced by 
proteasome inhibition more empirically, we obtained ES cell lines which contained 
either wild type p53 (E14 cells), or were null for p53 (R72D27 cells). One p53 allele 
had been deleted by gene targeting in these ES cells and the second allele 
spontaneously gained a mutation resulting in no functional p53 in this cell population 
(Corbet, 1998). These ES cells were treated with 3 different concentrations of 
M0132 for up to 48 hours and assayed for cell death and cell cycle status. The 
levels of apoptosis observed were greatly enhanced in the p53 wt cells as compared 
to the p53 null cells (Figure 5.1 la). Cell cycle analysis identified a G2/mitosis block 
in both cell types in contrast to death which was observed only in the p53wt cells. At 
higher concentrations this cell cycle blockage was accompanied by the appearance of 
a pre-GI DNA peak in the p53 wt cells e.g. 12.5% in the control (DM50) cells, 
which increased to 65.2% with lOp.M MG1 32 treatment (Figure 5.11b). The 
appearance of a pre-G1 peak in flow cytometry correlates with the appearance of 
apoptotic cells (Compton et al., 1988). In contrast the p53 null cells remained 
blocked in G2/mitosis with very little death observed e.g. 16.1% pre GI staining 
cells for lOj.tM MG132 treatment (Tables 5.5 and 5.6). These results are consistent 
with a role for p53 involvement in apoptosis induced by proteasome inhibition. 
5.5 Discussion 
The results in this chapter demonstrate that compounds capable of interfering 
with proteasome function induce apoptosis. KIM-2 mammary epithelial cells were 
incubated with inhibitors of the chymotrypsin-like function of the proteasome as well 
as with unrelated protease inhibitors. Of the two inhibitors that were capable of 
inducing cell death in these cells, both have been attributed with perturbing the 26S 
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Figure 5.11a p53 Dependence on Apoptosis Induced by Proteasome Inhibition. 
ES cells containing either wild type (wt) p53 (E14 cells) or which were null for p53 
(R72D27 cells) were grown to confluence and treated with different concentrations 
of MG 132 for up to 48 hours. Cells were harvested and an Annexin V assay 
performed. The results shown are expressed as the percentage of Annexin V positive 
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Figure 5.11b Effect of p53 on Cell Cycle distribution of ES Cells treated with 
Proteasome Inhibitor. ES cells which were wild type (wt) or null for p53 were 
cultured in full maintenance medium alone or supplemented with lOi.tM MGI 32 for 
24 hours. Cells were harvested and fixed prior to staining with propidium iodide. 
Cell cycle analysis was performed using a Coulter Epics flow cytometer. 
241 
Table 5.5. Cell Cycle Analysis of p53 wt ES Cells Treated by Proteasome 
Inhibition. Cells were treated with three concentrations of M0132 for 24 and 48 
hours. Cells were subsequently fixed and stained with PT for cell cycle analysis. 
Results shown are the mean of three experiments, and are expressed as the 
proportion of cells showing a Pre-GI DNA peak, 01, S phase, or G2/M phase DNA 
profile. 
Table 5.6. Cell Cycle Analysis of p53 null ES Cells Treated by Proteasome 
Inhibition. Cells were treated with three concentrations of M0132 for 24 and 48 
hours. Cells were subsequently fixed and stained with P1 for cell cycle analysis. 
Results shown are the mean of three experiments, and are expressed as the 
proportion of cells showing a Pre-GI DNA peak, 01, S phase, or 02/M phase DNA 
profile. UnQ represents samples that were unable to be quantified. The cells in these 
samples accumulated in G21M phase and this peak displayed a shoulder that 
obscured the proportion of cells in 01 and S phase. The proportion of cells at any 
stage further than 01 therefore could not be precisely quantified. 
Control 3.7 28.5 27.5 28.5 6.7 32.7 UnQ 
(0.238) (0.383) (0.584) (0.757) - (0.335) (0.664) t 
54M 15.6 11.3 11.5 49.7 14.8 10.7 UnQ 
MG132 (0.412) (0.197) (0.623) (0.548) (0.574) (0.458) t 
10MM 12.8 12.9 3.8 75.2 16.1 10.1 UnQ 
M0132 (0.395) (0.511). (0.417) (0.898) (0.592) (0.286) t 
25gM 15.5 8.6 10.6 65.9 16.8 9.7 UnQ 










Control 2.4 30.1 36.0 27.2 12.5 35.8 22.0 20.7 
(0.176) (0.573) (0.737) (0.664) (0.385) (0.754) (0.866) 
1 
(0.529) 
5gM 11.8 10.8 15.1 53.2 36.8 6.4 8.2 39.3 
MG132 (0.452) (0.241) (0.608) (1.105) (0.719) (0.299) (0.763) (0.832) 
10p.M. 30.9 10.1 20.5 29.7 65.2 6.2 6.1 14.6 
M0132 (0.682) (0.431) (0.589) (0.754) (1.153) (0.317) (0.360) (0.744) 
25p.M 45.2 13.5 18.5 6.8 77.8 4.4 4.9 6.9 
MG132 (0.815) (0.693) (0.523) (0.354) (0.128) (0.526) (0.510) (0.371) 
- j 	 - 
I 
243 
biochemical inhibitory effects on calpains but MG132 is three times more effective 
at inhibiting the 26S proteasome than ALLM (Rock et al., 1994) suggesting that the 
difference in response observed between these inhibitors in this study is due to 
proteasome inhibition and not to calpain or cathepsin B inhibition, Given that 
MG132 had no effect on KIM-2 cells at 33 °C, then the effects observed at 37 °C and 
39°C cannot to attributed to non-specific cytotoxicity. Therefore it would seem 
highly probably that the ubiquitin-proteasome pathway of protein degradation is 
linked to the regulation of apoptotic cell death. 
A major function of the 265 proteasome is the degradation of cell cycle 
proteins e.g. it is responsible for the degradation of cyclins, cdks, cdk inhibitors, c-
Myc, p53, Rb, and E2F-1. All of the above proteins are involved in cell cycle 
regulation and have been reported to be actively degraded at specific points during 
the cell cycle. In some cases, their degradation is necessary to ensure correct 
progression through the cell cycle (Nurse, 1994). Proteolysis is involved in 
controlling two stages in the cell cycle: the 01/S phase transition through the 
degradation of cdc34, and mitosis initiation and progression through the degradation 
of mitosis promoting factor (MYF). The effects exerted on the cdc34 pathway have 
shown that ubiquitination of the substrates is controlled by modulation of 
susceptibility of the substrate, rather than regulation of ubiquitinating enzymes as is 
generally the case for this degradation machinery (King et al., 1996). The 
irreversibility of proteolysis is exploited by the cell to provide directionality to the 
critical steps in the cell cycle. Proteolysis also plays a prime role in regulating the 
timing of the cell cycle transitions, suggesting that the interdependence of CDK-
activity and ubiquitin-dependent proteolysis ensure that cell cycle events occur in the 
proper order. Therefore it seems plausible that if this pathway is perturbed then the 
major effects seen will be on the progression of the cell cycle. Our results agree with 
previous reports showing that in actively proliferating cells, proteasome function is 
essential for cell cycle progression (Drexler, 1997, Lopes a' al., 1997). In this study 
we observed a limited amount of death in differentiated mammary epithelial cells. 
This would suggest that disruption of the 26S proteasome in a non-proliferating cell 
may result in an entirely different outcome than that observed in a dividing cell. 
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Evidence to support this theory has come from studies in Rat] cells, which had been 
rendered quiescent by serum starvation (Lopes et al., 1997). Proteasome inhibition 
failed to induce apoptosis in these quiescent cells. In contrast, both proliferating and 
differentiated PC12 cells could be induced to undergo apoptosis. Data conflicting 
with these results comes from work in neurons (Sadoul et al., 1996) and thymocytes 
(Grimm et al., 1996), which were seen to require proteasome function for induction 
of an apoptotic response. These results can be explained by the non-proliferating 
status of these two dell types. Indeed Grimm and colleagues (1996) have shown that 
in thymocytes, long term exposure to proteasome inhibitors can induce a background 
level of cell death. Both the thymocyte and neuron experiments suggested that the 
proteasome acted upstream in the apoptotic response prior to the activation of the 
caspases. One set of experiments that should answer the question of the relevance of 
the cell cycle on the apoptotic response is to render the IvIEC quiescent. Attempts to 
block these cells and treat with M0132 failed due to the inability of the drugs used to 
completely synchronise the cell population. Ideally, a drug which blocks cells at a 
specific stage of the cell cycle and has low toxicity to the cells should resolve this 
difficulty. Taken together, the data available would implicate the proteasome in 
functioning in both cell survival and cell death pathways. Whichever pathway the 
cell executes may depend on its proliferative state and other cell specific factors, 
which remain unknown to date. 
The results presented described a dependence on p53 function for the 
apoptotic response to proteasome inhibition. KIM-2 cells containing SV40 Tag at 
the non-permissive of 39 °C underwent >80% apoptosis in response to proteasome 
inhibition, whereas at the permissive temperature of 33 °C no induction of death was 
observed. Results from p53 null ES cells and HCI 1 cells confirmed this result. The 
results observed in HC  1 cells can be explained due to a mutation in p53 in this cell 
line (Merlo et al., 1995), providing further evidence in favour of a role for p53 
function in this pathway. KW-2 MEC treated with proteasome inhibitor were 
observed to accumulate in GuS phase prior to undergoing apoptosis. These cells 
also had difficulty traversing G2/M phase efficiently. In contrast to this ES cells 
arrested in G2/M phase prior to the induction of apoptosis. The evidence for cell 
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cycle arrest by proteasome inhibition is also conflicting. HeLa cells arrest in G2/M 
(Wojcik a al., 1996), identical to CHO cells containing an ubiquitin activating 
enzyme mutation (Kulka a al., 1988). Yeast cells containing ubiquitin mutants also 
G2LM arrest (Finley a al., 1994), whereas the human leukemic HL60 cells arrest in 
GuS phase (Drexler, 1997). it is possible that a GuS phase arrest could be induced 
as a result of a p53 dependent apoptotic response. p53 is linked to the Gl/S phase 
checkpoint through a DNA damage pathway, but p53 is also documented to trigger 
apoptosis via other responses e.g. in response to metabolite imbalance or to calcium 
phosphate (Evan a al., 1995) and can also induce death from other stages of the cell 
cycle e.g. from G2/M following DNA damage induced apoptosis (Guillouf et al., 
1995). 
The difference in cell cycle arrest cannot be explained by the presence of Tag 
itself SV40 Tag complexes with p53, Rb, and p107 at the permissive temperature of 
33°C. p53 is a known target of the ubiquitin-proteasome pathway. Previous studies 
have shown that the human papilloma virus (HPV) E6 protein, in association with a 
cellular factor named E6 associated protein (E6AP), complexes with p53 and 
promotes its degradation. E6AP functions as an E3 or ubiquitin ligase in this 
reaction; it catalyses the transfer of ubiquitin from the ubiquitin conjugating enzyme 
to the p53 protein. This facilitates the degradation of p53 by the 26S proteasome. 
Until recently, it was unknown whether E6AP acted to regulate p53 turnover in the 
absence of HPV infection in the cell. Maki and colleagues (1996) have recently 
identified p53-ubiquitin conjugates in cells treated with proteasome inhibitor that 
suggested that in vivo in the absence of viral infection, p53 was degraded by the 26S 
proteasome. The search for the in vivo equivalent of E6AP was resolved by the 
observation that the oncoprotein mdm2 interacted with p53. When p53 is bound by 
mdm2, its cell cycle arrest and apoptotic functions are inhibited (Kubbutat et al., 
1997). This interaction with p53 results in a large reduction of p53 protein levels 
through enhanced proteasome-dependent degradation. Mdm2 function has been 
observed to be crucial for regulating p53 function from studies with transgenic mice. 
Mice with mdm2 gene deletions show lethality early in embryogenesis only when the 
animals carry a functional p53. Mice with deletions of both mdm2 and p53 develop 
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normally (Montes de Oca et al., 1995, and Jones et al., 1995). Other evidence for 
mdm2 control of p53 function comes from studies of human sarcomas, where 
amplification of the mdm2 gene is found at high frequencies in tumours containing 
unaltered p53 (Oliner et al., 1992). This observation is consistent with the theory 
that high levels of mdm2 protein are as effective as a p53 mutation in knocking out 
the p53 pathway. The N-terminal region of mdni2 was shown to be essential for p53 
inhibition, and the remainder of the protein is thought to have other functions, which 
may include interactions with Rb (Xiao et al., 1995) and E2F (Martin et at, 1995). 
Although mdm2 binds to p53 and masks its transactivation domain, it is also 
transcriptionally activated by p53, thereby acting in an autoregulatory manner. This 
may contribute to the maintenance of low p53 levels in normal cells. Haupt and co-
workers (1997) have shown that elevated levels of mdm2 can repress mutant p53 
accumulation. This work suggested that in tumour derived cells, mdm2 acts to 
degrade p53 in situations where p53 would be otherwise stabilised. This may be a 
function of mdm2 inhibiting the phosphoiylation of p53 on N-terminal sites and thus 
acting to hinder stress induced p53 stabilisation. The data on p53 mutations 
currently conflicts with what is known regarding p53 degradation. Most of the 
mutations identified to date appear to result in an increase in the half-life of the 
protein (Brown etal., 1997) although they are clustered in areas of the protein which 
are not expected to alter ubiquitin-mediated degradation. The reasons for this 
stabilisation are not understood at present although p53 PEST sequences are often 
conserved in p53 mutants suggesting that there should be no effect on stability. 
PEST sequences act as one of the signals that target a protein for degradation by the 
26S proteasome pathway. The precise signals which determine whether p53 is 
degraded by the proteasome are not completely understood at present, but may be 
affected by p53 phosphorylation state, PEST sequences at the N-terminus, and also 
by p53 conformation. 
The results presented in this chapter suggested that p53 is not degraded by the 
26S proteasome in KIM-2 MEC. This data conflicts with what it currently known 
about p53 degradation. It has been shown that in PC12 and Rat 1 cells, a dominant 
negative p53 could abrogate the apoptotic response seen as a consequence of 
247 
proteasome inhibition (Lopes ci al., 1997). In cells expressing wild type p53, 
proteasome inhibition resulted in apoptosis and an upregulation of the p53 target 
genes mdm2 and p21. Scheffner and colleagues (1990) observed that in HPV 
infected cells, the E6 stimulated degradation of p53 was not inhibited by SV40 Tag, 
suggesting that E6 and Tag may bind to different regions of p53 or that E6 has a 
higher affinity for p53 than does Tag. These results would suggest that p53, when 
complexed to Tag appears to be accessible to the degradation machinery of the 26S 
proteasome. If it is proposed that mdm2 binds to an identical region on p53 as E6, 
the presence of Tag cannot explain the difference in p53 response in these cells. 
Further evidence suggesting that the p53 response in cells at 37 °C is normal is 
provided by the observation that KIM-2 cells will undergo >75% apoptosis as a 
response to UV irradiation, The experiments carried out with the temperature 
switched KlItvI-2 cells and those with ES cells suggest that the response we observed 
was p53 dependent. KIM-2 cells do not appear to be undergoing apoptosis as a 
response to elevated levels of p53 protein. These observations would suggest that 
part of the response to inhibition of the proteasome is cell type specific. The 
difference in p53 response between mammary cells and neuronal cells may be a 
consequence of Tag complexing to key cell cycle regulatory proteins, which 
themselves are targets of this degradation pathway. It is equally plausible that the 
presence of SV40 Tag may alter the susceptibility of p53 to this particular proteolytic 
complex. An additional explanation exists for the stability of p53 in KIM-2 cells. It 
has been shown in our laboratory that all of the p53 in these cells is complexed to 
Tag at 33°C and that at the semi-permissive temperature of 37°C only a proportion of 
the p53 present in the cell is bound by Tag. As the stability of p53 in this study was 
examined in cells grown at 37°C, it is possible that the p53 complexed to Tag was 
stabilised whilst the free p53 was available to the degradation machinery. This may 
have resulted in the net effect of no observed changes in p53 levels in these cells due 
to the presence of more than one pool of intracellular p53. Further experiments 
examining the stability of p53 at 33°C and 39°C are required to address this 
possibility. 
In KIM-2 cells, Rb function is also abrogated by SV40 Tag. Rb when 
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complexed to Tag is unable to function in regulating the activity of E21 7-1. E217  
proteins are a family of transcription factors composed of 5 E2F proteins (1-5) and 
three DP family members (1-3). E2Fs and DPs form heterodimers, which bind and 
transactivate promoters of several genes whose products are active in cell cycle 
regulation or DNA replication (Hoffman et al., 1996). E217 proteins bind 
hypophosphorylated Rb (pocket) proteins to stabilise themselves. During the 01 
stage of the cell cycle Rb binds in a hypophsophorylated form to E2F-1 suppressing 
its transactivation activity thus converting it to a transrepressor. In late 01, cdks act 
to phosphorylate Rb leading to a dissociation of the Rb/E2F-1 complex. This allows 
E2F-1/DP heterodimers, in conjunction with a cdk3 kinase activity, to reach their 
maximal transactivation potential (Hoffman and Livingston, 1996), After peaking at 
01/S and early in S phase, the transactivation activity of E21 7-1 decreases in a cyclin 
A/cdk2 dependent manner. This is thought to act to decrease the DNA binding 
capacity of E217-1 (Krek ci al., 1994). Mother level of control is exerted on this 
pathway with the degradation of E2F family proteins by the 26S proteasome. The C-
terminal region of E217-1 was seen to be essential for its degradation. It is thought 
that Rb acts as an inhibitor of E217-1 degradation by steric hinderance. The epitope 
within E217-1 that confers its ubiquitination and degradation by the 26S proteasome 
lies in close proximity to its pocket protein binding domain (Hateboer et at, 1996). 
This interaction with Rb prevents E21 7-1 degradation by the 26S proteasome by 
masking its degradation signal, and thus the protein is stable at the point in the cell 
cycle, 01/S phase transition, where its activity is essential for regulation (Hoffman ci 
al., 1996). The same is true for the regulation of activity of E2F-4 and p107 
complexes. As a consequence proteasome inhibition may result in elevated levels of 
E2F- 1, which have been reported to promote S phase entry followed by apoptosis 
(Shan and Lee, 1994). This suggests that death would be induced from Gl/S phase 
of the cell cycle, a similar effect to that which was observed in KIM-2 cells treated 
with proteasome inhibitor. The presence of viral proteins e.g. Adenovirus El 
proteins (E1A) results in dissociation of Rb/E2F-1 complexes. This action was 
thought to be counterproductive to the cell as it was expected to unmask E2F- l's 
degradation signal, but E1A was observed to act in stabilising E21 7 activity and 
preventing its turnover (Campanero and Flemington, 1997). The mode of action of 
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this stabilisation is unclear at present but is obviously how these viral proteins act to 
transform a cell without inducing apoptosis. Whether Tag can act in the same 
manner as E1A to stabilise E2F-1.'s activity is unknown at present. In KIM-2 cells 
Tag and proteasome inhibition might act in concert to result in an overexpression 
and/or stabilisation of E2F proteins. It is possible that the co-operation of these two 
independent pathways to induce elevated E21 7 proteins can act to induce apoptosis. 
In KIM-2 cells elevated levels of the Gi restriction point protein, p27 were 
observed. The observation of an increase in p27 expression is attributed to the 
inhibition of the proteasome as p27 has not been described as being processed by any 
other proteases (Vlach et al., 1997). Previous work has shown that overexpression of 
any one of the cdk inhibitors can result in a G  arrest (Vlach et al., 1996). As p27 
levels were observed to be elevated in KIM-2 cells following proteasome inhibition 
it is possible that this may contribute to the G!/S phase arrest observed prior to 
apoptosis. Indeed, overexpression of any number of cell cycle proteins can induce 
arrest and apoptosis e.g. a non-degradable mutant cyclin A expressed in the 
mammary gland of transgenic mice resulted in increased apoptosis (Bortner et al., 
1995). p27  associates with and inhibits cyclin E/cdk2. This induces an accumulation 
of Rb and p130 in their hypophosphorylated forms and also arrests cells in GI. The 
expression of c-myc prior to p27 results in inactivation of the cyclin E/cdk2 complex 
and allows continuous cell proliferation in the absence of p27, p27  and c-myc have 
opposite roles in growth control in response to mitogens e.g. p27 is induced by serum 
deprivation and is required for GI arrest (Coates etal., 1996), whereas withdrawal of 
mitogens in the presence of c-inyc prevents cell cycle arrest (Evan et al., 1992). 
Activation of c-myc is also seen to induce p77 degradation (Rudolph et al., 1996). 
Vlach and co-workers (1997) have shown that degradation of p27 is dependent on its 
association with active cyclin E/cdk2, and also that p27 must be phosphorylated on 
its conserved cdk2 binding motif in order to be degraded by the proteasome. C-Myc 
is also a known substrate of the ubiquitin-proteasome pathway. It would be of 
interest to examine the levels of c-Myc protein in these cells as c-Myc expression is 
generally low when p71 levels are elevated. This would confirm the theory that a 
cell is undergoing apoptosis through conflicting signals. Furthermore the proteasome 
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is implicated in functioning during S phase. Ubiquitination of histones have been 
observed during S phase, which is an essential function for the unwinding and 
replication of the DNA, although no degradation of ubiquitinated histories has been 
described (Vassilev ci al., 1995). These observations would further suggest an 
inability for a cell deficient in proteasome function to traverse the GuS phase of the 
cell cycle. 
The mechanism of apoptotic cell death induced by proteasome inhibition is 
assumed to be highly complex. The 265 proteasome is documented to degrade a 
wide range of proteins including proteins involved in the control of the cell cycle. A 
major consequence of proteasome inhibition is elevated levels of cell cycle proteins 
as well as the induction of an apoptotic response. This inhibition has an outcome 
leading to inappropriate expression of control proteins for a particular stage of the 
cell cycle. Alone, this one event can act to result in the induction of apoptosis. By 
disruption of this degradation pathway a number of cell cycle proteins will be 
inappropriately expressed. The outcome of this is similar to above where a cell may 
also be induced towards an apoptotic response, but as a result of conflicting signals. 
Therefore death from proteasome inhibition may occur due to elevated levels of one 
protein whose expression levels govern cell survival, or as a consequence of 
conflicting signals given to a cell from a number of incorrectly expressed proteins. 
For example, p53 is known to be degraded by the proteasome, therefore elevated 
levels may be due directly to inhibition or may be part of a p53 dependent apoptotic 
response to aberrant expression of another protein which itself induced the apoptotic 
response. Determination of the effector mechanism of this apoptotic response 
requires the removal of each substrate individually to resolve if only one signal or a 
number of signals are sufficient to induce cell death. At present the dissection of the 
precise signal that induces apoptosis as a result of proteasome inhibition is unknown. 
What has become clear recently is that the 265 proteasome degradation pathway acts 
to regulate key control mechanisms of the cell cycle. 
An apoptotic response and progression through the cell cycle initially appear 
as two unrelated processes with distinct biological endpoints. However, it has 
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become more apparent that the processes of cell loss and cell gain must be balanced, 
which suggested that these two antagonistic processes were linked. The evidence 
supporting this notion was based on the observations that some of the morphological 
changes occurring during apoptosis are reminiscent of mitosis e.g. cells lose their 
attachments, chromatin becomes condensed and nuclear laminins are phosphorylated 
and disassemble. The processes of apoptosis and mitosis are of similar duration, 
each taking around 30-60 minutes to complete (Ucker, 1991). Further evidence 
supporting this connection was based on the observation that healthy cells undergo 
apoptosis as part of their normal process of development suggesting that cell death 
was a normal physiological process. Neopiastic lesions that generate uncontrolled 
cell proliferation have also been seen to act as potent triggers of apoptosis providing 
further evidence of a link between these two pathways (Evan et al., 1995). Evidence 
for an interdependence between these two processes is strong. It is further supported 
by the observation that a number of proteins that act to control cell cycle progression 
also Induce apoptosis e.g. E1A, p53, Tag, and c-myc. The difference in response 
induced is often dictated by the level of the protein expressed e.g. elevated levels of 
c-myc can induce apoptosis. Whether the same biochemical pathways induce both of 
these responses is unknown at present. Given that a change in proteins levels is often 
all that is required for a switch from proliferation to an apoptotic response, then the 
26S proteasome must be a prime candidate for control of these processes. The 
proteasome is known to be involved in degrading key regulatory proteins implicated 
in cell cycle control and has also been observed to be essential for an apoptotic 
response. Whether this is through the degradation of the same set of substrates that 
act to induce survival under one set of circumstances and death under another has yet 
to be resolved. 
Chapter 6: 
Analysis of the Effects of a Dominant Negative TBP1 




In chapter 5 it was demonstrated that inhibition of the 26S proteasome using a 
peptide aldehyde inhibitor in KIM-2 MEC resulted in the induction of apoptosis. 
The apoptosis observed was shown to be a p53-dependent response, and the cells 
arrested following the 01/S phase of the cell cycle prior to undergoing apoptosis. 
The aim of the studies reported in this chapter was to establish whether TBP1 
function was essential for the 265 proteasome degradation pathway. TBP 1 was only 
recently biochemically identified as being a subunit present in the 195 regulatory 
complex (Richmond ci al, 1997). Prior to this it had not been identified in the 
complex due to its migration pattern in two-dimensional gels; it migrates identically 
to TBP7 thus it appeared that only 5 ATPases were present in the complex. This 
may be the reason why very few research groups have examined the role that TBP1 
plays in this pathway. The majority of the work pertaining to ATPase function in the 
regulatory complex has focussed on MSS1, 54, Sugi, and Sug2 proteins. It was 
hoped that by producing a dominant negative TBP 1, the role that this ATPase plays 
in the complex could be examined. This approach would also allows us to examine 
the effect of disruption of this pathway more specifically than with the use of the 
peptide inhibitors. 
6.2 Generation of Dominant Negative TBP1 Constructs 
Structurally, all of the 6 ATPases associated with proteasome function are 
highly conserved. The amino-terminal segments of these proteins are more divergent 
than the carboxy-terminal regions, which has led to the suggestion that the amino-
terminal regions may be involved in substrate recognition. Rechsteiner and 
colleagues (1993) suggested that different ATPases in the 195 regulatory complex 
may function to recognise distinct substrates for degradation and thus all six 
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ATPases may not be essential for functional degradation by this complex. To 
address this question dominant negative TBP1 constructs were generated. It was 
hoped that this would demonstrate whether TBP 1 function was an absolute 
requirement for this degradation pathway, or whether degradation of a particular set 
of substrates was disrupted when TBP 1 function was lost. The use of trans-dominant 
negative technology has greatly enhanced the knowledge of biological signalling 
pathways in the last decade. Previously the preferred method for analysing gene 
function was to delete the protein of interest and examine the resultant phenotype. In 
generating a dominant negative protein, a modification is made to the protein of 
interest to render it non-functional. This approach is of most use when the protein to 
be examined binds to either another protein or DNA. A mutant can be made in such 
a manner as to allow binding to its partner or DNA recognition site whilst loosing its 
functional response. This mutated protein is then introduced into either the in vitro 
or in vivo model system. When the mutant protein is expressed at levels in excess of 
the endogenous protein analysis of the disruption of function of the protein can be 
examined. One problem with deleting a protein entirely is that it is often not clear 
whether the complete loss of the protein of interest results in the phenotype observed 
or if the effects observed are due to disruption of other pathways in which the protein 
is involved e.g. if the deleted protein, A normally interacts with another protein, B it 
is often unclear whether protein B will function differently in the absence of protein 
A. As an example dominant negative IicBa proteins can be produced by mutating 
the two serine residues that are normally phosphorylated to signal degradation of this 
inhibitor. These mutated residues result in an IicBct protein that can no longer be 
phosphorylated thus inhibiting transactivation of the transcription factor NFicB. By 
producing a modified protein in this manner, it is rendered non-functional but still 
has the ability to interact with other proteins in this signalling pathway with which it 
would normally encounter, therefore the phenotype observed will be more relevant to 
the biological function of this protein. 
The approach used to generate a dominant negative TBP1 is shown in Figure 
6.1. Structural analysis had previously shown that TBP 1 contained a central 
functional domain, the ATPases module. This analysis also revealed that the amino- 
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Figure 6.1 TBP1 Deletion Constructs. Truncations in TBP1 were generated by 
PCR resulting in a number of deletion constructs which either contained 50bp of the 
functional ATPases module (TBPI 525), terminated at the boundary of the ATPase 
module (TBPI 475), or terminated lOObp upstream of the ATPase module (TBPI 
375). Full length TBPI (TBP1 wt) was also generated by PCR for ease of cloning. 
The lower panel represents the TBP1 deletion constructs generated by PCR from day 
15 gestation mammary gland cDNA. The negative control reaction was amplified in 
the absence of template eDNA. 
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terminal of this family of proteins was most divergent in sequence. This region of 
the protein contains a leucine zipper-like domain, which had led to the suggestion 
that this part of the protein is involved in conferring the substrate specificity and may 
also be involved in protein-protein interactions. Indeed, this region of TBP1 had 
been shown to be essential for binding to TBP7 (Ohana et al, 1993) although an 
interactions between TBP1 and TBP7 is now disputed. A number of deletion 
constructs were designed that contained progressively less of the functional domain 
of this protein. The longest deletion construct generated (TBP1A525) contained 
approximately 30bp of the ATPase module, but this did not include any of the 
nucleotide binding sites or helicase-like domains which were positioned in the 
carboxy-terminal region of the ATPase module. The construct TBP1475 terminates 
isbp prior to the start of this domain. The shortest construct TBP1A375 contained 
none of the ATPase module, and 1 OObp of the amino-terminal region was also 
deleted in this truncated protein. It was postulated that the loss of the ATPase 
module in these constructs should result in a protein which is no longer functional, 
but the retention of the amino-terminal should ensure that these mutant proteins can 
interact with other ATPases to form the 19S cap complex. The deletion constructs 
were prepared by PCR to allow introduction of restriction sites for ease of cloning 
(Figure 6.1). 
6.3 Expression of Dominant Negative TBP1 Constructs in KIM-2 Mammary 
Epithelial Cells 
The deletion constructs of TBP 1 generated by PCR were used for expression 
studies in KIM-2 mammary epithelial cells. The cloning strategy used is described 
in Figure 6.2. The PCR products were generated to contain 5' EcoRI and 3' XhoI 
restriction sites and these cDNAs were ligated to the expression vector pcDNA3. 
Following transformation, colonies were picked for further analysis. Double 
stranded sequencing was performed on clones containing inserts to check the correct 
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Figure 6.2 Dominant Negative Cloning Strategy. pcDNA3 vector was digested 
with the restriction enzymes EcoRI and XhoI. TBPI deletion constructs were 
generated by PCR to contain 5' EcoRl and 3' XhoI sites. These were subsequently 
ligated to the vector for transfection into KIM-2 cells. 
258 
construct was expressed in the clone chosen for expression in KIM-2 cells. DNA 
was purified by caesium chioride/ethidium bromide density gradient purification 
(described in section 2.1.8) prior to transfection into KIM-2 cells. 
Many methods have been described for high efficiency gene transfer. These 
include calcium phosphate precipitation, DEAE-dextran, electroporation, and various 
lipid based technologies. The preferred method is calcium phosphate precipitation, 
which is based on the uptake of the foreign DNA into cells in conjunction with a 
precipitate, mediated by phagocytic vesicles (Graham and van der Eb, 1973). 
Depending on the cell line used, high transfection efficiencies can be obtained using 
this method. However, this method has drawbacks, which include a high variability 
of transfection efficiency between experiments. In general mammary epithelial cells 
give relatively inefficient transfection efficiencies. This problem was also apparent 
with KIM-2 cells. Initially the calcium phosphate method was chosen for gene 
transfer as it had been previously tested in these cells. Proliferating KIM-2 cells 
were transfected with each of the constructs, and neomycin selection followed 48 
hours after the DNA was introduced into the cells. After 14 days selection, no 
colonies were obtained from these transfections, which suggested that expression of 
the dominant negative TBP 1 constructs was lethal to the KIM-2 cells. This result 
was not unexpected as the work described in chapter 5 suggested that disruption of 
the 26S proteasome degradation pathway induced apoptosis. 
The lethality of these expression constructs resulted in a different approach 
being attempted. Ideally an inducible expression system should have been used but, 
due to time constraints, it was decided to perform a transient tranfection on the KIM-
2 cells. This major limitation of this approach is that the maximal transfection 
efficiency in KIM-2 cells was approximately 0.4%. This would result in too few 
cells to analyse. To overcome with problem we attempted to increase the 
transfection efficiency in the KIM-2 cells. A number of transfection reagents were 
tested, which were mainly lipid based products that were commercially available e.g. 
Tfx-50 from Promega, Dosper from Boehringer, and Fugene from Boehringer. The 
results obtained with these products are shown in Figure 6.3. The Fugene reagent 
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appeared to be optimal for use in KIM-2 cells. It allowed an increase to 
approximately 0.7% in the transfection efficiency, which on average was twice as 
efficient as the calcium phosphate method. The major advantage of the Fugene 
product was that the transfection efficiency initially appeared to be reproducible, 
which is often not the case for the other methods used. Although the efficiency of 
this procedure had been increased, it did not result in a high enough number of 
transfected cells to analyse a phenotype e.g. if expression of a dominant negative 
TBP1 induced apoptosis, then only 0.7% of the cells would display this effect, and 
this would be difficult to discriminate from background death as a result of the 
transfection procedure. With this in mind, a system was chosen for use that would 
allow purification of transiently transfected cells. The Capture-Tec kit from 
Invitrogen allows the rapid selection of transiently transfected cells from total 
populations of both transfected and untransfected cells. This is achieved by virtue of 
a specially designed vector (p1-look), which expresses a single chain antibody (sPy) 
against a specific hapten on the surface of transfected cells. Transfected cells can 
then be isolated from the total cell population by binding to hapten coated magnetic 
beads. Co-transfection of this vector with the construct of interest allows isolation of 
cells expressing the gene of interest within as little as 2 hours post-transfection. This 
system was designed to allow for study of the effects of dominant negative mutations 
on growth regulating proteins or toxic gene products, and should allow the analysis 
of transient transfections in mammary epithelial cells. 
Further optimisation of the Fugene transfection method revealed 
inefficiencies within this system. In general the transfection efficiency appeared to 
be extremely sensitive to the template DNA quality. Only DNA which had been 
twice purified by CsCl density gradient centrifugation would transfect with the 
Fugene reagent. Batch differences in the template DNA also reduced the efficiency 
of this method e.g. one sample of a test plasmid, which was a LacZ reporter 
(pCH1 10), would give a successful transfection, whereas a different batch of the 
same plasmid produced in an identical manner, but at a different time would give no 
transfected cells at all. This problem was partially overcome by dialysing the 
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Figure 6.3 Comparison of Transfection Efficiencies in KIM-2 Cells using a 
Variety of Transfection Methods. KIM-2 cells were passaged 24 hours prior to 
transfection. Cells were transfected according to the manufacturer's instructions for 
each reagent, using a lacZ reporter plasmid, pCH1 10. Cells were transfected for a 
full 24 hours prior to fixation and staining. The number of blue cells per dish were 
counted and are expressed as the mean of three experiments ± sem. 
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the transfection. Initial transfections using Fugene were performed in six well plates 
over a 24 hour period. Ideally to express the TBP1 deletion constructs a large 
number of cells would have to express the construct to allow purification using the 
pHook system. Figure 6.4a shows results of experiments where the number of cells 
transfected were increased and the effect this had on the transfection efficiency 
monitored. Although approximately twice as many cells were transfected in a 90mm 
dish as compared to the 6 well plate, the large dish contained six fold more cells and 
the subsequent transfection efficiency rate was lower. These results were obtained 
when using 2sg DNA transfected in 100M1  diluted Fugene reagent in both samples. 
When the concentration of DNA was either increase or decreased (Figure 4.6b(i)) or 
the amount of Fugene reagent was increased, a decrease in the transfection efficiency 
was observed. This was also apparent when the number of cells plated was reduced 
(Figure 4.6b(ii)), From these experiments it appeared that the Fugene reagent 
worked optimally when 2jtg DNA was added to 341 Fugene diluted to lOOjil in 
medium. This created a potential problem with the use of the pHook system. It is 
recommended to transfect ten fold less of the pHook vector than test plasmid to 
increase the probability of purified cells expressing pHook in addition to the test 
plasmid. This would results in 24g test plasmid transfected with 02 j.tg of the pHook 
vector. This made it seem highly likely that very few cells would actually express 
the pHook vector in addition to the deletion construct due to the small amount of 
DNA used. 
Further optimisation of this system was required as a 24 hour transfection 
period was too long; the mutant TBP 1 constructs were predicted to be lethal when 
expressed in the cells, and would very likely be expressed within this 24 hour period. 
The duration of Fugene transfection, using the LacZ reporter pCH 110 was decreased 
from 24 hours to either 2 hours or 5 hours and the cells assayed for lacZ activity 
(Figure 6.4c). These results determined that the transfection efficiency was very low 
in cells following these short transfections. On average, fifty cells would stain 
positive for LacZ expression after 5 hours; this was too few cells for use with the 
pHook system. Logistically this resulted in it being impossible to perform the 
transient assay and purify the cells using the pHook vector as had been hoped. 
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Figure 6.4 Optimisation of Fugene Transfection Reagent. 
Effect of Cell Number on Transfection Efficiency. KIM-2 Cells were 
passaged 24 hours prior to transfection. 2g of test plasmid (pCH1 10) was mixed 
with lOOpi diluted Fugene reagent and added to the cells for 24 hours. Cells were 
subsequently fixed and stained and the number of LacZ positive cells counted. The 
results shown are the mean of three experiments ± sem. 
(i) Effect of DNA Concentration on Transfection Efficiency. KIM-2 cells 
were passaged 24 hours prior to transfection using three different concentrations of 
test plasmid (pCH1 10). Cells were transfected for 24 hours prior to fixing and 
staining. The results represent the number of cells stained positive for LacZ 
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Figure 6.4 (b) (ii) Effect of Plating Density on Transfection Efficiency. KIM-2 
cells were passaged into either 6 well plates or 90mm dishes at either a un 4 or 1 in 
6 split (1 in 4 corresponds to 0.66x10 6, or 0.66x10 7 cells in a 6 well plate, or a 90mm 
dish, and 1x106, or 1x10 7 cells at a 1 in 6 split in a 6 well plate or 90mm dish 
respectively). Cells were transfected with 2jig pCHI 10 over 24 hours, prior to 
fixation and staining of the cells. The results represent the number of cells stained 
positive for LacZ expression, and are shown as the mean of three experiments + sem. 
(c) Effect of Duration of Transfection on Transfection Efficiency. KIM-2 cells 
were passaged as normal 24 hours prior to transfection. Cells were transfected with 
2.ig DNA added to 100121 diluted Fugene reagent over a 24 hour period. Cells were 
subsequently fixed and stained for LacZ expression. The results are expressed as the 
mean of three experiments ± sem. 
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Although all of these expression experiments had failed to produce cells expressing 
mutant TBPI proteins it is not difficult to reconcile this with the lethality of TBPI. 
To attempt to address the question of lethality of mutant TBP1 in KIM-2 cells a 
transfection was performed using the deletion constructs in conjunction with the lacZ 
reporter construct pCH1 10. KIM-2 cells were transfected using Fugene with 2 xg 
TBP1 deletion construct in addition with 0.5gag pCH1 10. It was assumed that if 
expression of these TBP1 proteins were lethal to the cells then no cells expressing 
lacZ would be detected. Results of this experiment are shown in Figure 6.5. 
Expression of all three deletion constructs, in addition to wild type TBP1 was lethal 
to KIM-2 cells. In contrast to this, in cells transfected with a control vector 
(pBluescript) lacZ stained cells were observed. These results are highly suggestive 
of these constructs being lethal when expressed in vitro. Overexpression of TBP1 
alone appeared to be lethal to the cells and to answer this question more empirically 
we reversed the concentration of lacZ reporter and TBP 1 construct. This results in a 
small number of lacZ stained cells being detected suggesting that expression of 
TBP1 at high concentrations in KIM-2 cells is lethal. Whether the effect of 
overexpression of TBP 1 is due to disruption of protein degradation cannot be 
addressed within this system. 
6.5 Discussion 
The results presented in this chapter suggest that TBPI is an essential 
component within the cell. These results are an indication that at least the ATPase 
TBP 1 is required for proteasome function, which itself suggests that the function of 
all six ATPases may be a pre-requisite for proteasome function. If this was indeed 
the case then it would suggest that these proteins co-operate to unfold and degrade 
proteins, and it would seem highly unlikely that they act to process different 
substrates as has been previously suggested (Dawson etal., 1995). If these ATPases 
each act to degrade a different set of target proteins then it would be unlikely that an 
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Figure 6.5 Expression of TBP1 Deletion Constructs in KIM-2 Cells. Cells were 
passaged 24 hours prior to transfection using the Fugene reagent. Cells were 
transfected with either a lacZ reporter construct alone (pCHI 110), with pCH1 10 in 
addition to an unrelated control vector (pBluescript), or with pCHI 10 in addition to 
either wild type (wt) or deletions constructs of TBP1. Cells were transfected for a 
full 24 hours prior to fixation and staining. The figures in brackets express the 
average number of lacZ stained cells ± sern per dish (approximately 1-1.5 x 107  total 
cells per dish). The results shown are expressed as the mean of three experiments. 
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identical phenotype would be observed when two different subunits are deleted. 
Disruption of 54 in S. poinbe has shown that this ATPase is essential for survival 
(Gordon et al., 1993). The results presented in this chapter suggest but do not 
confirm that TBP1 is essential for proteasome function, and that loss of this protein 
cannot be compensated for by other ATPases. It was hypothesised that a degree of 
redundancy may exist in this system due to the high level of conservation between 
these proteins. Since disruption of TBPt function is highly likely to be lethal (as for 
54 in yeast) this suggests that other proteins, particularly ATPases, could not 
compensate for this loss of function. 
The studies in KIM-2 cells showed that loss of the functional ATPase module 
resulted in the inability to obtain clones that expressed the mutated constructs 
suggesting that this may be lethal to the cell. The studies performed in NEC were 
preliminary, and problems were encountered due to inefficient transfections in KIM-
2 cells. HC 11 MEC have been transfected with much higher efficiency than KIM-2 
cells, but for this study HCI I cells could not be used due to their loss of functional 
p53. Results presented in chapter 5 demonstrated that MG 132, although inhibiting 
degradation of ubiquitinated proteins, had no effect on the rate of apoptosis in HC 11 
cells, excluding their use in the transfection studies. Several fundamental problems 
were encountered when transfecting KIM-2 cells. Mammary epithelial cells are 
plastic in nature e.g. KIM-2 cells are thought to contain mammary gland progenitor 
cells. These cells have the ability to form either myoepithelial or luminal epithelial 
cells. KIM-2 cells have also been observed to spontaneously transform to cells that 
are more spindle-like in appearance. In general epithelial cells are highly dependent 
on cell to cell contacts. When clones are isolated cells lose this contact, which 
results in a number of the cells losing an epithelial phenotype. With time these cells 
expand and occupy much of the clone and therefore these clones have to be excluded 
from analysis. For these reasons large numbers of clones have to be selected for 
analysis to obtain a number of clones which appeared and behaved identically to the 
starting population. As analysis on cloned KIM-2 cell lines proceeded it became 
apparent that some cultures were loosing their ability to respond to lactogenic 
hormones. As with the changes in morphology observed, the degree of response to 
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lactogenic hormone expression changed. Some clones expressed -casein to a 
similar level as in the uncloned cells, whereas some lines expressed less milk protein, 
and other lines did not express any 13-casein. The problems with transfection 
efficiencies will be difficult to resolve in KIM-2 cells. The cells used in this thesis 
are currently the only MEC which can be induce to express the late differentiation 
marker WAP when grown in the absence of extracellular matrix. When these cells 
differentiate they form mammospheres or domes, which are comprised of an inner 
layer of epithelial cells with some myoepithlial cells present on the outer layer. This 
structure is very similar to the alveoli in vivo. The similarity in structure to the 
mammary gland is hypothesised to contribute to the differentiation capacity of these 
cells, which make KIM-2 cells the most relevant in vitro model of mammary gland 
differentiation. 
It could be assumed that transfection of the TBP1 dominant negatives into the 
KIM-2 cells resulted in a lethal phenotype from the inability to express these 
constructs in transfected cells. Since no stable cell lines could be generated, this 
reduced the ability to fully analyse the effect of disruption of this pathway and too 
few transiently transfected cells were available. In retrospect it may have been more 
prudent to choose an inducible system to analyse the TBP1 dominant negative 
constructs in KIM-2 cells. At the start of this study the tetracycline-regulated system 
would have been the ideal choice. The system is based on a tetracycline-controlled 
transactivator (tTA), which combines the tetracycline repressor (tetR) DNA binding 
domain with the transcriptional activation domain of VP 16 from the herpes simplex 
virus. The gene of interest is cloned downstream of a minimal promoter fused to 
seven repeats of the ter operon (tetO), When tTA binds to the tetO, transcription of 
the target gene is activated. In the presence of the antibiotic tetracycline, binding to 
tTA results in a conformational change that prevents binding to the tetO. The 
removal of tetracycline results in gene activation (Schockett et al., 1995). A reverse 
system is also available where mutations in the tetR result in binding to the tetO only 
in the presence of tetracycline. This system thereby allows the induction of gene 
expression by either the addition or the removal of tetracycline from the medium 
depending on the vectors used. The major advantage of this system is that 
tetracycline is not toxic at the concentrations required to induce/repress expression, 
the induction of gene expression is extremely rapid and expression of the regulated 
gene is very low in the uninduced state (Schmid, 1995). This system is based on 
producing a tTA stably expressing cell line, which can then be transfected with the 
gene of interest. The intermediate tTA expressing cell lines require to be tested for 
inducibility using a tetO reporter plasmid before further use. Within KIM-2 cells the 
tetracycline-regulated system would again be troubled with the transfection problems 
discussed above, and would require a lengthy period of optimisation for MEC. At 
present we have a KIM-2 cell line expressing the Tet repressor. Results from our 
laboratory and others have shown substantial problems with this system. The KIM-2 
cells expressing the Tet repressor do not show regulated expression e.g. these cells 
are leaky in expression resulting in the continual expression of the construct as 
opposed to the ability to switch on expression after stable clones have been 
generated. This is clearly a potential problem when disruption of a gene is expected 
to be lethal, as is the case for TBP1. In hindsight it was prudent not to have spent the 
time optimising expression using the tetracycline system as it would have proven 
impossible to generate cell lines stably expressing my TBP1 deletion constructs. 
Additional inducible expression systems are available, the ecdysone system being the 
most preferred of these. This system functions in a similar manner to the tetracycline 
system allowing tight regulation of expression will very low basal levels of 
expression. At present there are very few documented reports of the use of this 
system therefore it remains to be seen whether it will be more tightly regulated than 
the Tetracycline system. Even if the ecdysone system proves to be more regulatable 
than other inducible systems, the cloning problems inherent to mammary epithelial 
cells will still be encountered. At present the approach now favoured within our 
laboratory is the use of new generation retroviral vectors. When packaged, these 
vectors can result in high infection levels in cells and it is hoped that this will 
overcome the previous cloning problems encountered. 
The results presented in this chapter have demonstrated that TBP1 function 
may be essential for cell viability in KIM-2 MEC. This minors the results obtained 
using a chemical inhibitor of this degradation pathway. These results taken together 
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strongly suggest that degradation of ubiquitinated proteins is a pre-requisite for cell 
survival and that disruption of one component, TBP1, within the regulatory 






The results presented in this thesis detail an essential function for the 
ubiquitin-dependent protein degradation pathway in mammary epithelial cells. As 
part of these studies I optimised differential display for use in the mammary gland. 
This work describes the first isolation of the murine homologue of TBP1 and 
describes an absolute function for the 265 proteasome in the survival of a 
differentiated tissue. Studies in mammary epithelial cells suggested that disruption 
of this degradation pathway using either a chemical inhibitor of the 26S proteasome 
or a dominant negative construct of TBP 1 was lethal to these cells. An apoptotic 
response was induced that was shown to be cell cycle stage dependent in addition to 
being dependent on the presence of the tumour suppressor protein p53. Disruption 
of TBP 1 function was assumed to generate an identical response to that induced by 
MG132 due to the inability to select clones expressing these mutant constructs. 
These results suggest that TBP1 is an essential component of the ubiquitin-
dependent protein degradation pathway. The following sections discuss in more 
detail the regulation of protein degradation in the mammary gland and how this 
pathway may act to control cell cycle progression. I will also discuss future 
experiments required to answer some of the outstanding questions. 
7.2 Regulation of Proteolysis in the Mammary Gland 
The expression of the 26S proteasome increases from day 10 gestation 
onwards in the mammary gland. The reason why such an increase in the proteolytic 
machinery is required in late gestation is currently unknown, however this is the 
particular stage in gland development when the differentiation process is initiated, 
indeed it is when the gland first expresses the milk protein 13-casein. The relevance 
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between the onset of milk protein expression and the increase in proteasome 
expression levels may be coincidental but the possibility exists that the proteasome is 
required to degrade milk protein prior to secretion. By late gestation J3-casein 
mRNA accounts for around 20% of the total mRNA present in the cell. Whilst 
massive amounts of milk protein are being produced by the gland prior to parturition 
none of this protein is secreted. This function is thought to prepare the gland for 
lactation but the precise mechanism that prevents secretion of milk is unclear. In 
vitro studies on purified 20S proteasomes have shown that J3-casein can be degraded 
by this complex (Pereira ci' al., 1992). Whether casein can be degraded in vivo by 
the 26S proteasome is not known. It is equally possible that another proteolytic 
system acts to remove milk protein from the cell prior to lactation. Very little 
information is published with regard to proteasome expression in developing tissues, 
but the little that is known suggests that there are at least changes in localisation of 
the 20S proteasome when a developmental process is initiated. In general, 
expression is found to be nuclear in rapidly proliferating cells whereas cytoplasmic 
staining is more predominant in quiescent cells. Mechanisms such as protein 
degradation are thought to allow a cell to adapt to changes in signalling which are 
encountered during development. The increase in proteasome expression in the 
mammary gland may be a consequence of the progression of the cell towards a 
differentiated phenotype. An increase in the metabolism of the cell is also expected 
to occur when the cell differentiates. It is possible that an increase in protein 
degradation may be a consequence of the cell gaining a more specialised function 
such as the mammary cell does during pregnancy. This is in contrast to the decrease 
in the 20S proteasome during lactation and involution. The ability to alter the 
cellular environment by the removal of proteins through upregulation of the 
degradation machinery should promote a cell efficiently along the pathway towards 
gaining a specialised function. Whether this can account for the increase in 
proteasome function in the mammary gland during pregnancy is purely speculative. 
This theory may also fit with the observation of a decrease in the 20S proteasome 
early in the involution process. It would appear that the levels of this degradation 
machinery are of less importance as the structure of the gland remodels. The major 
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proteases involved in restructuring the mammary gland at this stage are the matrix 
metalloproteinases (section 1.3.5.1) thus there may be a lesser requirement for any 
additional proteolytic machinery during this process. In order to address this 
question studies on the localisation of the proteasome during pregnancy and lactation 
are required. In hindsight it would have been extremely valuable to raise an antibody 
against TBP 1. When good antibodies become available against the proteasome 
components, the function this complex plays during development may become 
clearer. The study described in this thesis is one of the first studies of proteasome 
expression in developing tissues. At present most of the research on proteasome 
function is based on biochemical purification of its components or yeast mutant 
analysis. Ideally, the question of TBP1 function in the developing mammary gland 
could be answered more empirically if a mouse model of TBP1 disruption was 
generated. The use of tissue specific, temporal specific technologies such as the 
lox/Cre recombination system would allow the examination of proteasome function 
in the mammary gland during its cycles of proliferation, differentiation and 
involution. What appears clear from the studies using mammary epithelial cells is 
that disruption of the proteasome in an actively proliferating cell results in a more 
severe apoptosis than disruption in a differentiated cell. The generation of a mouse 
carrying a dominant negative TBP1 construct would allow the expression levels of 
the major proteins involved in gland development to be examined when the 
proteasome is disrupted. 
The 26S proteasome has been implicated in processing and degrading a 
number of proteins that play a controlling role in mammary development. One of 
these is the Jak/Stat pathway, which signals through a range of cytokine receptors to 
control mammary development during pregnancy, lactation, and involution. This 
signalling pathway has recently been observed to be regulated by the proteasome. 
Kim and Maniatis (1996) have shown that proteasome inhibition of HeLa cells 
stimulated by IFN-y results in the ubiquitination and stabilisation of Stati. In general 
the phosphorylation and nuclear binding of Stat I is maximal 15 to 30 minutes 
following stimulation. The levels of Statl are then seen to rapidly decrease to 
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undetectable levels within 1 to 2 hours. The regulation of this response is of prime 
importance to the cell as it must be able to respond to stimulation from numerous 
cytokines simultaneously. Without this regulation the cell would rapidly accumulate 
toxic amounts of gene products and be unable to coordinate the cytokine responses. 
These studies demonstrated that phosphorylation of Stati was a prerequisite for its 
ubiquitination. In contrast to this, stimulation of Stat3 and Stat5 levels by 
interleukin-6 (IL-6) were unaffected in a hepatoma cell line treated with proteasome 
inhibitor (Rayanade et at, 1997). This study suggested that p53 played a role in 
protecting these transcription factors from proteasome degradation. It was 
hypothesised that in the presence of p53, a gene product was produced that masked 
Stat3 and StatS, but not Stati from being degraded by the 26S proteasome. More 
recently Callus and Mathey-Prevot (1998) have shown that TL-3 stimulation of the 
Jak/Stat pathway results in prolonged activation in the presence of proteasome 
inhibitors. This group observed sustained phosphorylation of StatS when the 265 
proteasome was disrupted. They found no evidence to suggest that StatS was 
inactivated by this pathway and its prolonged activity was due to persistent 
phosphorylation of Jak2. The mechanism by which the proteasome normally 
deregulates Jak activity is unknown but it has been suggested that its action may be 
indirect. It may function to process a phosphatase that acts to dephosphorylate the 
Jak proteins. In the mammary gland StatS is active during late pregnancy and 
lactation and stimulates milk protein gene production in response to prolactin. Stan 
and Stat 1 are found elevated during involution in the gland suggesting that they act 
either positively or negatively to control the apoptotic response of the gland. The 
increase in the 26S proteasome in the mammary gland cannot be accounted for 
simply by the increased requirement for the control of the Jak/Stat pathway. The 
increase in expression of these genes do not overlap and it seems unlikely that such a 
substantial amount of JaklStat signalling occurs in the gland that a ten-fold increase 
in the proteasome is required to counteract this. If a mouse model of proteasome 
disruption were available then the precise regulation of these signalling molecules 
could be examined. Mother approach to gain knowledge on the function of 
proteasome regulation of JaklStat proteins is to generate non-degradable forms of 
these proteins and examine the consequences of prolonged action. Absence of 
Stat5a in the mammary gland results in an inability to lactate therefore it seems 
reasonable to assume that prolonged activation of this protein would result in an 
elongated lactation period. It would be interesting to examine whether these mice 
would be able to undergo a successful involution, which would give details on 
whether StatS could act as a survival factor for the mammary gland. This is of 
interest to proteasome function as it is unclear whether the apoptotic response 
observed in response to proteasome inhibition is simply due to deregulation of the 
cell cycle or prolonged activation of pro-apoptotic factors. 
The transcription factor NFiB is another protein that is developmentally 
regulated during mammary gland development. It is highly active, as measured by 
DNA binding activity during the latter half of gestation, is absent during lactation 
and its activity is high again during involution (Dr R. Clarkson, pers. comm.). The 
exact function this protein exerts on mammary gland development is not clear. The 
proteasome controls NFicB in two ways: it proteolytically cleaves p105 to produce 
the active p50 component and it also ubiquitinates and degrades the inhibitor IicBa. 
NFicB has been suggested to function as a factor which can protect a cell against 
apoptosis. In T cells stimulated with TNFa, NFicB was observed to prevent an 
apoptotic response to a subsequent stimulus (Liu et al., 1996). Whether it plays this 
type of role in the mammary gland is unclear. Its expression profile may suggest that 
it acts in this manner as very little apoptosis can be observed in the gland in late 
gestation. Involution is characterised by a two stage response. The initial stage is 
characterised by apoptosis of the epithelial cells, and this stage is reversible. It may 
be that NFiB is highly expressed at this stage to ensure that an anti-apoptotic 
response can be initiated if required. It would seem logical to speculate that if the 
proteasome is disrupted then no active NFicB would be produced and this would 
result in the loss of a protective factor to the cell. This in itself may stimulate an 
apoptotic response if no other protective factors were present within the cell. In vivo 
it would seem highly unlikely that the increase in the proteasome is as a response to 
an increase in active NFicB. The expression profiles of these proteins do not fully 
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overlap e.g. the proteasome, like NFicB is expressed highly in the latter half of 
gestation, but it is also expressed highly during lactation when NFiB activity is low. 
When additional information is available on the function of NFkB in the mammary 
gland then it may be easier to judge whether disruption of this function would be 
lethal. 
Cyclin Dl is known as a target of this protein degradation pathway. Mice 
lacking cyclin Dl show no proliferation in response to steroid hormones during 
pregnancy (Sicinski et al., 1995). Within this thesis we have shown that the 26S 
proteasome is essential to the function of a proliferating epithelial cell. Whether the 
apoptosis observed following inhibition of this pathway is as a direct consequence of 
perturbing cyclin Dl expression is unclear. One way to address this question would 
involve producing a non-degradable form of cyclin Dl. Using this approach the 
direct effect of overexpression of this protein alone can be examined. 
7.3 The 26S Proteasome as a Mechanism for the Regulation of Apoptosis 
A major portion of the work described in this thesis detailed the apoptotic 
response induced by proteasome inhibition in mammary epithelial cells. Treatment 
with the proteasome inhibitor MG1 32 induced an apoptotic response that was 
dependent on the presence of p53 and occurred following the GuS phase of the cell 
cycle. Examination of the cdk inhibitor p27 revealed elevated expression suggesting 
that this protein, which controls entry into S phase, was deregulated. This suggested 
that cells were traversing the GuS phase prior to undergoing apoptosis. It was 
hypothesised that inhibition of the ubiquitin-dependent protein degradation pathway 
would result in the deregulation of a number of proteins that control progression of 
the cell cycle and this would be a trigger for the apoptotic response observed. 
Examination of each of the major control proteins for the cell cycle should reveal the 
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exact nature of the apoptosis induced. 
Treatment of KIM-2 cells with cell cycle blocking agents demonstrated that 
cells were able to traverse the G2/M boundary when this pathway was disrupted, 
although at a much slow rate than untreated cells, but were unable to progress 
forward from GuS phase. The data regarding proteasome inhibition on cell cycle 
status is conflicting at present. It appears that dependent on the cell type used a 01/S 
phase and/or a G2/M block can be induced. In this study treatment of ES cells with 
MG132 was observed to induce a 02/M block followed by apoptosis in p53wt ES 
cells, which contrasted to that observed in the KllvI-2 cells. Identical results to those 
described in this thesis for KJIvI-2 cells have been obtained in T cells. It was 
observed that proteasome activity was essential for cells to progress from the 01/S 
boundary to the G2/M phase, but not essential from the progress from G21M phase to 
the next 01 phase (Wang et al., 1998). In contrast to this, examination of the cell 
cycle kinetics in African trypanosomes demonstrated that procyclic forms of the 
parasite required the proteasome for progression from 02, whereas bloodstream 
forms could not progress from either 01/S phase or from G2/M when the proteasome 
pathway was blocked (Mutomba et at., 1997). These studies would suggest that cell 
cycle arrest by proteasome inhibition is dependent on the cell type and the cellular 
processes occurring at the time of inhibition. 
The induction of apoptosis following 01/S phase in KIM-2 cells led us to 
examine this particular stage of the cell cycle. Examination of the cdk inhibitor p27 
demonstrated that elevated levels of this protein were present. p27 is a protein that 
controls the progress of cells from the 01 phase of the cell cycle into S phase. 
Elevated levels of any of the cdk inhibitors have been shown to induce apoptosis in 
viiro. It is possible that proteasome inhibition induces apoptosis as a direct 
consequence of perturbing the expression of p27 but it would seem much more 
probable that the apoptosis observed was as a consequence of the deregulated 
expression of a number of cell cycle control proteins. The proto-oncogene c-myc is 
another target of the ubiquitin-dependent degradation system. Expression of c-myc 
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can induce either a proliferative or apoptotic response, which is dependent on the 
cellular environment. Generally levels of c-myc are elevated at the onset of 01 and 
this triggers the progression of the cell through this stage of the cell cycle. As the 
cell reaches late 01 c-myc levels fall and the levels of p27 rise. These events are 
thought to help trigger the entry of the cell into S phase. Elevated levels of c-myc 
prevent S phase entry and have been observed to induce apoptosis (Evan et al., 
1992). In progression of the cell cycle the levels of c-myc and p27 appear to be 
opposing. With this is mind we examined the levels of c-myc protein in KIM-2 cells 
to determine if both c-myc and p27 were elevated. The results generated were 
inconclusive as the antibody used was non-specific. This needs to be repeated to 
determine if there are conflicting levels of these two proteins. 
More recently another cdk inhibitor p21 has been shown to be regulated by 
the 26S proteasome (Wang et al., 1998). p21  increases in expression in response to 
p53 and triggers arrest of the cell cycle at 01 (Gartel etal., 1996). Its expression is 
normally tightly regulated and it can respond in both p53-dependent and independent 
manners. The apoptosis observed as a direct consequence of proteasome inhibition 
is p53 dependent suggesting that p21 may be activated in response to this signal. 
Proteasome inhibition has been previously shown to suppress the upregulation of p21 
during 01 suggesting that the proteasome might facilitate cell proliferation by 
augmenting expression of p21 during the 01 phase of the cell cycle. Modulation of 
p21 expression would hamper the entry of the cell into S phase and any progression 
from this stage, which is similar to the results observed with proteasome inhibition. 
The E2F family of transcription factors also contributes to cell cycle 
regulation and are substrates of the proteasome. E217 proteins interact with the pRb 
pocket proteins, and this interaction functions to inhibit the DNA binding activity of 
E2F in addition to masking it from degradation by the proteasome. Phosphorylation 
of pRb releases E2F allowing it to promote entry into S phase of the cell cycle. 
Various E217/poeket protein complexes exist and these are thought to perform 
different tasks as they are present at different stages of the cell cycle. E217 and the 
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pocket protein p130 are found predominantly in both quiescent and terminally 
differentiated cells, E2F/p107 complexes are present mostly in S phase, and E2F/pRb 
in early to mid 01 (reviewed in Bernards, 1997). E2F-1 has been shown to be a 
specific substrate for the 26S proteasome. Although the majority of E2F proteins can 
act to induce entry into S phase, E21 7-1 is the only family member that can induce 
apoltosis. Disruption of protein degradation by the ubiquitin-dependent proteasome 
pathway should result in overexpression of E2F, which can induce S phase entry 
followed by apoptosis (Shan and Lee, 1994). This is similar to the response 
observed in KIM-2 cells treated with M0132 but it may not be the direct cause of the 
apoptotic response. KIM-2 cells express SV40 Tag which complexes pRb. How this 
affects pRb binding to E2F-1 is unclear but the results observed in KI1v4-2 cells at 
33°C and ES cells and would suggest that p53 is a major component of the response 
to proteasome inhibition. In addition to controlling S phase entry E217 has a number 
of target genes which contribute to cell cycle regulation. A high level of free E2F in 
late G  initially suggested that its prime role was to activate genes during that period. 
These genes included cyclin A, cyclin E, the cdk inhibitor p16, p107, pRb, E2F-1 
and the nuclear proto-oncogenes c-myc, N-myc, and B-inyb ( Beij ersbergen and 
Bernards, 1996). Analysis of the promoters of these genes revealed that E2F 
elements in general act as negative elements during 01 as opposed to positive 
elements during S phase. Disruption of the 26S proteasome degradation pathway 
should result in elevated levels of E21 7 . This could equally be a consequence of pRb 
binding to SV40 Tag. This may further cause deregulation of its target genes which 
themselves are cell cycle regulated. Indeed some of the E21 7 targets are also 
degraded by the proteasome suggesting that by altering the expression of one protein 
a number of cell cycle proteins can be disrupted. 
p53 levels were observed not to increase as a result of proteasome inhibition 
in this study. This observation conflicts what is currently known with regard to p53 
degradation. It is well documented that p53 is degraded by the 265 proteasome in 
vivo. Ubiquitinated species of p53 have been observed in cells in vitro confirming 
this theory (Maki et al., 1996). p53  association with the oncoprotein mdm2 has been 
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observed to affect the susceptibility of this protein to ubiquitin mediated degradation. 
I have shown that although the presence of p53 is necessary for the initiation of an 
apoptotic response, elevated levels of p53 do not initiate this reaction. It has been 
observed in many situations that deregulation of p53 can induce an apoptotic 
response. If this protein was indeed degraded by the proteasome then it would have 
been the obvious conclusion to have reached e.g inhibition of the 26S proteasome 
should result in elevated levels of p53 which alone could be the trigger to induce 
apoptosis. The exact mechanism which prevents a stabilisation of p53 in the 
presence of M0132 in KIM-2 cells is unclear but may be due to the presence of 
SV40 Tag in these cells. Initially it was assumed that Tag should not affect the 
degradation of p53 as it had been observed that HIPV infected cells can degrade p53 
in the presence of SV40 Tag (Scheffner et al., 1990). It is possible that another 
proteolytic pathway may regulate p53 stability. Recently it has been suggested that 
calpains may also play a role in the degradation of p53. Calpains are calcium-
dependent intracellular proteases which are divided into two major groups: the 
ubiquitous calpains, termed milli- and microcalpains according to the concentration 
of calcium required for their activity, and tissue specific calpains (Croall and 
DeMartino, 1991). Ubiquitous calpains, which are predominantly cytoplasmic in 
nature, recognise proteins by structural determinants and cleave their substrates only 
partially. Pariat and colleagues (1997) demonstrated that p53 was susceptible to 
calpain proteolysis and that this degradation was dependent on p53 protein 
conformation. Wild-type p53 protein acts to either promote or suppress cell 
proliferation and these opposing functions correlate to alternative conformations of 
the protein. It has also been shown that mutations in p53 found in a number of 
tumours correlates with destabilised tertiary structures (reviewed in Milner, 1995). 
The data regarding p53 mutations is conflicting in some areas, it has been observed 
that mutations in regions of p53 that should have no effect on proteasome mediated 
degradation result in enhanced stability. In the context of KIM-2 cells it is possible 
that p53 when bound to SV40 Tag is in a conformation which is more susceptible to 
calpain degradation than that mediated by the 26S proteasome. It has been observed 
that p53 cannot be degraded by the 26S proteasome when bound to DNA (Molinari 
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and Milner, 1995). In contrast to this the degradation of p53 by calpains was 
observed to be functional when p53 was either free or bound to DNA. One caveat of 
these studies is that p53 is a predominantly nuclear protein and calpains are 
cytoplasmic proteases. The mechanism whereby p53 is encountered by calpains is 
unclear but may relate to breakdown of the nuclear envelope during mitosis. This 
evidence would suggest that more than one pathway may contribute to p53 
degradation and these may vary according to the cellular context and the 
physiological conditions encountered. It remains possible that the presence of SV40 
Tag may favour p53 degradation by calpain. Examination of the effect that calpain 
inhibitors have on KIM-2 cells will resolve the question of whether this pathway can 
contribute to p53 degradation in vivo. Preliminary studies with a range of protease 
inhibitors, including those which inhibit calpains showed that only proteasome 
inhibition induced apoptosis in KIM-2 cells. If indeed calpain inhibitors can act to 
stabilise p53 in KIM-2 cells then this should induce apoptosis. Analysis of the cell 
cycle profiles and p53 expression levels in these cells will reveal whether they have 
elevated p53 protein. 
In order to address the apoptotic response observed in more detail in these 
cells, careful dissection of each of the components of the 01/S phase of the cell 
cycle is required. Levels of GUS phase expressed proteins should be examined 
following proteasome inhibition. This should address the question as to whether 
deregulation of one or a number of proteins drives this response. It will also 
generate information on the most likely candidates for inducing apoptosis. An 
important observation to come from these studies was the requirement for p53 in the 
apoptotic response occurring as a response to proteasome inhibition. To answer this 
question it is necessary to compare KIM-2 cells with another cell type e.g. the p53 wt 
and null ES cells. This will allow discrimination between p53 and other Tag binding 
proteins in this apoptotic response. It would be of interest to examine a cell line 
overexpressing p53 to determine if this can cause a similar type of apoptosis in these 
cells. p53 could be re-expressed in p53 null ES cells and the level of this protein 
examined following proteasome inhibition. This may go some of the way to explain 
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if the difference I observed in p53 levels following proteasome inhibition was 
dependent on the presence of SV40 Tag. More questions are required to address 
whether the presence of Tag alters the sensitivity of p53 to the 26S proteasome. 
mdm2 is the protein that normally acts to alter p53 stability and it would be of 
interest to examine whether the function of mdmd2 is altered by the presence of Tag. 
The apoptotic response induced also requires further characterisation. Of most 
interest would be the examination of p53 target genes e.g. p21, Bel-2, Bax and 
caspase expression as all of these proteins have been suggested to be degraded by 
this complex. Examination of the downstream apoptotic pathway will reveal 
whether a conventional apoptotic response is initiated as a consequence of 
proteasome inhibition. Mother major target of the 26S proteasome is E217-I. We 
have shown that a component of this response is p53 dependent and I would like to 
examine the effects of rendering E217-1 non-degradable. Altering the expression of 
this one protein is likely to alter the expression of a number of 01/S phase proteins 
e.g. cyclin A, cyclin E, p16, p107, pRb, c-myc, and E2FI. It is of interest to examine 
whether the response observed in cells overexpressing E217-1 minors that seen 
following treatment with proteasome inhibitor and how the presence or absence of 
p53 effects this response. Inhibition of the 26S proteasome results in a high number 
of ubiquitinated proteins within the cell. Normally ubiquitination of proteins occurs 
as a stress response therefore it would be informative to examine stress activated 
pathways within the cell. Accumulation of these "stress signals" may trigger a 
response within the cell such as the activation of the stress activated kinase (SAPK) 
pathway. Prolonged activation of this pathway has been observed to induce 
apoptosis in some circumstances and therefore is one of a number of potential 
consequences of disruption of protein degradation. 
The induction of a 01/S phase arrest followed by apoptosis in KIM-2 
mammary epithelial cells in response to proteasome inhibition appears to be a 
complex response. The 26S proteasome has many substrates that are cell cycle 
regulated proteins. The timely expression of a number of these proteins acts to 
control the progression of the cell cycle. It follows that disruption of the expression 
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of these genes would alter the progression of the cell cycle. It is difficult to 
hypothesis that the deregulation of one particular substrate is the trigger for the 
apoptosis observed in these cells. It would appear much more probable that the 
apoptosis is occurring as a response to a number of conflicting signals to the cell e.g. 
during GI levels of c-myc, E2F and p27 would all be high as a result of proteasome 
inhibition. These are signals which the cell was not programmed to encounter 
simultaneously. It is likely that when such a situation occurs the cell will be 
triggered to abort its cycle and die as a mechanism to prevent loss of cell cycle 
control, which could ultimately lead to neoplastic transformation. 
Since the completion of the studies reported in this thesis a number of papers 
have been published concerning the apoptosis induced by proteasome inhibition. 
Bcl-2 is a member of a family of genes that act to regulate apoptosis. It is thought to 
suppress signals that induce apoptotic cell death. Bcl-2 has been shown to bind two 
proteins, one of which is Bax. Bax is 21% homologous to Bcl-2 and increased levels 
of expression of this protein appear to counteract the effects of Bcl-2 and promote 
apoptosis (Nunez and Clarke, 1994). Bcl-2 is thought to inhibit apoptosis activated 
by p53 by blocking a critical step that initiates the apoptotic cascade. Monney and 
colleagues (1998) have shown that overexpression of Bcl-2 in fibroblasts protected 
cells from apoptosis induced by decreased ubiquitination (due to an El mutation) in 
addition to treatment with proteasome inhibitor. They describe Bcl-2 as acting 
downstream of the accumulation of short-lived proteins as it did not prevent the 
overexpression of p53, p27, and cyclins Dl and BI. It is hypothesised that the 
accumulation of short-lived proteins may act to inhibit survival factors that are 
crucial to the cell. Conversely Bcl-2 may compensate for the absence of other 
survival factors which are substrates of this pathway e.g. NFKB. Bcl-2 has been 
shown to prevent apoptosis in response to a wide range of signals (Sentman et al., 
1994 and Cuende et al., 1993). Mdm2 and Bax have also been observed to be 
substrates of the 26S proteasome (Chang et al., 1998). Both of these genes are 
regulated by p53; p53  induction of Bax induces apoptosis and mdm2 alters the 
sensitivity of p53 to degradation by the proteasome. The increase in the stability of 
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these proteins following proteasome inhibition was observed to occur independently 
of p53. This would suggest that the proteasome normally acts to negatively regulate 
apoptosis by degrading the downstream target of p53, Bax. It was observed that Bcl-
2 levels are not altered following proteasome inhibition. Phosphorylation of Bc1-2 
inactivates the ability of Bel-2 to prevent apoptosis suggesting that a minimum of 
two mechanisms act to regulate the control of apoptosis by Bax, ubiquitination of 
Bax and phosphorylation of Bcl-2. It would be of interest to examine the levels of 
Bcl-2 and Bax in KIM-2 cells to determine if they are stabilised in response to 
proteasome inhibition. Clearly a different mechanism of death is induced in these 
cells as p53 was a definitive requirement for an apoptotic cascade. If Bcl-2 and Bax 
levels were the only factors controlling apoptosis in KIM-2 cells then death should 
have been observed at 33 °C in addition to 37°C. Chang and colleagues (1998) 
described an independence of p53 in this response that conflicts with the 
observations detailed in this thesis. 
The 26S proteasome degradation pathway has been linked to the function of 
heat shock proteins (Hsp), which increase cell tolerance to stresses. Hsp72 has been 
observed to bind damaged or misfolded proteins and acts either to facilitate the 
repair of the protein or to target it to the 26S proteasome. Mother pathway that is 
activated in a similar manner is the c-Jun terminal kinase (INK) signalling cascade. 
Prolonged activation of INK is harmful to the cell and ultimately leads to the 
induction of apoptosis. Hsp 72 interferes with the activation of INK and functions to 
prevent apoptotic signalling under certain stresses (Gabia et al., 1997). Meriin and 
coworkers (1998) have recently described activation of the INK signalling pathway 
and induction of F1sp72 in response to MGi 32 treatment in vitro followed by the 
induction of apoptosis. This effect could be abrogated when the iNK signalling 
cascade was suppressed suggesting that the proteasome mediates its apoptotic 
response by a lINK pathway. Given that so much conflicting information is available 
with regard to apoptosis induced by proteasome inhibition more research is required 
to clarify the precise pathway which is activated in response to this insult. 
7.4 26S Proteasome Implications in Disease 
The ubiquitin-proteasome degradation pathway has a vast number of 
substrates that are involved in many fundamental biochemical processes. This 
results in this pathway becoming a prime target for involvement in cancers or 
diseases arising from deregulation. The 26S proteasome pathway has recently been 
implicated in a number of neurodegenerative diseases. Transgenic mouse models of 
Huntingtons Disease (BID) have been observed to develop neuronal intranuclear 
inclusions that contain ubiquitin proteins (Davies ci al., 1997). Increases in both the 
proteasome and ubiquitin had also been observed in dystrophic neurites in Alzheimer 
Disease (AD) and Parkinson's Disease (Ii ci al., 1997). The amyloid 13  protein, 
which has been implicated in AD, has been shown to bind to the inner catalytic sites 
on the 20S proteasome (Gregori ci al., 1997). This may account for the increase in 
ubiquitinated proteins observed in many neurodegenerative diseases but it is unclear 
at present whether a reduction of proteolysis occurs as a result of the disease or 
whether it contributes to the disease. 
The HIV-1 Tat protein has been observed to interfere with the 26S 
proteasome pathway. The Tat protein causes a number of different effects during 
acquired immunodeficiency syndrome (AIDS) which determine infectivity and 
cytopathicity in the developing infection. Seeger and colleagues (1997) have 
observed Tat binding to both the 195 regulatory complex and the 20S proteasome. 
Tat was shown not to bind to the 11 S regulator and was shown to compete with the 
11 S subunit for binding to 20S proteasomes. Binding to the 205 proteasome by Tat 
inhibits this 205/1 IS complex while stimulating 265 proteasome activity. In vitro 
the effects of Tat on the proteasome system may result in a decrease in antigen 
processing and reduced MIHC class I presentation in infected cells. Tat also displays 
an immunosuppressive activity on lymphocytes, which in concert with its effects on 
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the proteasome pathway may contribute to the profound immunodeficiency seen in 
AIDS patients. 
The proteasome has additionally been described to function in events 
mediated by oncogenic viruses (Scheffher et al., 1990). In HPV-related cancers the 
oncogenicity of the papilioma virus is mediated by upregulation of p53 degradation 
by the proteasome. The E6 protein of high risk FIPV (e.g. HPV-16, -18, -5 and -8) 
binds to p53 and mediates its ubiquitin dependent degradation and this step is crucial 
for immortalisation of human cells by HPV. Low risk HPV (e.g. HPV-6 and -11) 
encodes an E6 protein that cannot bind to p53 and therefore does not promote its 
degradation. Alterations of p53 stability by the 26S proteasome may be functionally 
equivalent to p53 inactivation, which is observed in a high number of cancers. 
Progression through the cell cycle is promoted by the activity of the 
proteasome in addition to cdks. The cdk inhibitor p27, which is a substrate of the 
26S proteasome is emerging as a potential clinical marker. Low p27 protein levels 
have been found in a number of common tumours e.g. colorectal carcinomas and 
breast cancers. This is generally associated with a poor prognosis. In the case of 
breast cancer Catzavelos and co-workers (1997) have shown that increased 
proteolysis of p27 can be an early event in tumourigenesis. Cyclins B, Dl and E 
have all been shown to be overexpressed in breast cancers but it is unclear whether 
this is due to a decrease in proteolysis (reviewed in Spataro et al., 1998). These 
initial studies suggest that examination of the 26S proteasome pathway in situations 
where deregulation of cell cycle related proteins are observed may show that 
proteasome dysfunction contributes to the progression of these diseases. 
The proteasome is also implicated in events that control gene transcription. 
The proto-oncogene products c-Jun and c-Fos constitute the transcription factor AP- 1 
either as heterodimers or c-Jun homodimers. Both of these proteins are substrates of 
the ubiquitin-proteasome pathway. The degradation of c-Jun is determined by a 
region called the delta domain that is absent in its transforming retroviral counter- 
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part v-Jun. The increased stability of v-Jun is thought to contribute to its 
oncogenicity (Treier ci al., 1994). The transcription factor AP-1 has recently been 
implicated in multidrug resistance, which also has a link to the proteasome. The 
yeast homologue of AP-1, Pap-i confers multidrug resistance through the Pad-] 
protein. The human homologue of Pad-1, termed POH-1, has been shown to have 
homology to subunit 12 of the regulatory complex (Dubiel et al., 1995b). It has 
subsequently been shown that this protein is present in the 26S proteasome. POH-1 
also displays sequence similarity to JAB-I, which interacts with c-JUN to activate 
AP-1. Spataro and colleagues (1998) propose that proteasome subunit POH-1 could 
act to upregulate AP- I factors and confer multidrug resistance on the cell. As the 
proteasome pathway is highly conserved in mammals, it may act to confer drug 
resistance to anti-cancer agents in vitro and could potentially be involved in drug 
resistance in human tumours. 
DNA repair pathways are regulated by ubiquitin-proteasome activity. In & 
cerevisiae expressing a mutant Radó DNA repair enzyme, defects in ubiquitin 
conjugation was observed suggesting this enzyme has an E2 function. Further 
evidence supporting this came from studies on Rad23, which have shown that the 
ubiquitin-like region in this protein was essential for its function (Watkins et al., 
1993). Yeast mutants in El enzymes also display defects in DNA repair in response 
to UV induced DNA damage suggesting that the proteasome pathway is strongly 
implicated in DNA repair. At present it is unclear whether the entire pathway is 
involved or whether the ubiquitin binding proteins directly interact with the DNA 
repair pathway. The deubiquitinating enzymes may also play a potential role in 
oncogenic transformation. The human Ubp Tre-2 has been found to be tumourigenic 
when expressed at high levels (Papa and Hochstrasser, 1993) 
The 26S proteasome mediated degradation pathway has implications in a 
number of diseases and for these reasons it may represent a target for therapeutic 
intervention. To date, the best-known proteasome inhibitor is lactacystin, a 
Streptomyces metabolite. Lactacystin has been observed to inhibit cell cycle 
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progression in human osteosarcoma cells (Fenteany et al., 1994) and to induce 
apoptosis in a number of other cell types. It is not clear whether this drug has any 
anti-tumour effects. The majority of the other proteasome inhibitors available 
currently are peptide aldehydes, which can also induce apoptosis in human tumour 
cell lines (Fujita et al., 1996). The proteasome displays a very diverse range of 
substrates and any attempt to target these non-specifically might be associated with 
toxicity. The rapidly expanding knowledge of this proteolytic pathway in both 
normal and disease processes may soon provide the information necessary to 
generate a proteasome-targeting drug. The complexity and specificity of the 
proteasome may dictate that specific inhibitors of individual proteasome-mediated 
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